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 Genomic sequencing is poised for clinical application in diagnosis and management 
of patients, as well as pre-symptomatic screening in healthy individuals. To accomplish 
these goals, additional tools are required for clinical interpretation of human genetic 
variation. Variant interpretation guidelines, such as those established by the American 
College of Medical Genetics and Genomics (ACMG) and the Association for Molecular 
Pathology (AMP), provide a general framework for this process, but significant gaps exist in 
the ability to utilize evidence such as functional assays in the determination of clinical 
significance. Increased implementation of genetic testing has identified millions of individual 
variants, but the majority of these remain in the category of variant of uncertain significance 
(VUS) due to insufficient available evidence. VUS cannot be used for clinical decision-
making or risk assessment and thus complicate patient counseling. As such, potentially 
thousands of disease-associated genes are in need of functional assays to interrogate the 
significance of the complete allelic series of human variation. This effort will require 
standards for assay validation and a rigorous method to determine the weight of evidence 
assigned to resulting data within the overall classification scheme. This dissertation 
addresses the gaps in variant interpretation guidelines regarding functional evidence, 
helping to reduce the VUS burden that limits the clinical application of genomic sequencing. 
To do this, I first examined ACMG/AMP classification guidelines in a real world setting of 
expert variant curation to examine how the addition of strong pathogenic or benign 
 
iv 
functional evidence impacts clinical interpretation of missense VUS, permitting standardized 
prioritization of functional assays to develop and variants to assess. Next, I developed 
consensus recommendations and a structured procedure for systematically evaluating and 
applying existing functional evidence in the clinical interpretation of germline genetic 
variants. Included in this framework is a method for determining the evidence strength that 
can be applied based on given assay validation parameters. Finally, I validated a cell-based 
fluorescent reporter assay of variant-level DNA damage repair (DDR) outcomes in 
hereditary breast cancer genes, BRCA2 and PALB2. After benchmarking the assay with 
BRCA2 variants of known significance, I tested 25 PALB2 missense VUS alongside benign 
and truncating variant controls. This represents a novel pathway-based approach to assay 
validation for genes that have been limited by the availability of benchmarking controls. 
Seven PALB2 missense variants demonstrated an abnormal functional impact on DDR with 
a moderate level of evidence, suggesting that PALB2 missense variation in critical functional 
domains may have a larger role in disease pathogenesis than previously thought. In all, the 
body of work presented in this dissertation will advance the science of medicine by 
supporting clinical interpretation of genetic variants with methods for assay prioritization, 
development, validation, and evaluation. This will increase the capacity for development of 
high-throughput methods of functional variant assessment and reduce the burden of VUS 
complicating patient care, thus contributing to the body of knowledge required for expansive 
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 CHAPTER 1: INTRODUCTION AND BACKGROUND1 
1.1 Genetic variation and human disease 
Utilizing genetic information for precision medicine requires thorough understanding 
of sequence variation and causality across all diseases.1 For complex multifactorial 
diseases, such as diabetes, many common genetic variants make small contributions to 
disease risk, in combination with multiple non-genetic factors.2 Multifactorial contributions to 
disease etiology are interrogated by statistical means (e.g. Genome-Wide Association 
Studies), but the clinical utility of this information is currently limited by its poor predictive 
power. In contrast, Mendelian or monogenic disorders are characterized by rare variants in 
a single gene with a high impact on disease risk.3 In general, assertion of variant 
pathogenicity for a Mendelian disorder implies causality, although this does not always 
correlate with manifestations of disease. For example, in hereditary conditions that are 
characterized by increased cancer risks, the phenotype of each individual may vary due to 
incomplete penetrance and variable expressivity. While some disease mechanisms fall 
between these categories, arising from a combination of common variants of low effect and 
rare variants of greater effect, the binary approach (monogenic versus multifactorial) is 
currently the predominant organizing framework for disease causality.  
Genetics of hereditary breast cancer 
 Tumor suppressors have an important role in cancer pathogenesis. In hereditary 
 
1Parts of this chapter previously appeared in an article in Genetics in Medicine. The original citation is 
as follows: Strande NT, Brnich SE, Roman TS, Berg JS. Navigating the nuances of clinical sequence 




breast cancer in particular, germline defects in several tumor suppressor genes have been 
implicated in increased risk of disease. Most notably, mutations in breast cancer genes 1 
and 2 (BRCA1 and BRCA2) were found to increase risk of breast cancer, with about a 72% 
or 69% risk for developing breast cancer by age 80, respectively, as well as increased risk 
for ovarian cancer.4 Other implicated genes that are commonly tested in germline panel 
testing include ATM, TP53, PALB2 and PTEN.5  
 In the United States, about 13% of women will develop breast cancer at some point 
in their life.6 Women harboring a pathogenic variant in PALB2 have a 14% lifetime risk of 
breast cancer by age 50, which increases to a 35% lifetime risk by age 707, placing it 
amongst moderate-to-high breast cancer risk genes8. It is estimated that 0.6-3% of patients 
with breast cancer have a pathogenic PALB2 variant, depending on the population.7,9 One 
study found that breast cancer patients with a germline pathogenic variant in PALB2 had a 
10-year survival of 48%, compared to 75% in non-carriers, and 10% developed contralateral 
breast cancer.10  
 According to the National Comprehensive Cancer Network (NCCN), finding a 
germline pathogenic variant by clinical testing in one of these genes triggers a discussion of 
increased risk of disease and steps to manage that risk, as appropriate.9 Depending on the 
risk and penetrance of the particular genetic variant, options may include earlier initiation 
and increased stringency of screening by mammography or other modalities, as well as the 
option of risk-reducing mastectomy. For women with a current diagnosis of breast cancer, 
the finding of a pathogenic germline variant may change treatment options, such as surgical 
decisions to reduce recurrence risk, and the use of poly (ADP-ribose) polymerase inhibitor 
(PARPi) therapies, as they have been demonstrated to be effective in a subset of 
mutations.11,12 It also prompts cascade testing of family members, such as siblings or 




DNA Damage Repair 
Many of the genes implicated in hereditary breast cancer are normally involved in the 
repair of deoxyribonucleic acid (DNA) double-strand break (DSB) repair. DNA DSBs can 
occur as a result of exposure to ionizing radiation, topoisomerase inhibitors, crosslinking 
agents, or endogenous reactive oxygen species.13,14 Without effective repair, cells are 
susceptible to chromosome breakage and genome instability. Two of the major pathways of 
DSB repair are homology-directed repair, or homologous recombination (HR), and non-
homologous end-joining (NHEJ). HR is a high-fidelity repair mechanism occurring during 
G2/S phase that uses a homologous template strand to correctly repair breaks. After a DSB 
is detected, BRCA1-dependent resection occurs on either end of the break, exposing 3’ 
single-stranded DNA.13,15 For HR to occur, BRCA1 then recruits PALB2 to the site of 
damage, where it can be visualized as foci.16,17 PALB2 in turn loads BRCA2 and RAD51 to 
DSB sites and this complex stimulates RAD51-mediated invasion of an intact homologous 
sequence, which is used as a template for hi-fidelity repair.13,15,18  
Canonical NHEJ is active throughout the cell cycle, repairing breaks when HR is not 
possible by joining fully complementary ends through ligation.19 Alternative NHEJ (alt-
NHEJ), however is an error-prone mechanism involving PARP1 and other factors that leads 
to small insertions and deletions.14,19,20 Defects in HR and a reliance on NHEJ leads to a 
pattern of genome-wide instability and an accumulation of mutations, as seen in tumors with 
germline pathogenic variants in PALB2, BRCA1, and BRCA2.21,22 
PALB2 
PALB2 is located on chromosome 16p12.2 and consists of 13 exons that encode a 
1186 amino acid protein.23 PALB2 was first implicated in carcinogenesis based on 
observations in breast cancer patients with mutations in BRCA2 that disrupted BRCA2-
PALB2 binding and thus HR efficiency.16 Subsequent studies of familial breast cancer and 
Fanconi Anemia identified an association between PALB2 and hereditary cancer 
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predisposition.24,25 BRCA1 mutations that disrupt BRCA1-PALB2 complex formation and 
impair HR have also been found in cancer patients.17 PALB2 mediates DNA-loading of the 
BRCA2-RAD51 repair complex.16 PALB2 also binds KEAP1 as an oxidative stress sensor26 
and associates with nucleosome core histones H3 and H2B through its central chromatin-
association motif (ChAM).27   
Historically, germline pathogenic variants in PALB2 have been truncating (nonsense 
or frameshift) variants and have demonstrated defective HR and a reliance on error-prone 
alt-NHEJ, leading to a pattern of genome-wide mutations.21,22 Recent studies provide 
evidence that some missense variants in PALB2 also demonstrate defective HR and may be 
pathogenic.28–31 While these studies are promising, a lack of benchmarking controls has 
limited our ability to establish well-validated functional assays to evaluate the impact of other 
PALB2 missense variants on HR for use in clinical variant interpretation. 
Other hereditary cancer genes in the HR pathway have been sufficiently well-studied 
and have good benchmarking controls. For example, in BRCA2, missense variants have 
been characterized by their capacity for HR following induced DNA DSBs using a 
fluorescent reporter assay where GFP served as a marker for HR.32 Benign variants retain 
HR capacity and thus strongly express GFP, while pathogenic variants defective for HR do 
not. The established BRCA2 benign and pathogenic variants used in developing this assay 
constitute a gold standard panel for functional assay validation.33 In chapter 4, we evaluated 
whether we could use these same BRCA2 gold standard missense variants to benchmark 
an assay of DNA damage repair for PALB2 missense variants. 
1.2 Clinical variant interpretation 
In lieu of formal statistical approaches, significant efforts have been made to develop 
guidelines describing the evidence types needed to assess variants implicated in Mendelian 
diseases.34–36 This dissertation focuses on the evidence types articulated by the clinical 
genetics community as providing support for or against pathogenicity of a variant with 
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respect to a monogenic disorder, and the nuances inherent in combining the available 
evidence to arrive at a clinical interpretation. Accurate and efficient clinical variant 
interpretation is one of the greatest challenges to broad application of genomic medicine 
and is critical for understanding disease and counseling patients. 
Variant interpretation considers patient phenotype, population data, and an appraisal 
of the literature for each variant (Figure 1.1).37 Professional organizations such as the 
American College of Medical Genetics and Genomics (ACMG) and Association for 
Molecular Pathology (AMP) have variant interpretation guidelines that incorporate different 
types of evidence (patient phenotype, population frequency, segregation and allelic 
evidence, computational and predictive data, functional assessment) at various levels of 
strength: (benign supporting (BP1-6), strong (BS1-4), or stand-alone (BA1), or pathogenic 
supporting (PP1-5), moderate (PM1-6), strong (PS1-4), or very strong (PVS1). These 
guidelines also provide combining rules for a final classification (benign, likely benign, 
uncertain significance, likely pathogenic, pathogenic).34 
 
Figure 1.1: ACMG/AMP evidence codes for classifying sequence variants organized 
by data type and strength. Adapted from Strande et al.38.Evidence codes are divided into 
those that support a benign (B) or pathogenic (P) classification (first letter of code) and given 
a relative strength (second letter of code): VS, very strong; S, strong; M, moderate; and P, 
supporting. See Richards, et al.34 for complete description of codes. *Odds of pathogenicity 
corresponding to evidence strength, assuming a prior probability of 0.10 as would be 
anticipated for single-gene analysis39. +BA1 is considered a “stand-alone” evidence type and 
was not included in the Bayesian model used to derive the odds of pathogenicity.  
Strong Supporting Supporting Moderate Strong Very strong
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The first type of evidence typically considered in variant interpretation is population 
data (codes BA1, BS1, BS2, PM2, and PS4). For example, if the minor allele frequency 
(MAF) of a variant is higher than the frequency of the disease in question, it is less likely to 
be causative and thus the BS1 code can be applied. Any variant with MAF above 5% in any 
global population is considered stand-alone evidence for a benign classification (BA1). 
Similarly, absence of the variant from controls in population databases is considered 
moderate pathogenic evidence (PM2). Case-control data demonstrating increased 
prevalence in an affected population compared to controls provides strong evidence of 
pathogenicity (PS4). Strong benign evidence (BS2) can be applied when the variant is seen 
in a healthy individual and it is being evaluated for a highly penetrant condition. 
Next, co-segregation data considers whether the variant segregates with disease in 
family members (codes PS2, PM6, PP1, and BS4). Lack of segregation (e.g. variant 
inherited from the unaffected parent) is considered strong evidence for a benign 
classification (BS4). If the variant segregates in affected family members, PP1 can be 
applied (this strength can be increased with greater co-segregation evidence). Finally, with 
some caveats, de novo occurrence (unaffected parents test negative for the variant) 
provides moderate evidence supporting a pathogenic classification (PM6), but can be 
upgraded to strong evidence (PS2) if biological maternity/paternity are confirmed by identity 
testing. Allelic evidence (codes PM3, BP2, BP5) typically refers to data about whether the 
variant occurs in trans with another pathogenic variant (PM3 for recessive conditions or BP2 
for autosomal dominant), in cis with a pathogenic variant (BP2), or observed with another 
pathogenic variant in a different gene with a more compelling molecular basis for individual’s 
phenotype (BP5). 
Predictive criteria typically apply to specific types of variants, such as length-
changing (PM4), in-frame insertions/deletions (BP3), or synonymous (BP7) variants, Very 
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strong evidence for pathogenicity (PVS1) can be applied for null variants where loss-of-
function is a known disease mechanism, while strong evidence (PS1) is met for novel 
nucleotide changes that create the same amino acid change as a known pathogenic variant. 
If the missense change occurs at a residue where a different amino acid change is known to 
be pathogenic, it qualifies for moderate evidence (PM5). Other predictive criteria often 
require knowledge of disease mechanism and the types of variants that are tolerated, as this 
can affect the interpretation. For instance, in a gene where missense changes are rare, PP2 
can be applied for missense variants, but if only truncating variants are known to cause 
disease, BP1 applies. If located in a mutational hotspot, this is moderate evidence of 
pathogenicity (PM1). 
Computational criteria (PP3, BP4) includes in silico predictions of the effect of a 
particular amino acid change, often based on evolutionary conservation at a given residue 
and/or differences in the biophysical properties of the new amino acid relative to the native 
structure. Data from well-established functional assays showing a deleterious effect (PS3) or 
no effect (BS3) are considered strong evidence in the ACMG/AMP variant interpretation 
framework and will be discussed in further detail later in this chapter. 
Finally, other criteria that do not fit neatly into one of the previously mentioned 
categories include codes PP4, PP5, and BP6. PP4 applies when the patient’s phenotype is 
highly specific to a single gene, as in a clinical biochemical test result indicating defective 
enzyme activity in a particular gene. Codes PP5 and BP6 allow for supporting evidence to 
be applied when a classification has been previously submitted to a variant database from 
reputable sources (such as a clinical laboratory with expertise in a particular condition), but 
the evidence underlying the classification is not provided. More recent guidance has 
recommended that the use of PP5/BP6 codes be discontinued, as primary sources provide 
better evidence, clinical laboratories should be encouraged to share data, and because 
misapplication of the criteria could result in “double counting” the unshared evidence 
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underlying the reputable source’s interpretation if applied in subsequent classifications.40 
Combining rules and conflicting evidence 
  Richards et al. provided categorical “scoring rules” as a way to combine all of the 
available evidence for a particular sequence variant into a final interpretation.34 These 
criteria list what combinations of evidence, at specific levels of strength, are required to 
reach a benign, likely benign, likely pathogenic, or pathogenic classification. For example, at 
least two pieces of evidence supporting a benign classification (evidence codes BP1-7), or 
one strong and one supporting piece of evidence (codes BS1-4 and BP1-7, respectively) are 
required to meet the likely benign threshold.  
 The term “variant of uncertain significance” (VUS) applies in the case of conflicting 
evidence, or when insufficient evidence is available to reach another classification.34 
However, determining what constitutes conflicting evidence is challenging. Although not 
explicitly stated, the ACMG/AMP guidelines imply that the strength of conflicting evidence 
should be relatively equivalent. The guidelines do not address how to proceed when the 
strength of conflicting evidence is unbalanced (i.e. weighted more heavily towards 
pathogenic or benign). For example, should one piece of supporting evidence bring an 
interpretation into conflict if other evidence is much stronger? No approved method currently 
exists for resolving VUS classifications with conflicting evidence. 
Bayesian adaptation of ACMG/AMP guidelines 
 In 2018, Tavtigian and colleagues adapted the categorical 2015 ACMG/AMP 
combining rules34 to a more quantitative, Bayesian framework.39 This framework 
mathematically determines how the probability of variant pathogenicity changes with 
additional evidence, each weighted according to data-driven estimates.41 Other consortia, 
such as the International Society for Gastrointestinal Hereditary Tumors (InSiGHT)42 and the 
International Agency for Research on Cancer (IARC)32,43, and some clinical laboratories44 
use similar quantitative systems for variant classification. One benefit of such a system is 
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that it can give more granular estimates of evidence strength. For example, all evidence 
from the same functional assay does not need to be assigned the same weight. Instead, the 
readout can be equated to a likelihood ratio and directly incorporated into the variant 
interpretation. Another advantage of a quantitative, Bayesian classification framework is the 
ability to consider both benign and pathogenic evidence together, resolving some of the 
issues with conflicting evidence. 
1.3 Variants of uncertain significance (VUS) 
 The number of clinically identified genetic variants has increased with the number of 
available genetic tests.34,37,45 However, our ability to identify these variants on a genome-
wide scale has outpaced our ability to interpret their clinical significance, given the often-
limited data connecting variants to disease. 
Clinical burden of VUS 
Even among genes clearly linked to disease, VUS account for a large amount of total 
identified variation. At the end of 2019, there were more than 266,750 variants in the Clinical 
Variant Database (ClinVar) with uncertain significance classifications.45 In PALB2 alone, 
1,300 of the 2,682 clinically identified PALB2 variants listed in the ClinVar database46 are 
VUS, and ~91% of VUS are missense variants.47 A 2014 study of the prevalence of 
reportable PALB2 variants in 1479 patients referred for hereditary breast cancer testing 
found 12 pathogenic/likely pathogenic variants (0.8%), but 59 VUS in 57 of the 1479 
patients (3.9%).48 Of those 59 VUS, 57 were predicted to have a missense consequence in 
the translated protein.48 According to the Centers for Disease Control and Prevention (CDC), 
each year about 250,000 women are diagnosed with breast cancer, and about 10% of those 
cases are familial. If 4% of those women carry a VUS in PALB2 that equates to about 
10,000 women per year. Between 9,100-9,600 would have a missense variant in PALB2. 
Clinical approach to VUS 
 VUS pose significant challenges to post-test counseling and patient care. In 
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hereditary cancer, genetic testing is critical for risk assessment and management, since 
identification of inherited pathogenic variants allows early screening and discussion of 
prophylactic risk-reduction treatments and surgeries.49 However, VUS cannot be used for 
diagnosis or clinical decision-making, creating confusion for patients and clinicians.34,50–52 
The case of hereditary breast cancer illustrates the importance of accurate variant 
interpretations. Germline genetic testing results influence surgical decisions, both in patients 
that are seeking treatment for breast cancer, as well as in patients that have not yet 
developed breast cancer.53,54 If a VUS is incorrectly interpreted as pathogenic for an 
inherited predisposition to cancer, the patient may elect to undergo a risk-reducing 
prophylactic mastectomy.55 This may still be appropriate in the context of a strong family 
history of aggressive breast cancer, but it raises concerns that misunderstanding VUS will 
lead to inappropriate, irreversible clinical consequences. 
1.4 Functional assay criteria 
The rarity of most individual VUS limits the collection of patient and family data, thus 
efforts to resolve VUS classification have focused on computational and functional 
approaches because they are not dependent on clinical data.50,56 This represents an 
opportunity to define functional assays for many genes and work to decrease the clinical 
burden of VUS. An important limitation is that functional assays are time-consuming and 
costly to develop, and there are many genes and VUS in need of functional assessment.50 
Decisions on where to focus limited resources are important and should be untaken 
systematically. In chapter 2 of this dissertation, I assess the theoretical ability of strong 
functional data to push a VUS towards a benign or pathogenic classification, in both the 
categorical and Bayesian variant interpretation frameworks. The results of this study provide 
a method that is foundational for the systematic prioritization of assay development and 
variant assessment. 
Lack of guidance on what constitutes a “well-established” assay has resulted in 
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subjective application of these criteria, and interlaboratory interpretation differences are not 
always resolved through data sharing.57 Often, assays are performed in research 
laboratories, which may or may not meet clinical laboratory standards. For sufficient 
predictive power, functional assays require extensive reproducibility and experimental rigor, 
including benchmarking against multiple variants with definitive clinical interpretations as 
determined by genetic or other evidence.56,58–60 An exemplary validated assay is the 
homology-directed DNA damage repair (HR) assay employed by Guidugli and colleagues, 
which demonstrated 100% sensitivity and specificity for pathogenicity determination.33,59,60 
 A well-validated assay should also provide variant-level evidence of the effect on the 
gene or gene product to satisfy PS3 or BS3 criteria, whereas assays on patient samples that 
evaluate biochemical parameters may suggest a specific clinical diagnosis but not pinpoint a 
causative variant. For example, an in vitro assay of enzyme activity in whole blood from a 
patient demonstrating impaired enzyme activity implicates the gene encoding the non-
functional enzyme, but does not isolate a specific variant’s effect and thus would not meet 
PS3 criteria. This information might be relevant to the PP4 criteria (patient’s phenotype is 
highly specific for a disease with a single genetic etiology) but caution is advised in applying 
this rule.  
For clinical interpretation, a functional assay should also be relevant to disease 
mechanism and manifestation. Cell-based or cell-free in vitro assays and in vivo organismal 
studies such as zebrafish or mouse models can be used to probe variant effects, but should 
be closely relate to the known etiology. Cell lines should be disease-relevant and carefully 
selected; a transformed cell line may not be ideal for isolating a variant’s tumorigenic 
effects.61 A negative result (equivalent to wild-type function) may support a benign 
classification, but should be contingent on how thoroughly the assay evaluates the 
gene/protein function. For example, a protein-protein binding assay might evaluate part of a 
protein’s normal function, but may provide an incomplete assessment if catalytic activity is 
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not evaluated. Multiple assays that comprehensively probe gene function are likely to better 
reflect clinical significance. Determining the most appropriate functional assay requires 
gene- and disease-specific knowledge, often beyond the expertise of variant reviewers.57 
This underscores the importance of expert consensus on these issues and the adaptation of 
the ACMG/AMP guidelines for individual genes or diseases. 
1.5 Addressing gaps with ClinGen Expert Panels 
 The 2015 ACMG/AMP sequence variant interpretation guidelines were intended to 
be broadly applicable, but by nature of their generality, gene- and disease-specific questions 
must be individually determined. One aim of the Clinical Genome Resource (ClinGen), a 
National Institute of Health (NIH)-funded consortium, is to resolve differences in variant 
interpretation across clinical laboratories.62 To do this, ClinGen has established Variant 
Curation Expert Panels (VCEPs) with multi-institutional and interdisciplinary membership 
that are working to refine and specify guidance for gene-disease pairs.63 VCEP criteria 
specifications have been developed and applied in ClinVar variant curations for a number of 
genes and diseases thus far.64–70  
 An analysis of these expert specifications for PS3/BS3 criteria revealed diversity in 
how these groups evaluated and applied functional evidence in variant interpretations.71 
While differences are to be expected given the variety in conditions examined, basic 
characteristics and metrics required to qualify a functional assay as “well-established” 
diverged substantially. For example, requirements for replicates, controls, and thresholds for 
result interpretation were only specified by two VCEPs each, strength applied ranged from 
supporting to strong evidence, and statistical analyses were inconsistently applied in the 
primary literature approved for clinical use.71 The 2015 ACMG/AMP guidelines34 do not 
specify how many variant controls are required to reach a particular level of evidence 
strength (very strong, strong, moderate, supporting), nor provide an approach for genes with 




 Altogether, this points to an urgent need to support VCEPs and clinical laboratories 
with detailed recommendations regarding PS3/BS3 criteria application to improve the 
harmonization of variant interpretation. Similar guidance has been developed for other 
ACMG/AMP criteria (BA172, PVS173, PP5/BP640) by the ClinGen Sequence Variant 
Interpretation Working Group (SVI), which reviews each criterion systematically for 
improvements and oversees VCEP specifications. Chapter 3 of this dissertation refines the 
definition of a “well- validated” functional assay, offers a preliminary framework for the 
evaluation and application of functional data in clinical variant interpretation, and includes a 
method for the determination of evidence strength in collaboration with the ClinGen SVI. 
Taking the first step towards reducing the VUS burden in PALB2, chapter 4 presents 
the development and validation of a pathway-based functional assay for PALB2 missense 
variation. Since PALB2 has few missense variants with definitive benign and pathogenic 
interpretations to serve as benchmarking controls, we used well-studied BRCA2 missense 
variants to perform preliminary validation. This represents a functional assay capable of 
examining variants in a multi-gene pathway that can be adapted for future multiplexing. 
1.6 Focus of this dissertation 
In this dissertation, I address the role of functional evidence in clinical variant 
interpretation and examine how functional data can contribute to the reinterpretation of 
missense VUS for direct clinical benefit, with particular emphasis on VUS in hereditary 





CHAPTER 2: QUANTIFYING THE POTENTIAL OF FUNCTIONAL EVIDENCE TO 
RECLASSIFY VARIANTS OF UNCERTAIN SIGNIFICANCE IN THE 
CATEGORICAL AND BAYESIAN INTERPRETATION FRAMEWORKS2 
2.1 Introduction 
Genomic sequencing is primed to advance screening, diagnosis, and management 
of disease for improved patient care.1 To achieve these goals, additional tools are required 
to understand the clinical significance of human genetic variation. Professional 
organizations, including the American College of Medical Genetics and Genomics (ACMG) 
and Association for Molecular Pathology (AMP), have developed variant interpretation 
guidelines to aid in this process.34 Variant interpretation involves an examination of patient 
phenotype, population data, and an appraisal of the literature for each variant.37 The 
ACMG/AMP guidelines assign a code to each piece of evidence by type (e.g. population, 
computational prediction, functional, or segregation data) and strength: benign supporting 
(BP1-6), strong (BS1-4), or stand-alone (BA1), or pathogenic supporting (PP1-5), moderate 
(PM1-6), strong (PS1-4), or very strong (PVS1). Then, evidence codes are evaluated in 
combination using a categorical system to assign a variant’s final interpretation along a 5-
tiered spectrum from benign to pathogenic34, as represented in Figure 2.1. The “variant of 
uncertain significance” (VUS) classification is applied in two situations: variants with 
conflicting evidence, or variants with insufficient evidence, as is often the case for novel 
missense variants.34,50 
 
2This chapter previously appeared as an article in Human Mutation. The original citation is as follows: 
Brnich SE, Rivera-Muñoz EA, Berg JS. Quantifying the potential of functional evidence to reclassify 
variants of uncertain significance in the categorical and Bayesian interpretation frameworks. Hum 




Figure 2.1: ACMG/AMP categorical combining rules for variant classification. Possible 
evidence combinations are represented alongside the corresponding variant classification 
according to Richards et al. 2015 combining rules34. The first letter of each evidence code 
indicates support towards a pathogenic (P) or benign (B) classification and the second letter 
indicates the assigned evidence strength: supporting (P), moderate (M), strong (S), very 
strong (VS), or stand-alone (A). Evidence code boxes are colored by evidence strength. 
Final classifications are determined by combinations of evidence codes resulting in the 
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Increased application of genetic testing has identified millions of individual variants, 
but lacking sufficient evidence for a definitive classification, the majority of these remain in 
the category of VUS.37,50 Clinical practice guidelines caution against using VUS for risk 
assessment and decision-making, which complicates patient counseling and 
management.34,49,50,52,74 
 Data from well-established in vivo or in vitro functional studies are considered strong 
evidence in the ACMG/AMP framework.34 Functional assays can probe a genetic variant’s 
effect on the gene or protein product, even in the absence of available patient or 
segregation data, providing an attractive approach to reclassify VUS.56,75,76 However, the 
impact of functional data on variant classification within the ACMG/AMP interpretation 
framework has not been assessed.  
 The Clinical Genome Resource (ClinGen) consortium62 established a Sequence 
Variant Interpretation (SVI) Work Group to refine and enhance the ACMG/AMP guidelines, 
providing additional recommendations for specific criteria, supporting gene and disease-
specific adaptations through Expert Panel groups, and developing quantitative approaches 
to variant interpretation. The categorical 2015 ACMG/AMP guidelines for clinical sequence 
variant interpretation34 were recently adapted to a quantitative, Bayesian framework 
described by Tavtigian and colleagues39. Bayesian analysis calculates how the probability of 
a hypothesis (e.g. pathogenicity) changes with the addition of evidence from multiple 
sources41, which can be utilized in variant classification schemes based on data-driven 
estimates of weights for each piece of evidence. 
In this manuscript, we first used an algorithmic approach to identify the theoretical 
contribution of well-validated functional assays towards reclassification of missense VUS 
globally. We examined the categorical ACMG/AMP rule combinations34 and assessed how 
the availability of strong functional evidence could theoretically improve the ability to make a 
benign or pathogenic assertion. Next, we examined the potential for VUS reclassification in 
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the recent Bayesian adaptation of the ACMG/AMP guidelines39. We followed this with 
analysis of actual evidence combinations met by missense variants curated through 
ClinGen’s Inherited Cardiomyopathy Expert Panel (CMP-EP) curation of MYH7-associated 
cardiomyopathies and RASopathies Expert Panel (RAS-EP) curations of variants in ten 
established RASopathy-associated genes. These variants served as a case study of 
functional assays in the context of actual evidence combinations applied in expert variant 
curation. Importantly, these analyses clarify the utility of functional evidence for clinical 
variant interpretation in both the categorical and quantitative frameworks. Finally, this 
analysis lays the groundwork for identifying genes and variants that stand to benefit the 
most from functional data and thus an evidence-based method for prioritizing assay 
development and validation. 
2.2 Methods 
Applicable rules by variant type 
We analyzed the ACMG/AMP variant interpretation guidelines to determine the 
evidence codes applicable to variants grouped by molecular consequence (missense, 
truncation, in-frame insertion/deletion, or synonymous) (Figure 2.2), in order to focus on the 
typical scenario of a rare missense VUS. PVS1 applies only to loss-of-function or truncating 
variants, PM4 refers to variants that affect protein length, BP3 is specific to in-frame 
insertions or deletions, and BP7 is specific to synonymous variants.34 We also excluded PP5 
and BP6 (reputable source reports) for all variant types, following the recent 





Figure 2.2: ACMG/AMP evidence codes for classifying sequence variants as 
applicable to variant molecular consequence. The first letter of each evidence code 
indicates support towards a pathogenic (P) or benign (B) variant classification, and is 
followed by an indicated weight of evidence: supporting (P), moderate (M), strong (S), very 
strong (VS) or stand-alone (A). See Richards et al.34 for a complete description of each 
code. Variant type refers to the molecular consequence (truncating, missense, in-frame 
indel, synonymous). If evidence applies to the specific variant type, it is indicated with a “/”, 










Evidence Truncating Missense In-frame	indel Synonymous
PVS1 / X X X
PS1 X / X X
PS2 / / / /
PS3 / / / /
PS4 / / / /
PM1 X / / X
PM2 / / / /
PM3 / / / /
PM4 X X / X
PM5 X / X X
PM6 / / / /
PP1 / / / /
PP2 X / X X
PP3 X / / /
PP4 / / / /
PP5 X X X X
BA1 / / / /
BS1 / / / /
BS2 / / / /
BS3 / / / /
BS4 / / / /
BP1 X / X X
BP2 / / / /
BP3 X X / X
BP4 X / / /
BP5 / / / /
BP6 X X X X




Algorithm for Combination Rule Assessment 
We wrote a Python script that iteratively calculates the resulting variant interpretation 
from combinations of satisfied evidence codes, using the ACMG/AMP combining rules 
outlined by Richards and colleagues34. Richards et al. described 30 criteria for variant 
classification, which includes 28 uniquely named evidence codes and two that account for 
the ability to increase the strength of pathogenic segregation evidence (PP1) to moderate or 
strong.34 For this purpose, we assumed that each piece of evidence considered was 
independent and met or not met (coded as one or zero). We set up the guidelines as a 
permutation problem, defining all possible combinations of evidence as: Comball = 230 = 
1,073,741,824. 
 To create all possible permutations, we used the itertools package product function 
for Python. Then, each combination was run through a filter to exclude rule combinations 
that exceeded a maximum of one rule in each of the following categories: population or 
allele frequency (BA1, BS1, BS2, PS4, PM2), segregation (PP1_Strong, PP1_Moderate, 
PP1), and de novo variant (PS3 or PM6). Additionally, we grouped inverse rules such that 
only one of each type could be met (i.e. functional—PS3 or BS3; computational—PP3 or 
BP4; segregation—PP1_Strong/PP1_Moderate/PP1 or BS4; allelic—PM3 or BP2). 
Next, we evaluated and filtered each combination by its applicability to variant type 
(truncating, synonymous, missense, in-frame insertion/deletion) according to Figure 2.2. For 
example, combinations including PVS1 (truncating variant in genes where loss of function is 
a known mechanism of disease) are binned as “truncating” only, while combinations with 
criteria that are not specific to a particular molecular consequence were included in all four 
variant type classes.  
As the 2015 ACMG/AMP guidelines34 do not provide a method to resolve conflicting 
evidence, combinations with both benign and pathogenic evidence were excluded from the 
initial analysis based on the combining rules. Non-conflicting evidence combinations were 
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then assigned a final classification (pathogenic, likely pathogenic, VUS, likely benign, or 
benign) using the combining criteria described in Table 5 of Richards et al.34.  
Algorithmic Analysis of Functional Evidence Impact 
We then used this tool to accomplish an analysis of the theoretical utility of a well-
validated functional assay, if it were to exist and if the variant were to demonstrate either a 
damaging effect or no effect on the gene or gene product (PS3 or BS3 in Figure 1 of 
Richards et al.34). This script generated combinations of the ACMG/AMP criteria for 
missense variants resulting in a VUS interpretation due to insufficient, not contradictory, 
evidence. We then examined which of these possible evidence combinations were missing 
functional criteria (PS3/BS3) and how adding this type of strong evidence would affect the 
ability to assert a benign or pathogenic interpretation. We modified the combinations to 
include PS3 or BS3 and reanalyzed them using the Richards et al. combining criteria34 to 
obtain a variant classification. We counted the number of combination scenarios that moved 
from VUS to other categories. 
Bayesian Adaptation of the Combining Rules Algorithm 
We next asked how this theoretical permutation analysis would change when 
adapted to the quantitative Bayesian framework recently described by Tavtigian and 
colleagues39. We modified the previous script to include contradictory evidence 
combinations, as the Bayesian framework provides a method for considering both 
pathogenic and benign criteria simultaneously. For each evidence combination previously 
described, we tallied the included evidence by weighted pathogenicity: supporting, 
moderate, strong, or very strong for pathogenic; and supporting or strong for benign. We did 
not analyze any combinations including stand-alone benign evidence, as meeting this 
criterion classifies a variant as benign regardless of other evidence, which is contrary to 
Bayesian reasoning39. We used the tallies (N) of each category (PP, PM, PS, PVS, BP, BS) 
















This then factored into the calculation of the posterior probability of pathogenicity (Post_P) 
for each combination, using a default prior probability (Prior_P) of 0.10 as previously 
described39: 
 Post_P = 4556789:∗7<=><(
((4556789:10)∗7<=><_7*0
 
Each Post_P was then assigned a variant classification as follows: benign <0.001; 0.001 ≤ 
likely benign < 0.1; 0.1 ≤ VUS < 0.90; 0.90 ≤ likely pathogenic < 0.99; 0.99 ≤ pathogenic. As 
an example, if the algorithm generated a combination of evidence including PM2, PP3, and 
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The Post_P would then be 0.325 and the combination classified as VUS.  
 As before, we then analyzed the impact of adding strong functional criteria to 
evidence classifications that did not include PS3 or BS3 criteria, recalculating the Post_P 
and reassigning a variant classification. Using the previous example, the Post_P would be 
0.900 (likely pathogenic) with PS3, or 0.025 (likely benign) with BS3. We then counted the 
number of combinations that moved from VUS to another class. 
Curated Variant Analysis 
Recently, two ClinGen Expert Panels (EPs) published recommendations for adapting 
the ACMG/AMP variant classification framework for specific genes and diseases64,65. The 
ClinGen Inherited Cardiomyopathy Expert Panel (CMP-EP) curated MYH7 variants using 
reference transcripts LRG_384t1 and NM_000257.3.65 The ClinGen RASopathies Expert 
Panel (RAS-EP) curated variants in nine genes using the indicated reference transcripts: 
BRAF (LRG_299t1, NM_004333.4), HRAS (NM_005343.2), KRAS (NM_004985.4, 
NC_000012.12(NM_004985.4)), MAP2K1 (LRG_725t1, NM_002755.3), MAP2K2 
(LRG_750t1, NM_030662.3), PTPN11 (LRG_614t1, NM_002834.3), RAF1 (LRG_413t1, 
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NM_002880.3), SHOC2 (LRG_753t1, NM_007373.3), and SOS1 (NM_005633.3)64. Both 
groups submitted variants to ClinVar as 3-star expert panel-reviewed interpretations. 
We examined their published variant curations, including the ACMG/AMP evidence 
codes satisfied for each variant, to determine the role of strong functional evidence in the 
application of the ACMG/AMP combining rules for a final variant classification. For each 
variant, we extracted the evidence codes applied in expert curation from the respective 
publications and inserted them in a tabular file for analysis. 
We asked how many curated variant interpretations included evidence from a well-
validated functional assay demonstrating a damaging effect (PS3) or no effect (BS3) on the 
gene or gene product, and how this evidence affected the overall classification. We sorted 
variants by satisfaction of PS3 or BS3 criteria and then grouped them by expert panel-
assigned classification. We modeled the impact of strong functional evidence (if it were to 
become available) on variant reclassification by tabulating the curated evidence plus BS3 or 
PS3 criteria using the combining rules approach described in Table 5 of Richards et al.34.  
In addition, we tallied the evidence for and against pathogenicity for each variant 
according to strength and entered this into the recent Bayesian adapted guidelines39. We 
again modeled how the addition of PS3 and BS3 criteria affected variant classification by 




Figure 2.3: Reclassifying missense VUS evidence combinations in the categorical 
ACMG/AMP framework and the adapted Bayesian framework. (A) Modeling the addition 
of well-validated functional evidence showing a damaging effect (PS3) or no effect (BS3) to 
non-conflicting missense variant evidence combinations in the categorical ACMG/AMP 
framework34 finds 97% of combinations would be reclassified with functional data. (B) 
Theoretical conflicting and non-conflicting missense evidence combinations resulting in a 
VUS classification in the categorical ACMG/AMP combining rules (Prior class categorical) 
were entered into the Bayesian adaptation39 and the corresponding variant classifications 
are shown (New class Bayesian). (C) From the theoretical missense evidence combinations 
resulting in a VUS classification in (B), we examined those that did not include PS3 or BS3 
criteria (Prior Class Bayesian). Modeling the addition of well-validated functional evidence 
(BS3 or PS3) reclassified all combinations (New class Bayesian) by posterior probability 
calculations in the Bayesian framework39. ACMG/AMP, American College of Medical 
Genetics and Genomics/Association for Molecular Pathology; B, benign; BS3, well-
established functional studies show no deleterious effect; LB, likely benign; LP, likely 
pathogenic; P, pathogenic; PS3, well established functional studies show a deleterious 
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Algorithmic Analysis of Theoretical Missense Evidence Combinations 
 We first used our categorical algorithm to identify the theoretical contribution of well-
validated functional assays toward reclassification of missense VUS globally. The 
categorical rules called 970,762 missense-applicable evidence combinations “VUS”. Of 
these, 195 missense evidence combinations returned a VUS classification due to limited, 
not conflicting, evidence and did not include “strong” pathogenic or benign functional 
evidence codes (PS3 or BS3). We found that 97% could be reclassified with the addition of 
strong functional data according to the categorical ACMG/AMP combining rules, suggesting 
that such assays could substantially improve missense VUS interpretations (Figure 2.3A). 
Interestingly, this analysis found that satisfaction of the PS3 criterion would be able to 
reclassify more non-conflicting missense VUS in the categorical framework than the BS3 
criterion. 
 In the categorical framework, adding evidence (of any type) to conflicting VUS does 
not change variant interpretation, as there are no specifications for how much evidence is 
required to outweigh conflicting criteria34. This can be modeled in the Bayesian quantitative 
framework, however, so we addressed the issue of conflicting evidence in the quantitative 
adaptation of our Python tool, which contains a formula for calculating the posterior 
probability of pathogenicity if both pathogenic and benign evidence apply39. Even without 
additional evidence, when considering both conflicting and non-conflicting missense VUS 
evidence combinations in the Bayesian-adapted framework, less than 30% remained VUS 
(Figure 2.3B). In other words, the quantitative system reclassified about 70% of all missense 
VUS evidence combinations, likely due to its ability to evaluate a mix of benign and 
pathogenic evidence. Of the remaining missense VUS combinations that did not include 
PS3 or BS3, adding PS3 reclassified 76%, while adding BS3 reclassified 63% (Figure 2.3C). 
100% of VUS could be reclassified as likely pathogenic or likely benign in the quantitative 
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framework if the functional assay results are in the same direction as the initial probability of 
pathogenicity.   
 While this approach reveals the theoretical combinations of evidence that would be 
amenable to reclassification due to additional functional evidence, it does not evaluate gene- 
or disease-specific evidence, or indicate the fraction of actual variants that meet those 
combinations. As such, we followed this theoretical analysis with an examination of publicly 
available, expertly curated sequence variants for MYH7-associated cardiomyopathies and 
RASopathies. 
 
Functional Assay Utility in Expert Panel Curation 
ClinGen’s RAS-EP and CMP-EP curated evidence for a total of 163 variants in 10 
different genes. Of these 163 variants, only 39 met PS3 criteria and expert panels assigned 
a final classification of pathogenic to all 39. Only one variant (PTPN11 p.Leu560Phe) met 
BS3 criteria, which in combination with one piece of supporting benign evidence was 
sufficient to push the final classification from VUS to likely benign (Table 2.1, Supplemental 
material). It is more difficult to experimentally demonstrate that a variant has no effect on the 
gene or gene product, as few assays capture all relevant protein functions. Thus, it is 





Figure 2.4: Non-conflicting missense variants classified as VUS by expert panels. 
aEvidence Satisfied, as determined by expert panels64,65, where abbreviations indicate 
specific criteria described in Richards et al.34. Boxes are colored according to evidence 
strength. bVariant listed by gene, cDNA, and protein. Variants were curated by expert panels 
using the following reference transcripts: HRAS (NM_005343.2), MAP2K2 (NM_030662.3), 
RAF1 (NM_002880.3), SHOC2 (NM_007373.3), and MYH7 (NM_000257.3). c Variant class 
assessed according to categorical ACMG/AMP combining rules34, with Expert Panel (EP) 
variant classifications considering only evidence satisfied in (a). dVariant class with the 
addition of either PS3 or BS3 criteria in the categorical interpretation framework34. eVariant 
class in Bayesian-adapted framework was determined by posterior probability of 
pathogenicity (Post_P). Post_P was calculated by entering evidence totals by strength in 
Supplemental Table 1 from Tavtigian et al.39, using the default settings: Prior Probability 
(Prior_P) = 0.100; Odds Path Very Strong = 350; Exponential progression (X) = 2.000. 
fThese column shows the Post_P value if a strong pathogenic criteria (PS3) or strong benign 
criteria (BS3) were to be added within the quantitative framework as described in (e). Box 
colors in (c-f) are coded by variant classification. BS3, well-established functional studies 
show no deleterious effect; EP, expert panel; LBEN, likely benign; LPATH, likely pathogenic; 
N/A, none applied; PS3, well established functional studies show a deleterious effect; VUS, 
variant of uncertain significance  
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 Of 137 missense variants curated, expert panels classified 20 as VUS across six 
genes (MYH7, HRAS, MAP2K2, PTPN11, RAF1, and SHOC2) and none of these VUS met 
strong, functional evidence criteria (PS3/BS3). We modeled how adding either PS3 or BS3 
criteria would affect the final variant classification, first using the categorical ACMG/AMP 
combining rules34 and then the quantitative system39. Eight non-conflicting VUS reached a 
likely pathogenic classification with the addition of PS3, and two reached a likely benign 
classification with the addition of BS3 (Figure 2.4). The addition of strong functional 
evidence did not affect the classification of seven non-conflicting VUS, as they either met 
only one supporting pathogenic criteria or none at all. In all, 10 out of 17 non-conflicting VUS 
(~59%) would be resolved with strong functional evidence using the categorical combining 
rules. It should be noted that this number does not include 3 missense variants that were 
VUS due to conflicting evidence. 
 In the Bayesian framework, two non-conflicting missense VUS (MAP2K2 
p.Val262Ile and RAF1 p.Val312Ala) reached a likely benign classification simply based on 
the evidence applied by expert panels (one supporting benign, BP4, in both cases). 
Modeling the addition of PS3, eight variants reached a likely pathogenic classification, 
consistent with the categorical assessment. Adding BS3 in the quantitative framework, 11 
out of 17 non-conflicting missense VUS reached a likely benign classification, including the 
two reclassified before adding functional criteria. In sum, 100% of the variants reached a 
different interpretation in at least one scenario (with either BS3 or PS3).  
Using the Bayesian adapted framework, we were also able to model how conflicting 
variant interpretations might change with the addition of strong functional evidence. We 
found that for conflicting missense variants with Post_P values from 0.100 to 0.500 
(interpreted as VUS in the Bayesian adaptation), adding BS3 reclassified them as likely 
benign, while the reciprocal (adding PS3) only returned likely pathogenic for one variant 




Figure 2.5: Expert-curated missense variants with conflicting evidence. aEvidence 
Satisfied, as determined by expert panels64,65, where abbreviations indicate specific criteria 
described in Richards et al.34. Boxes are colored according to evidence strength. bVariant 
listed by gene, cDNA, and protein. Variants were curated by expert panels using the 
following reference transcripts: SOS1 (NM_005633.3), PTPN11 (NM_002834.3), and MYH7 
(NM_000257.3). cExpert Panel (EP) Class as determined by CMP-EP or RAS-EP using 
modified categorical ACMG/AMP combining rules. dVariant class in Bayesian-adapted 
framework was determined by posterior probability of pathogenicity (Post_P). Post_P was 
calculated by entering evidence totals by strength in Supplemental Table 1 from Tavtigian et 
al.39, using the default settings: Prior Probability (Prior_P) = 0.100; Odds Path Very Strong = 
350; Exponential progression (X) = 2.000. e,fThese columns show the Post_P value if a 
strong pathogenic criteria (e) or strong benign criteria (f) were to be added within the 
quantitative framework as described in (d). Box colors in (c-f) are coded by variant 
classification. BS3, well-established functional studies show no deleterious effect; EP, 
expert panel; LBEN, likely benign; LPATH, likely pathogenic; N/A, none applied; PATH, 
pathogenic; PS3, well established functional studies show a deleterious effect; VUS, variant 
of uncertain significance 
 
Expert panel and quantitative approaches to conflicting evidence 
 Expert panels documented evidence in both pathogenic and benign categories for 
seven missense variants, with five in MYH7 and one each in SOS1 and PTPN11 (Figure 
2.5). Of these seven conflicting variants, the expert panels interpreted two as likely benign, 
one as likely pathogenic, one as pathogenic, and three as VUS. The quantitative Bayesian 
framework is congruent with these classifications with two exceptions. First, the CMP-EP 
interpreted MYH7 p.Ala893Val as likely pathogenic, but the combined evidence in the 
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quantitative framework only reached a Post_P of 0.5, and would be considered a VUS.  
Second, MYH7 variant p.Asn1327Lys was interpreted as VUS by the CMP-EP, but reached 
a Post_P of 0.012 and would be considered likely benign in the Bayesian adaptation of the 
combining rules. Interestingly, another MYH7 variant, p.Lys1459Asn, also met one 
supporting pathogenic (PP3) and one strong benign (BS1 instead of BS4) and reached a 
Post_P of 0.012. In this instance, the CMP-EP interpreted it as likely benign, indicating that 
they permitted BS1 to outweigh PP3 (thus over-riding the “conflicting evidence” guidance in 
the ACMG/AMP combining rules). Overall, expert panels determined a final, clinically 
significant variant interpretation for most variants with mixed evidence, and the quantitative 
approach to conflicting evidence generally agreed with these classifications. Interestingly, 
we also found that variant MYH7 p.Arg723Cys met pathogenic criteria regardless, indicating 
that with a Post_P of 1.000, even strongly weighted benign evidence would not be sufficient 
to alter its classification. 
 
2.4 Discussion 
The Untapped Potential of Functional Evidence 
 Functional assays are powerful tools for clinical variant interpretation as 
demonstrated here. Functional data would reclassify 97% of non-conflicting missense VUS 
evidence combinations globally in the categorical framework (Figure 2.3A). Interestingly, 
94% of those combinations would be reclassified if the data supports a pathogenic 
classification (PS3), while only 4% would be reclassified if the data supports a benign 
classification (BS3). In the quantitative evidence framework analysis, which also included 
conflicting missense VUS combinations, PS3 would reclassify 76% and BS3 would 
reclassify 63% of theoretical evidence combinations (Figure 2.3C).  
 We found that of the missense variants in the ten genes curated by expert panels, 17 
non-conflicting VUS met nine unique combinations of evidence. Six unique combinations 
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met by a total of ten variants (59%) could be reclassified with strong functional evidence in 
the categorical framework, while 100% could be reclassified in the quantitative analysis. 
Additionally, all non-conflicting missense variants deemed likely benign by expert panels 
would be benign with the addition of BS3, while the majority of variants deemed likely 
pathogenic would be reclassified as pathogenic with the addition of PS3 (Table 2.2, 
Supplemental material). The study of real-world genetic variants was limited by the number 
of variants with publicly available clinical interpretations that include the ACMG/AMP 
evidence codes used in curation. As such, we were unable to perform a gene-by-gene 
analysis, which may ultimately reveal gene-specific characteristics relevant to functional 
assay utility. Even so, this preliminary study does support the assertion that strong 
functional data has great potential to resolve variants relegated to VUS classification due to 
insufficient evidence (typically rare, missense variants). 
  
Bayesian quantitative analysis is important to resolve conflicting VUS 
 No standardized method exists within the current ACMG/AMP variant interpretation 
guidelines to classify variants meeting “conflicting” benign and pathogenic evidence as 
anything other than VUS39. Further, it is unclear what amount of evidence should be 
considered “conflicting” on either the pathogenic or the benign side. Meeting one strong 
pathogenic criterion (e.g. PS3) and one supporting benign criterion (e.g. BP4) is not the 
same as a variant meeting two strong, four moderate, and one supporting pathogenic 
criteria in “conflict” with only one supporting benign criterion (e.g. MYH7 p.Arg723Cys, 
Figure 2.5). There is lack of consensus on this issue, with different groups approaching 
conflicting evidence in their own ways. One clinical laboratory developed a hierarchical 
approach to conflicting variants that places more weight on clinical evidence than functional 
evidence44. An examination of the conflicting missense variants in Figure 2.5 identifies 
inconsistencies in consideration of evidence strength for an overall classification, even at the 
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level of disease experts. As previously noted, the CMP-EP weighed BS1 criteria more 
strongly than BS4 criteria, though Richards et al.34 and Tavtigian et al.39 treat them equally. 
 The recently described Bayesian framework provides a standardized, quantitative 
method for addressing these issues.39 Evidence of the same type and strength (e.g. PS3 
and PS4) are weighted equally, and a formula is provided that permits inclusion of evidence 
on both ends of the classification spectrum. As demonstrated in Figure 2.5, unlike the 
categorical framework, the Bayesian adaptation can model variant classification in the 
presence of both benign and pathogenic evidence. This has the potential to reclassify 
variants restricted to the VUS category based on “conflicting” evidence. Another useful 
application of the quantitative approach is identification of the types or strengths of evidence 
required to reach a particular classification. 
Quantifying the categorical combining rules: emerging inconsistencies 
 We entered each of the criteria met by the EP-curated non-conflicting missense 
variants into the Bayesian framework using the supplemental table in Tavtigian et al.39 and 
compared the resulting classifications to the EP class. While mostly consistent, we identified 
two instances that demonstrate the utility of comparison between the categorical and 
quantitative methods for combining evidence. First, two missense variants reached a likely 
benign classification using the Bayesian combining rules based on just one supporting 
benign piece of evidence (BP4 in both cases), while the EP interpreted them as VUS. This 
might reflect an inconsistency in the Bayesian adaptation of the ACMG/AMP combining 
rules, as Richards et al.34 requires at least two supporting benign criteria for a “likely benign” 
classification. It is possible that the prior probability assumption (Prior_P) or odds of 
pathogenicity (OddsPath) may need to be adjusted so that one supporting benign criterion 
returns a posterior probability in the range of VUS. Similarly, two variants in RAF1 
(p.Ser257Pro and p.Val263Gly) were interpreted as likely pathogenic by the RAS-EP, in 
agreement with the categorical combining rules. However, calculating the Post_P 
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demonstrates that two supporting and four moderate pathogenic criteria would be nearly 
sufficient to meet the pathogenic threshold at 0.994. This represents another inconsistency 
of the ACMG/AMP combining rules when adapted to the Bayesian model, suggesting that 
the ClinGen SVI should further evaluate combinations of evidence outside of those explicitly 
outlined by Richards et al.34 for future guideline revisions and recommendations.  
Challenges of assigning evidence strength to functional data 
 For reproducible variant interpretations, evidence must be applied consistently. 
Questions remain about how functional assays should qualify as “well-established” in the 
interpretation of clinical variants, resulting in inconsistent application of the PS3/BS3 
criteria.57 Richards et al.34 specify that assays validated in a Clinical Laboratory 
Improvement Amendments (CLIA) certified laboratory are the most well established. 
However, such validation does not necessarily indicate that the level of evidence supporting 
a pathogenic or benign interpretation is “strong” in the Bayesian quantitative sense for each 
assay or each variant. In addition, should equally compelling evidence from non-CLIA 
certified labs carry less weight? Further, as it is more difficult to appropriately apply the BS3 
criterion in variant interpretation, could curators downgrade the strength of BS3 for less 
comprehensive studies demonstrating no effect on the gene or gene product? A complete 
evaluation of a variant’s functional impact may require results from multiple experimental 
assays (e.g. splicing, protein stability, enzyme activity), though guidelines for integrating 
these data are vague. The ACMG/AMP guidelines outline strength stratifications for 
increasing evidence weight with segregation data (PP1), but do not include moderate 
strength or very strong benign criteria, so modifying BS3 strength poses challenges in the 
current categorical framework34. One consideration is that the categorical combining rules 
cannot be applied as written for moderate benign evidence, though by the Bayesian logic 
outlined by Tavtigian et al.39, moderate evidence is equivalent to the combined weight of two 
supporting criteria.  
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 Robust validation requires benchmarking results with variants of known clinical 
significance in order to determine the assay’s sensitivity and specificity. Other consortia 
such as the International Society for Gastrointestinal Hereditary Tumours (InSiGHT), the 
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), and 
the International Agency for Research on Cancer (IARC) already established this as a 
requirement for functional assay application42,56,75. This type of performance benchmarking 
permits the calculation of likelihood ratios that can then be converted to qualitative strengths 
(very strong, strong, moderate, or supporting) as described in the categorical ACMG/AMP 
framework, or directly applied as odds of pathogenicity in the Bayesian framework. This 
approach also would permit the stratification and consideration of multiple pieces of 
functional evidence in a single variant’s clinical interpretation, similar to how it is considered 
in the Sherloc adaptation described by Nykamp and colleagues44. The ClinGen SVI should 
work to address these questions as guidelines evolve and more expert panels adapt the 
guidelines for specific diseases and genes.  
Potential as prioritization method 
 The analysis presented here lays the groundwork for identifying genes and variants 
that stand to benefit the most from functional data and thus an evidence-based method for 
prioritizing assay development and validation. While methods of mass mutagenesis and 
variant evaluation have advanced substantially, permitting saturated variant assessment for 
relatively small genes like PPARG77, the processes involved in developing and validating a 
high-throughput assay are still costly and time-consuming. As such, an evidence-based 
method for prioritizing reclassification of the numerous clinically challenging VUS is 
necessary to best allocate resources and research efforts50. All of the genes examined by 
the CMP-EP and RAS-EP have at least one in vivo or in vitro assay approved for variant 
interpretation applications, yet few variants met PS3 or BS3 evidence criteria64,65. The VUS 
identified in Figure 2.4 that would benefit from the addition of strong functional evidence 
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should be prioritized for analysis using these approved methods. Further, as larger and 
more well annotated datasets become available, mining them for evidence codes applied in 
variant curation will provide a high-throughput, evidence-based method of prioritizing genes 
and variants for functional assessment, and will contextualize the importance of 
experimental evidence for meaningful clinical interpretation.  
 Finally, there is a strong need for a centralized database of approved functional 
assays and associated data to support curation efforts as we define what a “well validated” 
functional assay means. This type of database will be imperative for the next steps in 
prioritizing the reanalysis and functional assessment of VUS that stand to benefit most. As 
expert panels and others identify well-validated experimental assays for variant 
interpretation, they should be submitted to a central repository that links to the ClinGen 
Variant Curation Interface (https://curation.clinicalgenome.org) and to ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/).  
 
2.5 Supplemental material 
The following tables provide data for the expert variant curations, including the evidence 
satisfied for each variant, the overall classification in the categorical and Bayesian 






EP classified as pathogenic, met PS3a Evidence Satisfied (MET PS3)b Categoricalc Quantitativee 
Gene cDNA Amino Acid Variant 
Type 
PP PM PS PVS BP BS BA EP 
Class 
-PS3 Class Post_P 
PTPN11 c.794G>A p.Arg265Gln Missense 2 2 2 1 0 0 0 P P P 1.000 
BRAF c.770A>G p.Gln257Arg Missense 2 2 1 1 0 0 0 P P P 1.000 
BRAF c.1406G>A p.Gly469Glu Missense 2 2 1 1 0 0 0 P P P 1.000 
MAP2K1 c.389A>G p.Tyr130Cys Missense 2 2 1 1 0 0 0 P P P 1.000 
MYH7 c.2155C>T p.Arg719Trp Missense 1 3 4 0 0 0 0 P P P 1.000 
MYH7 c.1357C>T p.Arg453Cys Missense 1 2 4 0 0 0 0 P P P 1.000 
PTPN11 c.922A>G p.Asn308Asp   Missense 2 1 4 0 0 0 0 P P P 1.000 
HRAS c.34G>A p.Gly12Ser Missense 2 3 3 0 0 0 0 P P P 1.000 
MYH7 c.1208G>A p.Arg403Gln Missense 1 3 3 0 0 0 0 P P P 1.000 
RAF1 c.775T>A p.Ser259Thr Missense 4 2 3 0 0 0 0 P P P 1.000 
KRAS c.40G>A p.Val14Ile Missense 2 2 3 0 0 0 0 P P P 1.000 
PTPN11 c.1403C>T p.Thr468Met Missense 2 2 3 0 0 0 0 P P P 1.000 
SOS1 c.1642A>C p.Ser548Arg Missense 2 2 3 0 0 0 0 P P P 1.000 
SHOC2 c.4A>G p.Ser2Gly Missense 1 2 3 0 0 0 0 P P P 1.000 
BRAF c.736G>C p.Ala246Pro Missense 2 3 2 0 0 0 0 P P P 1.000 
BRAF c.1741A>G p.Asn581Asp Missense 2 2 2 0 0 0 0 P P P 1.000 
BRAF c.1787G>T p.Gly596Val Missense 2 2 2 0 0 0 0 P P P 1.000 
KRAS c.173C>T p.Thr58Ile Missense 2 2 2 0 0 0 0 P P P 1.000 
KRAS c.178G>C p.Gly60Arg Missense 2 2 2 0 0 0 0 P P P 1.000 
KRAS c.65A>G p.Gln22Arg Missense 2 2 2 0 0 0 0 P P P 1.000 
MAP2K2 c.383C>A p.Pro128Gln Missense 2 2 2 0 0 0 0 P P P 1.000 
PTPN11 c.188A>G p.Tyr63Cys Missense 2 2 2 0 0 0 0 P P P 1.000 
SOS1 c.322G>A p.Glu108Lys Missense 2 2 2 0 0 0 0 P P P 1.000 
MYH7 c.1594T>C p.Ser532Pro Missense 2 2 2 0 0 0 0 P LP P 1.000 
HRAS c.350A>G p.Lys117Arg Missense 1 2 2 0 0 0 0 P LP P 0.999 
RAF1 c.770C>T p.Ser257Leu Missense 1 2 2 0 0 0 0 P LP P 0.999 
MAP2K1 c.199G>A p.Asp67Asn Missense 2 1 2 0 0 0 0 P LP P 0.999 
PTPN11 c.1510A>G p.Met504Val Missense 2 1 2 0 0 0 0 P LP P 0.999 
RAF1 c.1837C>G p.Leu613Val Missense 1 1 2 0 0 0 0 P LP P 0.997 
KRAS c.458A>T p.Asp153Val Missense 0 1 2 0 0 0 0 P LP P 0.994 
MAP2K1 c.158T>C p.Phe53Ser Missense 2 3 1 0 0 0 0 P LP P 0.999 
MAP2K2 c.170T>G p.Phe57Cys Missense 2 3 1 0 0 0 0 P LP P 0.999 
SOS1 c.508A>G p.Lys170Glu Missense 2 3 1 0 0 0 0 P LP P 0.999 
SOS1 c.2536G>A p.Glu846Lys Missense 2 3 1 0 0 0 0 P LP P 0.999 
MAP2K2 c.401A>G p.Tyr134Cys Missense 2 2 1 0 0 0 0 P LP P 0.994 
PTPN11 c.417G>C p.Glu139Asp Missense 2 2 1 0 0 0 0 P LP P 0.994 
RAF1 c.768G>T p.Arg256Ser Missense 2 2 1 0 0 0 0 P LP P 0.994 
RAF1 c.1472C>T p.Thr491Ile Missense 2 2 1 0 0 0 0 P LP P 0.994 
RAF1 c.781C>T p.Pro261Ser Missense 1 2 1 0 0 0 0 P LP LP 0.988 
EP classified as likely benign with BS3a Evidence Satisfied (MET BS3)b Categoricald Quantitativee 
Gene cDNA Amino Acid Variant 
Type 
PP PM PS PVS BP BS BA EP 
Class 
-BS3 Class Post_P 
PTPN11 c.1678C>T p.Leu560Phe Missense 0 0 0 0 1 1 0 LB VUS LB 0.0028 
aExpert panel (EP)-curated variants that met either PS3 or BS3 functional criteria. The following reference transcripts were used: 
PTPN11 (NM_002834.3), BRAF (NM_004333.4), MAP2K1 (NM_002755.3), MYH7 (NM_000257.3), HRAS (NM_005343.2), RAF1 
(NM_002880.3), KRAS (NM_004985.4), SOS1 (NM_005633.3), SHOC2 (NM_007373.3), and MAP2K2 (NM_030662.3). 
bEvidence Satisfied, as determined by EPs64,65, shown as number satisfied in each category described in Richards et al.34 
c,d Final variant classification according to categorical ACMG/AMP combining rules34. EP variant classifications only consider evidence 
satisfied in (b). Categorical variant class if PS3 or BS3 had not been met are shown as “-PS3” in (c), or “-BS3” in (d).  
eVariant class according to the quantitative, Bayesian-adapted framework was determined by posterior probability of pathogenicity 
(Post_P). Post_P was calculated by entering evidence totals by strength in Supplemental Table 1 from Tavtigian et al.39, using the 
default settings: Prior Probability (Prior_P) = 0.100; Odds Path Very Strong = 350; Exponential progression (X) = 2.000. Each Post_P 
was then assigned a variant classification as follows: benign <0.001; 0.001 ≤ likely benign < 0.1; 0.1 ≤ VUS < 0.90; 0.90 ≤ likely 
pathogenic < 0.99; 0.99 ≤ pathogenic. BS3, well-established functional studies show no deleterious effect; EP, Expert Panel; LB, likely 
benign; LP, likely pathogenic; P, pathogenic; Post_P, posterior probability of pathogenicity; PS3, well established functional studies 
show a deleterious effect; VUS, variant of uncertain significance. 





EP classified as benigna Evidence Satisfied (no PS3/BS3)b Categoricalc Quantitativee 
Gene cDNA Amino Acid Variant Type PP PM PS PVS BP BS BA EP Class +PS3d +BS3d Class Post_P +PS3 Post_P +BS3 Post_P 
RAF1 c.119G>A p.Arg40His Missense 0 0 0 0 1 1 1 B CON B All of these meet BA1, which is not included 
in Bayesian framework described by 
Tavtigian et al.39 
BRAF c.1227A>G p.Ser409= Synonym. 0 0 0 0 3 0 1 B CON B 
SHOC2 c.1302C>T p.Asn434= Synonym. 0 0 0 0 3 0 1 B CON B 
SOS1 c.1230G>A p.Gln410= Synonym. 0 0 0 0 3 0 1 B CON B 
BRAF c.1433-19A>G n/a Intronic 1 0 0 0 2 0 1 B CON CON 
RAF1 c.1108+9_1108+21delGGGGCCCTCCCT
T 
n/a Intronic 0 0 0 0 2 0 1 B CON B 
HRAS c.257A>C p.Asn86Thr Missense 0 0 0 0 1 0 1 B CON B 
KRAS c.531_533delGAA p.Lys180del Deletion 0 0 0 0 1 0 1 B CON B 
MAP2K1 c.848C>T p.Ala283Val Missense 0 0 0 0 1 0 1 B CON B 
MAP2K1 c.694-8_694-7dupTC n/a Intronic 0 0 0 0 1 0 1 B CON B 
MAP2K2 c.844C>T p.Pro282Ser Missense 0 0 0 0 1 0 1 B CON B 
PTPN11 c.1658C>T p.Thr553Met Missense 0 0 0 0 1 0 1 B CON B 
SHOC2 c.10A>C p.Ser4Arg Missense 0 0 0 0 1 0 1 B CON B 
MYH7 c.327C>T p.Tyr109= Synonym. 0 0 0 0 1 0 1 B CON B 
MYH7 c.3036C>T p.Ala1012= Synonym. 0 0 0 0 1 0 1 B CON B 
MYH7 c.2162+4G>A n/a Intronic 0 0 0 0 1 0 1 B CON B 
BRAF c.968C>T p.Ser323Leu Missense 0 0 0 0 0 0 1 B CON B 
HRAS c.81T>C p.His27= Synonym. 0 0 0 0 0 0 1 B CON B 
KRAS c.519T>C p.Asp173= Synonym. 0 0 0 0 0 0 1 B CON B 
MAP2K2 c.1162C>T p.Arg388Trp Missense 0 0 0 0 0 0 1 B CON B 
PTPN11 c.525+12G>C n/a Intronic 0 0 0 0 0 0 1 B CON B 
PTPN11 c.854-32A>C n/a Intronic 0 0 0 0 0 0 1 B CON B 
PTPN11 c.925A>G p.Ile309Val Missense 0 0 0 0 0 0 1 B CON B 
RAF1 c.212A>G p.Asn71Ser Missense 0 0 0 0 0 0 1 B CON B 
SHOC2 c.38A>C p.Glu13Ala Missense 0 0 0 0 0 0 1 B CON B 
SOS1 c.749T>C p.Val250Ala Missense 0 0 0 0 0 0 1 B CON B 
SOS1 c.2122G>A p.Ala708Thr Missense 0 0 0 0 0 0 1 B CON B 
SOS1 c.73C>T p.Pro25Ser Missense 0 0 0 0 0 0 1 B CON B 
SOS1 c.2371C>A p.Leu791Ile Missense 0 0 0 0 0 0 1 B CON B 
SOS1 c.3032A>G p.Asn1011Ser Missense 0 0 0 0 0 0 1 B CON B 
BRAF c.64G>A p.Asp22Asn Missense 0 0 0 0 0 2 0 B CON B B 0.0003 LB 0.0059 B 0.00002 
EP classified as likely benigna Evidence Satisfied (no PS3/BS3)b Categoricalc Quantitativee 
Gene cDNA Amino Acid Variant Type PP PM PS PVS BP BS BA EP Class +PS3d +BS3d Class Post_P +PS3 Post_P +BS3 Post_P 
SOS1 c.350T>G p.Val117Gly Missense 1 0 0 0 1 1 0 LB CON CON LB 0.006 VUS 0.100 B 0.0003 
MYH7 c.4377G>T p.Lys1459Asn Missense 1 0 0 0 0 1 0 LB CON CON LB 0.012 VUS 0.188 B 0.0007 
SOS1 c.109A>G p.Thr37Ala Missense 0 0 0 0 2 1 0 LB CON B LB 0.001 LB 0.025 B 0.0001 
BRAF c.92C>G p.Ala31Gly Missense 0 0 0 0 1 1 0 LB CON B LB 0.003 LB 0.051 B 0.0002 
RAF1 c.66T>G p.Phe22Leu Missense 0 0 0 0 1 1 0 LB CON B LB 0.003 LB 0.051 B 0.0002 
HRAS c.510G>A p.Lys170= Synonym. 0 0 0 0 3 0 0 LB CON LB LB 0.012 VUS 0.188 B 0.0007 
BRAF c.111G>A p.Ser37= Synonym. 0 0 0 0 2 0 0 LB CON LB LB 0.025 VUS 0.325 LB 0.0014 
KRAS c.451-14T>C n/a Intronic 0 0 0 0 2 0 0 LB CON LB LB 0.025 VUS 0.325 LB 0.0014 
MAP2K2 c.*8C>T n/a 3' UTR 0 0 0 0 2 0 0 LB CON LB LB 0.025 VUS 0.325 LB 0.0014 





Gene cDNA Amino Acid Variant Type PP PM PS PVS BP BS BA EP Class +PS3d +BS3d Class Post_P +PS3 Post_P +BS3 Post_P 
MYH7 c.2539_2541delAAG p.Lys847del Deletion 1 2 1 0 0 0 0 LP P CON LP 0.988 P 0.999 VUS 0.812 
MYH7 c.2539A>G p.Lys847Glu Missense 1 2 1 0 0 0 0 LP P CON LP 0.988 P 0.999 VUS 0.812 
MYH7 c.3158G>A p.Arg1053Gln Missense 1 2 1 0 0 0 0 LP P CON LP 0.988 P 0.999 VUS 0.812 
MYH7 c.4066G>A p.Glu1356Lys Missense 1 2 1 0 0 0 0 LP P CON LP 0.988 P 0.999 VUS 0.812 
MAP2K1 c.275T>G p.Leu92Arg Missense 3 1 1 0 0 0 0 LP P CON LP 0.988 P 0.999 VUS 0.812 
MAP2K2 c.619G>A p.Glu207Lys Missense 3 1 1 0 0 0 0 LP P CON LP 0.988 P 0.999 VUS 0.812 
RAF1 c.1082G>C p.Gly361Ala Missense 3 1 1 0 0 0 0 LP P CON LP 0.988 P 0.999 VUS 0.812 
MYH7 c.5135G>A p.Arg1712Gln Missense 2 1 1 0 0 0 0 LP P CON LP 0.975 P 0.999 VUS 0.675 
MYH7 c.428G>A p.Arg143Gln Missense 1 1 1 0 0 0 0 LP P CON LP 0.949 P 0.997 VUS 0.500 
MYH7 c.3133C>T p.Arg1045Cys Missense 1 1 1 0 0 0 0 LP P CON LP 0.949 P 0.997 VUS 0.500 
MYH7 c.4130C>T p.Thr1377Met Missense 1 1 1 0 0 0 0 LP P CON LP 0.949 P 0.997 VUS 0.500 
MAP2K1 c.388T>C p.Tyr130His Missense 2 3 0 0 0 0 0 LP P CON LP 0.975 P 0.999 VUS 0.675 
RAF1 c.769T>C p.Ser257Pro Missense 2 4 0 0 0 0 0 LP P CON P 0.994 P 1.000 VUS 0.900 
RAF1 c.788T>G p.Val263Gly Missense 2 4 0 0 0 0 0 LP P CON P 0.994 P 1.000 VUS 0.900 
MYH7 c.1106G>A p.Arg369Gln Missense 0 4 0 0 0 0 0 LP P CON LP 0.975 P 0.999 VUS 0.675 
MAP2K2 c.400T>C p.Tyr134His Missense 3 3 0 0 0 0 0 LP P CON LP 0.988 P 0.999 VUS 0.812 
MYH7 c.2608C>T p.Arg870Cys Missense 2 3 0 0 0 0 0 LP P CON LP 0.975 P 0.999 VUS 0.675 
MYH7 c.2678C>T p.Ala893Val Missense 1 3 0 0 0 1 0 LP CON CON VUS 0.500 LP 0.949 LB 0.051 
MYH7 c.2791_2793delGAG p.Glu931del Deletion 1 3 0 0 0 0 0 LP P CON LP 0.949 P 0.997 VUS 0.500 
MYH7 c.1157A>G p.Tyr386Cys Missense 1 3 0 0 0 0 0 LP P CON LP 0.949 P 0.997 VUS 0.500 
HRAS c.175G>A p.Ala59Thr Missense 4 2 0 0 0 0 0 LP P CON LP 0.975 P 0.999 VUS 0.675 
BRAF c.1595G>A p.Cys532Tyr Missense 2 2 0 0 0 0 0 LP P CON LP 0.900 P 0.994 VUS 0.325 
MAP2K1 c.169A>C p.Lys57Gln Missense 2 2 0 0 0 0 0 LP P CON LP 0.900 P 0.994 VUS 0.325 
MYH7 c.3658_3660delGAG p.Glu1220del Deletion 2 2 0 0 0 0 0 LP P CON LP 0.900 P 0.994 VUS 0.325 
MYH7 c.5401G>A p.Glu1801Lys Missense 2 2 0 0 0 0 0 LP P CON LP 0.900 P 0.994 VUS 0.325 
MYH7 c.5740G>A p.Glu1914Lys Missense 2 2 0 0 0 0 0 LP P CON LP 0.900 P 0.994 VUS 0.325 
PTPN11 c.155C>T p.Thr52Ile Missense 2 2 0 0 0 0 0 LP P CON LP 0.900 P 0.994 VUS 0.325 
MYH7 c.4258C>T p.Arg1420Trp Missense 1 2 0 0 0 0 0 LP LP CON VUS 0.812 LP 0.988 VUS 0.188 
MYH7 c.5726G>C p.Arg1909Pro Missense 1 2 0 0 0 0 0 LP LP CON VUS 0.812 LP 0.988 VUS 0.188 
EP classified as pathogenica Evidence Satisfied (no PS3/BS3)b Categoricalc Quantitativee 
Gene cDNA Amino Acid Variant Type PP PM PS PVS BP BS BA EP Class +PS3d +BS3d Class Post_P +PS3 Post_P +BS3 Post_P 
MAP2K2 c.169T>G p.Phe57Val Missense 2 2 0 1 0 0 0 P P CON P 1.000 P 1.000 P 0.994 
MYH7 c.2167C>T p.Arg723Cys Missense 1 4 2 0 1 0 0 P CON CON P 1.000 P 1.000 P 0.999 
MYH7 c.1207C>T p.Arg403Trp Missense 1 3 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.997 
MYH7 c.2146G>A p.Gly716Arg Missense 1 3 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.997 
MYH7 c.2156G>A p.Arg719Gln Missense 1 3 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.997 
MYH7 c.2167C>G p.Arg723Gly Missense 1 3 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.997 
BRAF c.1785T>G p.Phe595Leu Missense 3 2 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.997 
PTPN11 c.1529A>C p.Gln510Pro Missense 3 2 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.997 
HRAS c.37G>T p.Gly13Cys Missense 2 2 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.994 
SOS1 c.806T>C p.Met269Thr Missense 2 2 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.994 
SOS1 c.1654A>G p.Arg552Gly Missense 2 2 2 0 0 0 0 P P CON P 1.000 P 1.000 P 0.994 
MYH7 c.788T>C p.Ile263Thr Missense 1 2 2 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.988 
MYH7 c.2722C>G p.Leu908Val Missense 1 2 2 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.988 
MYH7 c.1988G>A p.Arg663His Missense 0 2 2 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.975 
MYH7 c.2609G>A p.Arg870His Missense 0 2 2 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.975 
MYH7 c.2717A>G p.Asp906Gly Missense 0 2 2 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.975 




MYH7 c.2221G>C p.Gly741Arg Missense 2 4 1 0 0 0 0 P P CON P 1.000 P 1.000 P 0.994 
MYH7 c.1358G>A p.Arg453His Missense 1 4 1 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.988 
MYH7 c.2221G>T p.Gly741Trp Missense 1 4 1 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.988 
HRAS c.173C>T p.Thr58Ile Missense 3 3 1 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.988 
BRAF c.730A>C p.Thr244Pro Missense 2 3 1 0 0 0 0 P P CON P 0.999 P 1.000 LP 0.975 
PTPN11 c.781C>T p.Leu261Phe Missense 1 3 1 0 0 0 0 P  P CON P 0.997 P 1.000 LP 0.949 
MYH7 c.1750G>C p.Gly584Arg Missense 1 3 1 0 0 0 0 P P CON P 0.997 P 1.000 LP 0.949 
MYH7 c.2681A>G p.Glu894Gly Missense 1 3 1 0 0 0 0 P P CON P 0.997 P 1.000 LP 0.949 
MYH7 c.2207T>C p.Ile736Thr Missense 0 3 1 0 0 0 0 P P CON P 0.994 P 1.000 LP 0.900 
KRAS c.101C>T p.Pro34Leu Missense 2 2 1 0 0 0 0 P P CON P 0.994 P 1.000 LP 0.900 
MYH7 c.2513C>T p.Pro838Leu Missense 2 2 1 0 0 0 0 P P CON P 0.994 P 1.000 LP 0.900 
KRAS c.15A>T p.Lys5Asn Missense 2 2 1 0 0 0 0 P P CON P 0.994 P 1.000 LP 0.900 
EP classified as VUSa Evidence Satisfied (no PS3/BS3)b Categoricalc Quantitativee 
Gene cDNA Amino Acid Variant Type PP PM PS PVS BP BS BA Class +PS3d +BS3d Class Post_P +PS3 Post_P +BS3 Post_P 
MYH7 c.732+1G>A n/a Splice donor 1 2 0 0 0 0 0 VUS LP CON VUS 0.812 LP 0.988 VUS 0.188 
MYH7 c.3169G>A p.Gly1057Ser Missense 1 2 0 0 0 0 0 VUS LP CON VUS 0.812 LP 0.988 VUS 0.188 
MYH7 c.1477_1478delAT p.Met493fs Frameshift 0 2 0 0 0 0 0 VUS LP CON VUS 0.675 LP 0.975 VUS 0.100 
MYH7 c.4588C>T p.Arg1530* Nonsense 0 2 0 0 0 0 0 VUS LP CON VUS 0.675 LP 0.975 VUS 0.100 
RAF1 c.1193G>T p.Arg398Leu Missense 2 1 0 0 0 0 0 VUS LP CON VUS 0.675 LP 0.975 VUS 0.100 
MYH7 c.4276G>A p.Glu1426Lys Missense 2 1 0 0 0 0 0 VUS LP CON VUS 0.675 LP 0.975 VUS 0.100 
MYH7 c.5302G>A p.Glu1768Lys Missense 2 1 0 0 0 0 0 VUS LP CON VUS 0.675 LP 0.975 VUS 0.100 
MYH7 c.5329G>A p.Ala1777Thr Missense 2 1 0 0 0 0 0 VUS LP CON VUS 0.675 LP 0.975 VUS 0.100 
MYH7 c.5588G>A p.Arg1863Gln Missense 2 1 0 0 0 0 0 VUS LP CON VUS 0.675 LP 0.975 VUS 0.100 
MYH7 c.4354-7C>T n/a Intronic 1 1 0 0 1 0 0 VUS CON CON VUS 0.325 LP 0.900 LB 0.025 
HRAS c.277A>G p.Ile93Val Missense 1 1 0 0 0 0 0 VUS LP CON VUS 0.500 LP 0.949 LB 0.051 
MYH7 c.2360G>A p.Arg787His Missense 0 1 0 0 1 0 0 VUS CON CON VUS 0.188 VUS 0.812 LB 0.012 
SHOC2 c.519G>A p.Met173Ile Missense 0 1 0 0 0 0 0 VUS LP CON VUS 0.325 LP 0.900 LB 0.025 
PTPN11 c.244A>G p.Met82Val Missense 1 0 0 0 1 0 0 VUS CON CON VUS 0.100 VUS 0.675 LB 0.006 
MYH7 c.3981C>A p.Asn1327Lys Missense 1 0 0 0 0 1 0 VUS CON CON LB 0.012 VUS 0.188 B 0.0007 
MAP2K2 c.281C>T p.Ser94Leu Missense 1 0 0 0 0 0 0 VUS VUS CON VUS 0.188 VUS 0.812 LB 0.012 
MYH7 c.3286G>T p.Asp1096Tyr Missense 1 0 0 0 0 0 0 VUS VUS CON VUS 0.188 VUS 0.812 LB 0.012 
MYH7 c.3578G>A p.Arg1193His Missense 1 0 0 0 0 0 0 VUS VUS CON VUS 0.188 VUS 0.812 LB 0.012 
MYH7 c.5326A>G p.Ser1776Gly Missense 1 0 0 0 0 0 0 VUS VUS CON VUS 0.188 VUS 0.812 LB 0.012 
MAP2K2 c.784G>A p.Val262Ile Missense 0 0 0 0 1 0 0 VUS CON LB LB 0.051 VUS 0.500 LB 0.003 
RAF1 c.935T>C p.Val312Ala Missense 0 0 0 0 1 0 0 VUS CON LB LB 0.051 VUS 0.500 LB 0.003 
MYH7 c.3382G>A p.Ala1128Thr Missense 0 0 0 0 0 0 0 VUS VUS VUS VUS 0.100 VUS 0.675 LB 0.006 
MYH7 c.4909G>A p.Ala1637Thr Missense 0 0 0 0 0 0 0 VUS VUS VUS VUS 0.100 VUS 0.675 LB 0.006 
MYH7 c.5704G>C p.Glu1902Gln Missense 0 0 0 0 0 0 0 VUS VUS VUS VUS 0.100 VUS 0.675 LB 0.006 
SHOC2 c.-1C>T n/a 5' UTR 0 0 0 0 0 0 0 VUS VUS VUS VUS 0.100 VUS 0.675 LB 0.006 
aExpert panel (EP)-curated variants that met neither PS3 or BS3 functional criteria, grouped by EP classification. Reference transcripts used: PTPN11 (LRG_614t1, intronic variants; 
NM_002834.3, all others), BRAF (LRG_299t1, intronic variants; NM_004333.4, all others), MAP2K1 (LRG_725t1, intronic variants; NM_002755.3, all others), MYH7 (LRG_384t1, intronic and 
splice variants; NM_000257.3, all others), HRAS (NM_005343.2), RAF1 (LRG_413t1, intronic variants; NM_002880.3, all others), KRAS (NC_000012.12, intronic variants; NM_004985.4, all 
others), SOS1 (NM_005633.3), SHOC2 (LRG_753t1, 5’ UTR variants; NM_007373.3, all others), and MAP2K2 (LRG_750t1, 3’ UTR variants; NM_030662.3, all others). bEvidence Satisfied, as 
determined by EPs64,65, shown as number satisfied in each category described in Richards et al.34 cFinal variant classification according to categorical ACMG/AMP combining rules34. EP variant 
classifications only consider evidence satisfied in (b). dVariant class with the addition of either PS3 or BS3 criteria in the categorical framework. eVariant class in the quantitative, Bayesian-adapted 
framework, determined by posterior probability of pathogenicity (Post_P). The last four columns show variant classification according to Post_P if strong pathogenic criteria (PS3) or strong benign 
criteria (BS3) were to be added within the quantitative framework. B, benign; CON, conflicting; EP, Expert Panel; LB, likely benign; LP, likely pathogenic; n/a, not available; P, pathogenic; Post_P, 
posterior probability of pathogenicity; Synonym., synonymous; UTR, untranslated region; VUS, variant of uncertain significance. 





CHAPTER 3: RECOMMENDATIONS FOR APPLICATION OF THE FUNCTIONAL 
EVIDENCE PS3/BS3 CRITERION USING THE ACMG/AMP SEQUENCE VARIANT 
INTERPRETATION FRAMEWORK 3 
3.1 Background 
The American College of Medical Genetics (ACMG) and the Association for 
Molecular Pathology (AMP) jointly developed standards and guidelines for assessment of 
evidence to increase consistency and transparency in clinical variant interpretation34. One 
type of evidence defined in this guideline was the effect of a variant on gene/protein function 
as determined by a “well-established” functional assay, which provides strong support of a 
pathogenic or benign impact (rule codes PS3 and BS3, respectively). The full definition is 
provided in Table 3.1. Functional studies can provide powerful insight into the effect of a 
variant on protein function and have the capacity to reclassify variants of uncertain 
significance (VUS) 78, underscoring the need for experimental evidence to be applied 
accurately and consistently in variant interpretation. However, the ACMG/AMP standards did 
not provide detailed guidance on how functional evidence should be evaluated, and 
differences in application of the PS3/BS3 codes represent a major contributor to variant 
interpretation discordance among clinical laboratories57. 
  
 
3This chapter previously appeared as an article in Genome Medicine. The original citation is as 
follows: Brnich SE, Abou Tayoun AN, Couch FJ, Cutting GR, Greenblatt MS, Heinen CD, Kanavy 
DM, Luo X, McNulty SM, Starita LM, Tavtigian SV, Wright MW, Harrison SM, Biesecker LG, Berg JS; 
Clinical Genome Resource Sequence Variant Interpretation Working Group. Recommendations for 
application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant 
interpretation framework. Genome Med. 2019 Dec 31; 12(1):3. doi: 10.1186/s13073-019-0690-2. 
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“Functional studies can be a powerful tool in support of pathogenicity; however, not all 
functional studies are effective in predicting an impact on a gene or protein function. For 
example, certain enzymatic assays offer well-established approaches to assess the 
impact of a missense variant on enzymatic function in a metabolic pathway (e.g., α-
galactosidase enzyme function). On the other hand, some functional assays may be less 
consistent predictors of the effect of variants on protein function. To assess the validity of 
a functional assay, one must consider how closely the functional assay reflects the 
biological environment. For example, assaying enzymatic function directly from biopsied 
tissue from the patient or an animal model provides stronger evidence than expressing 
the protein in vitro. Likewise, evidence is stronger if the assay reflects the full biological 
function of the protein (e.g., substrate breakdown by an enzyme) compared with only one 
component of function (e.g., adenosine triphosphate hydrolysis for a protein with 
additional binding properties). Validation, reproducibility, and robustness data that assess 
the analytical performance of the assay and account for specimen integrity, which can be 
affected by the method and time of acquisition, as well as storage and transport, are 
important factors to consider. These factors are mitigated in the case of an assay in a 
Clinical Laboratory Improvement Amendments laboratory–developed test or commercially 
available kit. Assays that assess the impact of variants at the messenger RNA level can 
be highly informative when evaluating the effects of variants at splice junctions and within 
coding sequences and untranslated regions, as well as deeper intronic regions (e.g., 
messenger RNA stability, processing, or translation). Technical approaches include direct 
analysis of RNA and/or complementary DNA derivatives and in vitro minigene splicing 
assays.” 
Table 3.1: Text of Original ACMG/AMP Recommendation for Functional Assays,  
Reproduced with Permission 34  
 
In response to calls to further standardize variant interpretation57,79, the Clinical 
Genome Resource (ClinGen) established the Sequence Variant Interpretation Working 
Group (SVI)80 and condition-specific Variant Curation Expert Panels (VCEPs) to refine 
ACMG/AMP guidelines for each evidence criterion63. As of June 2019, six VCEPs have 
published recommendations, including their assay validation requirements and which 
assays were ultimately approved for PS3/BS3 evidence application64–67,69,70. VCEP-
approved assays varied greatly and included splicing assays, animal and cellular models, 
and different in vitro systems71. VCEPs generally approved assays that considered the 
disease mechanism and most included wild-type controls, but statistical analyses and the 
inclusion of other controls were less consistent. The VCEPs vary significantly in how they 
defined which assays were “well-established”71, including consideration of parameters such 
as experimental design, replication, controls, and validation, indicating the subjective nature 
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of assessing the quality and applicability of functional evidence, potentially leading to 
discordance in variant classification.  
In this manuscript, we detail additional guidance developed by the SVI regarding 
assessment of the clinical validity of functional studies and a provisional framework for the 
determination of suitable evidence strength levels, with the goal that experimental data cited 
as evidence in clinical variant interpretation meets a baseline quality level. We expect to 
further refine these approaches in collaboration with VCEPs as they apply these 
recommendations moving forward. 
 
3.2 Methods 
In November 2018, during the monthly SVI Working Group conference call, we first 
outlined our goals of defining what constitutes a well-established functional assay and how 
functional assay evidence should be structured for computation and curation. In this 
meeting, we presented a preliminary approach to curating functional evidence and important 
considerations for assay validation. This process was subsequently presented at the 
ClinGen Steering Committee in-person meeting in Seattle, WA, in December 2018 for 
comments and further refinement. The proposed PS3/BS3 evaluation process was then 
discussed on the SVI Working Group call in March 2019 and again in-person at the 
American College of Medical Genetics and Genomics (ACMG) meeting in April 2019. 
Subsequently, a smaller subgroup developed a final version of these recommendations, 
incorporating feedback from ClinGen biocurators and VCEPs, which were then approved by 
the SVI Working Group. 
We used curated functional evidence from VCEP-developed rule specifications71 and 
expert opinions throughout the PS3/BS3 criterion refinement process. Feedback from the 
broader SVI working group, ClinGen Steering Committee, and outside experts were 
incorporated into the recommendations at multiple stages of development. 
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To estimate the magnitude of evidence strength that is appropriate for a given assay 
in the absence of rigorous statistical analysis, we estimated the Odds of Pathogenicity 
(OddsPath) that could be obtained for a theoretical assay that evaluated various numbers of 
previously classified controls (see Supplemental material, Tables 3.4 and 3.5). We treated 
the proportion of pathogenic variants in the overall modeled data as a prior probability (P1), 
and the proportion of pathogenic variants in the groups with functionally abnormal or 
functionally normal readouts as posterior probabilities (P2). The stringency of the thresholds 
determining an abnormal versus normal readout is related to the confidence in the assay 
result. We initially estimated an optimistic OddsPath that could be achieved by a perfect 
binary classifier, where the readout for all control variants tested is consistent with the 
variant interpretation (Table 3.4). We then sought to estimate a more conservative 
OddsPath for imperfect assays where one of the control variants had an intermediate or 
indeterminate readout, but the remaining pathogenic and benign controls would have 
readouts concordant with their classification (Table 3.5)81,82. To circumvent posterior 
probabilities of zero or infinity, and to account for the possibility that the next variant tested 
in the assay might have a discordant result, we added exactly one misclassified variant to 
each set83. The OddsPath was estimated for each as: OddsPath=[P2 x (1- P1)] / [(1- P2) x 
P1]84. Each OddsPath was then equated with a corresponding level of evidence strength 
(supporting, moderate, strong, very strong) according to the Bayesian adaptation of the 
ACMG/AMP variant interpretation guidelines39. 
 
3.3 Points to consider and general recommendations 
Physiologic context 
The genetic construct and context being evaluated in an assay are important 
considerations for determining appropriateness for clinical variant interpretation. The assay 
material being utilized (e.g., patient-derived sample, model organism, cellular in vivo or in 
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vitro system) should be taken into account when evaluating the validity of a functional assay. 
When using patient-derived samples, a functional assay evaluates a broader genetic and 
physiologic background (other variants in cis and in trans, epigenetic effects, cell type, 
assay conditions, etc.). For conditions inherited in an autosomal recessive pattern, biallelic 
variants are required, often in a loss of function mechanism where the penetrance and 
expressivity of disease manifestations may depend on thresholds of overall protein activity 
that reflect the cellular/biochemical phenotype arising from a combination of variants and 
potentially other cellular gene products. In this case, it will be important to distinguish the 
overall protein activity levels that cause different phenotypes (severe versus mild disease) 
from the functional assay results that would qualify for variant-level evidence toward a 
pathogenic or benign interpretation. If a variant is known to be homozygous (either by 
segregation analysis or exclusion of a large deletion in trans), and can be evaluated in 
multiple unrelated individuals, functional assay evidence from patient-derived material can 
be interpreted with greater confidence. 
 
Recommendation 1: Functional evidence from patient-derived material best reflects 
the organismal phenotype and, in general, it would be better to use this evidence to satisfy 
PP4 (specific phenotype) and to delineate the expected disease phenotype in patients with 
certain combinations of variants or homozygous variants with known pathogenicity. If the 
curator decides to proceed with evaluating an assay performed in patient-derived material, 
the level of strength applied should be determined based on validation parameters (see 
below). In the context of a VCEP, gene-specific guidance should include the required 
number of unrelated individuals in whom the variant has been tested, in order for the 
evidence to qualify for variant interpretation.  
 
Typically, model organisms are used to implicate the role of a gene in a disease 
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(e.g., the gene is deleted, interrupted, or an artificial mutation is made to recapitulate a 
phenotype as evidence of the genetic etiology). Issues related to cost and throughput have 
typically limited the generation of extensive allelic series intended for the purpose of clinical 
variant interpretation. In addition, it can be challenging to assess how well the model 
organism reflects human anatomy/physiology/genetic context, or whether the full phenotype 
must necessarily be recapitulated in order to satisfy the functional evidence criteria. The 
genome of the organism may include an orthologous gene (having equivalent or similar 
function), or the model organism may lack relevant homologs that affect the phenotype in 
humans, thus affecting the degree to which an artificially introduced genetic variant can 
cause a relevant phenotype. Even within a given species, measurable phenotypes can vary 
depending on the genetic background of the organism (e.g., compensatory variation) and 
therefore studies using more than one strain or line would be preferable, further increasing 
the cost of such assays. Therefore, the recommendations herein will primarily focus on 
cellular and biochemical in vivo or in vitro assays, which are commonly encountered in 
laboratory evaluations of variants implicated in human disease. 
 
Recommendation 2: From the point of view of clinical variant interpretation, 
evaluation of functional evidence from model organisms should take a nuanced approach, 
considering the caveats described above. If model organism data are to be used in variant 
interpretation, the strength of evidence should be adjusted based on the rigor and 
reproducibility of the overall data provided. 
 
Molecular consequence 
 The nature of the variant and the context in which it is studied can significantly affect 
the assay readout. The effect of the variant on the expressed gene product must be 
carefully considered when determining the clinical validity of an assay that utilizes an 
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artificially engineered variant. For example, CRISPR-introduced genetic variants in an 
otherwise normal genomic context will use the endogenous cellular transcriptional and 
splicing machinery, although off-target effects must be carefully considered. In contrast, 
transient expression of cDNA constructs, which usually contain artificial promoters and other 
regulatory sequences that can result in variant overexpression, should be carefully 
standardized using controls to ensure that the overexpression does not mask the true 
effects of variants. Nonsense and frameshift variants that result in premature termination 
codons before the 3’-most 50 nucleotides of the penultimate exon are expected to undergo 
nonsense-mediated decay (NMD) and eliminate the mRNAs85,86; therefore, studying such 
variants in the context of cDNA or systems where NMD is not active may not reflect the 
endogenous situation. Similarly, the effects of a nucleotide substitution or other in-frame 
variant on splicing cannot be assessed using a cDNA construct. On the other hand, when 
the variant results in an expressed protein with an in-frame deletion or a single nucleotide 
substitution, an engineered cDNA construct may reasonably reflect the functional impact, at 
least at the protein level.  
 
Recommendation 3: While testing variants in a more natural genomic context is 
preferable, it is not a requirement of a well-validated assay. Instead, one should consider 
how the approach impacts the interpretation of the results and take into account whether the 
study controls for these limitations when assigning strength of evidence. 
 
Since an individual functional assay may not fully capture all gene or protein 
functions relevant to disease pathogenesis, a “normal” result in a laboratory assay may 
simply reflect that the functional effect of the specific variant was not suitably assayed in the 
experiment. Therefore, in order to determine when, and at what strength, to apply the BS3 
criterion, it is essential to understand how well the assay captures the molecular 
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consequence of the variant and its impact on the expressed protein or functional domain. A 
more complete assessment of protein function permits scoring the result as having a benign 
effect, whereas an assay that is limited to a specific domain or functional readout may 
provide less strong evidence for having a benign effect. It should also be noted that a 
missense or synonymous variant that does not affect protein function might still have a 
negative impact by introducing a cryptic splice site87. These caveats should be taken into 
account when deciding whether to apply BS3, and at what strength.  
Messenger RNA splicing is a complex process, and clinical variant interpretation can 
take into account both predictive and laboratory evidence. RNA splicing assays, developed 
using the endogenous genomic context, or using artificial mini-gene assays, can be useful to 
determine the impact of variants on splicing integrity. However, unlike protein assays, the 
readout (e.g., exon skipping, or intron retention) does not necessarily correlate with protein 
function. For example, abnormal splicing of the last exon might lead to a truncated protein 
whose function is still intact. In general, abnormal splicing can have heterogenous outcomes 
with respect to mRNA fate and the protein-reading frame. Abnormally spliced transcripts 
might undergo NMD, while other abnormal transcripts can lead to a shortened or truncated 
protein with or without functional consequences.73 The relative transcript abundance of 
various splice isoforms in different cell types may also affect the downstream 
pathophysiological impact. 
Because RNA splicing assays do not provide a direct measure of protein function, 
additional recommendations are needed to determine the applicability of splicing assays to 
satisfy PS3/BS3 versus PVS1 (loss-of-function). For canonical ±1,2 splice variants, PVS1 
application is based on the predicted impact of a variant on mRNA stability and protein-
reading frame whereas a functional assay may conclusively demonstrate abnormal splicing 
and confirm a loss of function impact. Additional data and considerations are needed to 
determine the appropriate aggregate strength of PVS1 and PS3 in the scenario that 
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functional data is present and supports PVS1 application. Similarly, splicing assays could be 
used to bolster support for in silico predictions for variants outside the canonical ±1,2 splice 
sites. An SVI subgroup is currently working on recommendations for the incorporation of 
predictive and functional evidence of altered splicing into the ACMG/AMP framework.  For 
variants impacting protein length that are not predicted to lead to loss-of-function, such as 
in-frame exon skipping due to abnormal splicing or a large in-frame deletion, the change in 
protein length alone could be used to justify application of PM4, while application of 
PS3/BS3 could also be appropriate if a functional assay examined the protein function of the 
resulting product.  
 
Terminology 
Standardized, structured language can improve communication and transparency 
across clinical laboratories, physicians, and patients. Uniform terminology should be used to 
describe the readout of a laboratory assay of protein function and document the curation of 
functional evidence. As such, the variant-level results of functional assays should not be 
categorized as “pathogenic” or “benign,” since these falsely equate functional impact with a 
clinical determination that involves a number of other evidence lines. In addition, terms 
describing assay results as “deleterious”, or “damaging” can be confusing since their 
meanings are greatly context-dependent and generally only apply when loss of function is 
the mechanism of disease. For example, in conditions where the mechanism involves gain 
of function, a variant may be damaging or deleterious to the organism but not to protein 
activity as measured in a functional assay. Establishing standardized language to describe 
assay readout is an important step to prevent the misinterpretation of published data and to 
reduce inter-laboratory discordance with respect to PS3/BS3 application57,88. 
 
Recommendation 4: The terms “functionally normal” or “functionally abnormal” 
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should be used to describe the functional impact of a variant as measured in a given assay. 
Further granular specifications should be used to describe the “functionally abnormal” 
impact (i.e., complete loss of function, partial loss of function/intermediate 
effect/hypomorphic, gain of function, dominant-negative) as outlined by Spurdle, et al.88 The 
final assessment of the evidence should take into account both the functional effect in the 
assay and the mechanism of disease (see below). 
 
CLIA laboratory developed tests 
The 2015 ACMG/AMP guidelines assert that “functional studies that have been 
validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting 
are considered to be the most well established”34. All tests conducted in a Clinical 
Laboratory Improvement Amendments (CLIA) laboratory or with a commercially available kit 
are subject to analytical validation for in-house use. However, these assays should also be 
evaluated for the strength of evidence based on the controls used, as detailed below. One 
should also consider that in vitro assays developed in CLIA laboratories that are conducted 
with patient samples for diagnostic use89 may not necessarily provide variant-level evidence 
relevant to interpretation (see Recommendation 1, above). Data from research laboratories 
are not subjected to specific regulatory oversight and thus may be validated to different 
degrees, though any in vivo or in vitro study can satisfy PS3/BS3 criteria with a strong level 
of evidence if it demonstrates the appropriate validation.  
 
Recommendation 5: The entity performing a functional assay should not govern 
whether PS3/BS3 criteria are satisfied, or at what strength. This determination should be 
based primarily on the validation of the assay, including the use of appropriate laboratory 




Experimental controls and clinical validation controls 
Good laboratory practice is essential for application of functional evidence in clinical 
variant interpretation. Every experiment should include internal controls that demonstrate 
the dynamic range of the assay (e.g., the readout of the assay with wild type and null effect). 
In some cases, the readout may be normalized to a wild type value, which should generally 
be run in the same conditions as the variants being tested to avoid a batch effect. Well-
conducted experiments typically use technical replicates that control for the random 
differences associated with protocol or instrument-associated variation, to demonstrate 
reproducibility of the result within a given experiment. Similarly, biological replicates (e.g., 
different colonies, cells, aliquots, or animals) are included to control for random biological 
variation in parallel measures of unique biological samples and to demonstrate 
reproducibility of the result between instances of the same experiment. Biological replicates 
are more important for understanding the variance within a population, while technical 
replicates can reduce measurement error90. 
Furthermore, well-validated assays are benchmarked by including known pathogenic 
and known benign variants that establish the ranges of assay readout for these classes of 
variants and define the thresholds beyond which the result can be considered functionally 
abnormal, indeterminate, or functionally normal. It is important to note that the clinical 
interpretation of these validation control variants should reach a pathogenic/likely 
pathogenic or benign/likely benign interpretation using lines of evidence independent of 
functional data, so as to avoid circularity in defining the assay’s predictive value. The 
number of controls required depends on the dynamic range of the assay and the variance of 
each replicate; controls should also be relevant to the disease mechanism (such as gain-of-
function or loss-of-function) and the type of variant under consideration (e.g., missense 
controls for evaluating missense variants of uncertain significance). For genes associated 
with multiple disorders through different mechanisms, an assay validated for one disorder 
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may not necessarily be applied universally to analyze variant effect in other disorders if the 
mechanisms of disease are different. Variants in the Genome Aggregation Database 
(gnomAD)91 that have population allele frequencies exceeding the threshold for BA1 or BS1, 
but have not yet been added to the Clinical Variant Database (ClinVar), could serve as a 
source of benign controls. Additionally, one could consider if pathogenic or benign controls 
from different genes related via a disease mechanism and functional pathway could be used 
at a lesser strength of evidence.  
Many previously published assays do not identify known benign or known pathogenic 
variant controls, or may have only tested a few variant controls in the same assay. To 
address this, it may be possible for analysts to assemble these controls from multiple 
specific instances of the same general class of assay. Any tested variant that could be 
classified as likely benign/benign (LB/B) or likely pathogenic/pathogenic (LP/P) without 
functional criteria would qualify as a control for the determination of evidence strength. The 
assay readout for each of these variants, as tested across multiple instances of the same 
general class of assay, can be plotted together in order to set thresholds for normal, 





Figure 3.1: Assembly of variant controls to set readout thresholds for normal and 
abnormal function. Readout values across multiple specific instances of the same type can 
be plotted for any tested variant that reaches a likely benign/benign (LB/B) or likely 
pathogenic/pathogenic (LP/P) classification without PS3 or BS3 criteria. Each point on the 
plot represents the assay readout from a specific instance of an assay for the variant listed 
on the x-axis. Multiple points for the same variant indicate that the variant was tested in 
multiple specific instances of the same general class of assay. In this example, all LB/B 
variant controls (B1-B6) had readouts above 60%, with the exception of variant B6. When 
setting a readout threshold above which the readout is considered normal function, curators 
may draw this threshold at 60% and consider B6 to have an indeterminate readout. All LP/P 
variant controls (P1-P5) had readouts below 30%, with the exception of one specific 
instance for variant P1. With just 1 LB/B control variant with an indeterminate readout from a 
total of 11 variant controls (6 LB/B and 5 LP/P), PS3_moderate can be applied to variants 
with a readout indicating abnormal function and BS3_moderate can be applied to variants 
with a readout indicating normal function (Table 3.4). Variants of uncertain significance 
(VUS) tested on the same class of assay are plotted in the middle of the graph (indicated by 
light gray shading). VUS1 has an assay readout in the range of LB/B controls and would be 
above the threshold for normal function, so BS3_moderate could be applied. VUS3 has an 
assay readout consistent with LP/P control variants, below the threshold for abnormal 
function, so PS3_moderate could be applied. VUS2 has an indeterminate assay readout, so 
































































3.4 Provisional framework for functional evidence evaluation and application 
 The SVI Working Group recommends that evaluators use a four-step process to 
determine the applicability and strength of evidence of functional assays for use in clinical 
variant interpretation: 1. Define the disease mechanism; 2. Evaluate applicability of general 
classes of assays used in the field; 3. Evaluate validity of specific instances of assays; 4. 
Apply evidence to individual variant interpretation. Unlike the ACMG/AMP guidelines 34, in 
which well-established functional studies can provide a default “strong” level of evidence 
(PS3/BS3), the SVI recommends that evaluation of functional assays should start from the 
assumption of no evidence, and that increasing clinical validation can allow application of 
evidence in favor of a pathogenic or benign interpretation at a level of strength (supporting, 
moderate, strong) concomitant with the demonstrated validation metrics as described below. 
 
1. Define the disease mechanism 
 In order for functional assays to be useful in clinical variant interpretation, the 
underlying gene-disease mechanism must be reasonably well understood. The VCEP or 
individual interpreting variants in a given gene should first delineate this mechanism to 
determine what functional assays can be considered applicable. This is an important first 
step since some genes are associated with different diseases depending on the mechanism 
(e.g., gain-of-function vs. loss-of-function). A structured narrative using ontologies or other 
specific terms can be used to describe the gene-disease mechanism (Table 3.2). 
 
2. Evaluate applicability of general classes of assays used in the field  
 Next, the general types or classes of assays used in the field should be defined and 
documented, including the model system, experimental method, and functional outcome 
being evaluated. The defined gene-disease mechanism should guide an evaluation of how 
well a general class of assay models pathogenesis (e.g., loss of function, gain of function, 
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specific pathway output, etc.). Relative strengths and weaknesses of the model system 
should be assessed and disease-specific assertions regarding the appropriateness of 
animal, cellular, and in vitro models should be addressed (see above: physiologic context, 
molecular consequence). The purpose of this step is to delineate the types of assays that 
are deemed appropriate (if sufficiently validated) for use in clinical variant interpretation. It is 
important to reiterate that the strength of evidence is not determined by the class of assay 
but rather by the validation metrics (specified in step three). 
 For expert groups that are establishing gene-specific guidance, we also recommend 
that they refrain from making blanket statements limiting the general classes of assay that 
are deemed valid or applicable, and should not cap the strength of evidence based on the 
class of assay. In some cases, a VCEP may wish to endorse a particular type of assay that 
could be used for variant interpretation if developed in the future.  
 
1. Gene name: HUGO Gene Nomenclature Committee (HGNC) gene symbols 92 
2. Associated disease: Monarch Disease Ontology (MONDO) terms93 
3. Mode of inheritance: structured MONDO terms  
a) Autosomal dominant (HP:0000006) 
b) Autosomal recessive (HP:0000007) 
c) Mitochondrial (HP:0001427) 
d) X-linked (HP:0001417) 
e) Undetermined (HP:0000005) 
4. Molecular mechanism of disease pathogenesis 
a) Loss-of-function 
b) Gain-of-function 
c) Dominant negative 
5. Biological pathways: Gene Ontology (GO) terms 94,95 
Table 3.2: Components of the structured narrative describing the gene-disease 




Figure 3.2: Decision tree for evaluation of functional data for clinical variant 
interpretation. The SVI Working Group recommends that evaluators use a four-step 
process to determine the applicability and strength of evidence of functional assays for use 
in clinical variant interpretation (evidence codes PS3/BS3): 1. Define the disease 
mechanism; 2. Evaluate applicability of general classes of assay used in the field; 3. 
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3. Evaluate validity of specific instances of assays 
 For the general classes of assay that are deemed applicable, the curator should next 
evaluate specific instances of those assays as performed by various groups. Many different 
laboratories may generate functional evidence using the same general class of assay, but 
given the differences in the specific methods used and the level of validation provided by 
each group, evaluation of each individual assay iteration is required before data can be 
applied in a clinical interpretation (see above section on experimental controls and clinical 
validation controls). Assays having sufficient numbers of validation controls to calculate 
positive predictive value or determine the OddsPath provide the most robust functional 
assay evidence39. Without this level of clinical validation, the predictive value of the assay is 
limited. A provisional framework for this evaluation is shown in Figure 3.2.  
• Functional evidence should not be applied in the following scenarios unless 
the dynamic range of the assay and the thresholds for defining a functionally 
normal, indeterminate, or functionally abnormal result are extremely well 
understood:  
o Assays that do not include both negative (normal or wild-type) and 
positive (abnormal or null) controls. 
o Assays that do not include technical and/or biological replicates. 
• Supporting level evidence in favor of pathogenicity (PS3_supporting) or 
benign interpretation (BS3_supporting) may be applied in the following 
scenarios: 
o Assays that include experimental controls and replicates but have 10 
or fewer validation controls to assess the ability of the assay readout 
to distinguish pathogenic from benign variants (Table 3.5). 
o Classes of assays that have been broadly accepted historically, 
previously validated, or provided as a kit with defined performance 
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characteristics, but where controls and replicates are not documented 
for the specific instance of the assay. 
• Moderate level evidence in favor of pathogenicity (PS3_moderate) or benign 
interpretation (BS3_moderate) may be applied in the following scenarios: 
o Assays with at least 11 total validation controls including a mix of 
benign and pathogenic variants, but no formal statistical analysis of 
the ability to discriminate between pathogenic and benign variants 
(Table 3.5) 
• Any level of evidence in favor of pathogenicity may be applied when rigorous 
statistical analysis enables a formal OddsPath to be calculated, with the 
strength of evidence correlating to the calculated OddsPath (Table 3.3).  
• Evidence in favor of a benign interpretation up to a strong level (BS3) may be 
applied when rigorous statistical analysis enables a formal OddsPath to be 
calculated, with the strength of evidence correlating to the calculated 
OddsPath (Table 3.3). 









Table 3.3: Evidence strength equivalent of Odds of Pathogenicity. *Since there are no 
moderate strength benign evidence codes included in the Richards, et al.34 guidance, 
moderate level evidence is equivalent to two instances of supporting-level benign evidence39 
 
VCEPs should document the specific assay instances that qualify (and why) and the 
specific instances of assays that do not qualify (and why). Documentation should include 
PMID or other universal reference to the source of the assay evaluated (e.g., DOI), the type 
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of assay readout (qualitative/quantitative) and units, the range of assay results that qualify 
for a given strength of evidence according to level of validation as above, and the range in 
which the assay result is indeterminate with respect to PS3/BS3. 
 
4. Apply evidence to individual variant interpretation 
Once the specific instance of an assay has been evaluated as a whole, the results from that 
assay for a given variant can be applied as evidence in variant interpretation.  
• If the assay demonstrates a functionally abnormal result consistent with the 
mechanism of disease, the PS3 criterion can be applied at a level of strength 
based on the degree of validation detailed above.  
• If the assay demonstrates a functionally normal result, the BS3 criterion can 
be applied at a level of strength based on the degree of validation detailed 
above. 
• Variants demonstrating an intermediate level of impact on function merit 
special consideration, as this could be because the assay does not fully 
reflect the protein function (decreasing strength applied to the assertion), or 
may provide evidence supporting a hypomorphic or partial loss-of-function 
effect, such as in a condition with incomplete penetrance and/or less severe 
expressivity. Consideration of disease mechanism should help guide the 
appropriate level of strength to be applied for these types of variants. 
When PS3/BS3 are applied by any variant analyst, documentation of the supporting 
evidence should reference the strength of clinical validation of the functional assay. 
 
Stacking Evidence 
 When multiple functional assay results are available for a single variant (different 
instances of the same class of assay performed by different laboratories, or multiple lines of 
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evidence from different classes of assay), the evaluator should apply evidence from the 
assay that is the most well-validated and best measures the disease mechanism. 
• For a variant analyzed by multiple assays (belonging to the same or different class): 
o If the results are consistent (both show a functionally abnormal effect, or both 
show a functionally normal effect), apply PS3/BS3 at the level of strength 
appropriate for the most well-validated assay. 
o If the results are conflicting, the assay that most closely reflects the disease 
mechanism and is more well-validated can override the conflicting result of 
the other and evidence should be applied at the strength indicated by the 
assay’s validation parameters. If the assays are essentially at the same level 
of validation, conflicting functional evidence should not be used in the 
interpretation of the variant. 
• The committee did not reach consensus on whether results from different classes of 
functional assay could be combined (e.g. applying two pieces of supporting level 
evidence from different assay classes to reach PS3_moderate). The primary concern 
with this approach is that it is extremely difficult to ascertain that two assays are 
measuring independent functions and that this would lead to double counting the 
same evidence regarding variant function. Another concern is that stacking evidence 
from multiple assays could lead to a conflated interpretation of the disease risk for a 
particular variant (e.g. two PS3_supporting could be interpreted as concordant 
evidence that the variant confers moderate disease risk; alternatively, two 
PS3_supporting results could stack to PS3_moderate as a high-risk variant). On the 
other hand, if the assays are measuring different functions, the evidence may be 
complementary and increase confidence in the overall result, especially for the 
assertion of BS3 criteria. Variant curators and expert groups will need to decide how 







 This provisional framework for the evaluation and application of functional evidence 
in clinical variant interpretation represents the first important steps towards reducing 
discordance in the use of PS3/BS3 criteria. Moving forward, this approach will be tested with 
a range of diverse disorders in collaboration with ClinGen VCEPs. We recognize that many 
historical publications may not meet the specifications outlined here, which will limit our 
ability to apply these assays as strong evidence in the ACMG/AMP variant interpretation 
framework, though they may still qualify for supporting-level evidence if performed rigorously 
and with appropriate laboratory controls. The applicability of these recommendations for rare 
diseases with small numbers of known pathogenic variants will also need to be tested. As 
always, clinical laboratories will need to make a judgement call about the rigor, 
reproducibility, and clinical validation of any piece of available functional evidence and 
determine its strength, hopefully adhering to the spirit of these recommendations even if the 
specific circumstances do not permit the analytic process suggested here. Undoubtedly, 
many other kinds of evidence will be re-weighted as the ACMG/AMP guidelines are revised 
and this provisional framework will evolve alongside these updates. 
 
Bayesian adaptation 
As the field moves to develop assays with sufficient controls and validation to permit 
the calculation of an OddsPath, more quantitative approaches for stacking evidence and 
assigning evidence strength may be adopted, as outlined in the Bayesian adaptation of the 
ACMG/AMP variant interpretation framework39. This quantitative method will reconcile 
conflicting benign and pathogenic evidence, which is common when considering the results 
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of multiple functional assays, and will help reduce the number of VUS. Furthermore, many 
assays provide continuous quantitative measures of protein function, and converting their 
numeric readout to a binary PS3/BS3 interpretation can obscure the richness of those data. 
Using a more quantitative Bayesian system could convert raw data to OddsPath that more 
completely capture the assay results. This would be especially useful for hypomorphic 
variants that have an intermediate effect on normal protein function. 
 
Multiplexed functional assays 
While typical functional assays cited as evidence in variant curations analyze 
relatively few variants71, new multiplexed assays can analyze thousands of variants in a 
single experiment77,96,97. This kind of increased throughput facilitates the reproducibility, 
replication, and assay calibration using many definitive pathogenic and benign variant 
controls. These metrics are required to determine assay sensitivity and specificity, which can 
then guide the interpretation of assay readout according to thresholds set by known benign 
and known pathogenic variant performance. Similarly, thresholds could be drawn based on 
OddsPath to apply different strengths of evidence based on the specific assay result. 
Multiplexed assays are still heavily dependent upon the existence of well-characterized 
pathogenic and benign variants for assay validation. The availability of allelic variant controls 
may be limited for some genes, but threshold determination may still be feasible depending 
on the assay’s dynamic range and the distribution of results relative to null and wild-type 
controls (including variants with high allele frequency incompatible with a pathogenic role for 
rare Mendelian diseases). In the future, these large datasets of functional evidence could be 
ingested into the Variant Curation Interface (VCI) or Evidence Repository and made 
available to variant curators in an automated fashion alongside pre-determined thresholds 
for interpretation and strength assignment, expediting the curation process. Such an 
automated repository could re-assess sensitivity and specificity automatically as more 
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variants are added. It is important to note that even if the functional data reach an OddsPath 
equivalent to very strong evidence, the functional evidence criteria are not stand-alone 
evidence for either a benign or pathogenic classification and at least one other evidence 
type (e.g., PS4, prevalence in affected individuals is significantly increased relative to 
controls) is required to reach a pathogenic classification. 
 
Prioritization methods for functional assay development and validation 
 As it is time-consuming and expensive to develop and sufficiently validate novel 
functional assays, effort and resources should be directed to have the greatest clinical 
benefit. One could prioritize assays that would examine genes with the greatest number of 
genetic tests performed or individuals tested annually, or focus on the genes with the 
greatest proportion of VUS that could be adjudicated with functional evidence78. 
Alternatively, one could focus on genes associated with highly actionable conditions, where 
a change in variant interpretation might dramatically change medical management (e.g., 
BRCA2 VUS would be reclassified as likely pathogenic with functional evidence, leading to 
increased early surveillance and recommendations regarding cancer prophylaxis and 
management).  
We hope that these recommendations will help develop productive partnerships with 
basic scientists who have developed functional assays that are useful for interrogating the 
function of a variety of different genes98. Realistically, many researchers may not envision a 
use for their assays in clinical variant interpretation, and may not recognize the need for 
extensive validation when applying this evidence clinically (nor possess the expertise to 
independently determine the clinical interpretation of variants in the gene of interest). We 
look forward to partnerships between VCEPS and basic scientists to apply the results of in 
vitro and in vivo tests in clinical variant interpretation. Publishing and/or submitting these 
results to ClinGen along with appropriate documentation of validation and thresholds for 
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interpretation will greatly enhance curation and application of these data. Greater awareness 
of the validation requirements, especially the use of an allelic series containing known 
pathogenic and known benign variants to evaluate the predictive value of the assay, may 
enable such assays to be used for clinical interpretation more broadly in the future. 
 
3.6 Supplemental material 
The following two tables model the OddsPath and strength of evidence based on the 
number of known benign and known pathogenic variants tested and the ability of the assay 
to correctly classify those variants, either as a perfect binary (normal/abnormal) readout 
(Table 3.4) or permitting one variant control (either benign or pathogenic) to have an 










OddsPath=[P2 x (1- 
P1)] / [(1- P2) x P1]  




normal Pathogenic Benign Pathogenic Benign 
6 3 3 0.50 3 3 0.75 0.25 3.0 0.333 
  2 4 0.33 2 4 0.67 0.20 4.0 0.500 
  4 2 0.67 4 2 0.80 0.33 2.0 0.250 
8 4 4 0.50 4 4 0.80 0.20 4.0 0.250 
  3 5 0.38 3 5 0.75 0.17 5.0 0.333 
  5 3 0.63 5 3 0.83 0.25 3.0 0.200 
10 5 5 0.50 5 5 0.83 0.17 5.0 0.200 
  4 6 0.40 4 6 0.80 0.14 6.0 0.250 
  6 4 0.60 6 4 0.86 0.20 4.0 0.167 
20 10 10 0.50 10 10 0.91 0.09 10.0 0.100 
  8 12 0.40 8 12 0.89 0.08 12.0 0.125 
  12 8 0.60 12 8 0.92 0.11 8.0 0.083 
30 15 15 0.50 15 15 0.94 0.06 15.0 0.067 
  12 18 0.40 12 18 0.92 0.05 18.0 0.083 
  18 12 0.60 18 12 0.95 0.08 12.0 0.056 
40 20 20 0.50 20 20 0.95 0.05 20.0 0.050 
  16 24 0.40 16 24 0.94 0.04 24.0 0.063 
  24 16 0.60 24 16 0.96 0.06 16.0 0.042 
50 25 25 0.50 25 25 0.96 0.04 25.0 0.040 
  20 30 0.40 20 30 0.95 0.03 30.0 0.050 
  30 20 0.60 30 20 0.97 0.05 20.0 0.033 
100 50 50 0.50 50 50 0.98 0.02 50.0 0.020 
  40 60 0.40 40 60 0.98 0.02 60.0 0.025 
  60 40 0.60 60 40 0.98 0.02 40.0 0.017 
200 100 100 0.50 100 100 0.99 0.01 100.0 0.010 
  80 120 0.40 80 120 0.99 0.01 120.0 0.013 
  120 80 0.60 120 80 0.99 0.01 80.0 0.008 
300 150 150 0.50 150 150 0.99 0.01 150.0 0.0067 
  120 180 0.40 120 180 0.99 0.01 180.0 0.0083 
  180 120 0.60 180 120 0.99 0.01 120.0 0.0056 
500 250 250 0.50 250 250 1.00 0.00 250.0 0.0040 
  200 300 0.40 200 300 1.00 0.00 300.0 0.0050 
  300 200 0.60 300 200 1.00 0.00 200.0 0.0033 
750 375 375 0.50 375 375 1.00 0.00 375.0 0.0027 
  300 450 0.40 300 450 1.00 0.00 450.0 0.0033 
  450 300 0.60 450 300 1.00 0.00 300.0 0.0022 
1000 500 500 0.50 500 500 1.00 0.00 500.0 0.0020 
  400 600 0.40 400 600 1.00 0.00 600.0 0.0025 
  600 400 0.60 600 400 1.00 0.00 400.0 0.0017 
The “+1 proportions” column essentially "adds 1.0" to the numerator and denominator in order to do the OddsPath 
calculation. Odds of Pathogenicity and strength equivalents: <0.0029 (BS2_very strong^), <0.053 (BS3), <0.23 
(BS3_moderate*), <0.48 (BS3_supporting), 0.48-2.1 (Indeterminate), >2.1 (PS3_supporting), >4.3 (PS3_moderate), >18.7 
(PS3), >350 (PS3_very strong). ^Very strong benign included only for modeling purposes as there are no very strong benign 
criteria in Richards et al.34 *BS3_moderate is equivalent to 2 instances of supporting-level benign evidence. 
Table 3.4 Odds of Pathogenicity (OddsPath) estimates for a perfect binary readout. 
Table modeling the Odds of Pathogenicity and strength of evidence based on the number of 
known benign and known pathogenic variants tested and the ability of the assay to correctly 












OddsPath=[P2 x (1- P1)] / 
[(1- P2) x P1]  
Total Pathogenic Benign Abnormal Indeterminate Normal Pathogenic Benign Pathogenic Benign 
5 1 4 0.20 1 1 3 0.50 0.25 4.0 1.333 
  2 3 0.40 2 1 2 0.67 0.33 3.0 0.750 
  2 3 0.40 1 1 3 0.50 0.25 1.5 0.500 
  3 2 0.60 3 1 1 0.75 0.50 2.0 0.667 
  3 2 0.60 2 1 2 0.67 0.33 1.3 0.333 
  4 1 0.80 3 1 1 0.75 0.50 0.8 0.250 
6 1 5 0.17 1 1 4 0.50 0.20 5.0 1.250 
  2 4 0.33 2 1 3 0.67 0.25 4.0 0.667 
  2 4 0.33 1 1 4 0.50 0.20 2.0 0.500 
  3 3 0.50 3 1 2 0.75 0.33 3.0 0.500 
  3 3 0.50 2 1 3 0.67 0.25 2.0 0.333 
  4 2 0.67 4 1 1 0.80 0.50 2.0 0.500 
  4 2 0.67 3 1 2 0.75 0.33 1.5 0.250 
  5 1 0.83 4 1 1 0.80 0.50 0.8 0.200 
7 1 6 0.14 1 1 5 0.50 0.17 6.0 1.200 
  2 5 0.29 2 1 4 0.67 0.20 5.0 0.625 
  2 5 0.29 1 1 5 0.50 0.17 2.5 0.500 
  3 4 0.43 3 1 3 0.75 0.25 4.0 0.444 
  3 4 0.43 2 1 4 0.67 0.20 2.7 0.333 
  4 3 0.57 4 1 2 0.80 0.33 3.0 0.375 
  4 3 0.57 3 1 3 0.75 0.25 2.3 0.250 
  5 2 0.71 5 1 1 0.83 0.50 2.0 0.400 
  5 2 0.71 4 1 2 0.80 0.33 1.6 0.200 
  6 1 0.86 5 1 1 0.83 0.50 0.8 0.167 
8 1 7 0.13 1 1 6 0.50 0.14 7.0 1.167 
  2 6 0.25 2 1 5 0.67 0.17 6.0 0.600 
  2 6 0.25 1 1 6 0.50 0.14 3.0 0.500 
  3 5 0.38 3 1 4 0.75 0.20 5.0 0.417 
  3 5 0.38 2 1 5 0.67 0.17 3.3 0.333 
  4 4 0.50 4 1 3 0.80 0.25 4.0 0.333 
  4 4 0.50 3 1 4 0.75 0.20 3.0 0.250 
  5 3 0.63 5 1 2 0.83 0.33 3.0 0.300 
  5 3 0.63 4 1 3 0.80 0.25 2.4 0.200 
  6 2 0.75 6 1 1 0.86 0.50 2.0 0.333 
  6 2 0.75 5 1 2 0.83 0.33 1.7 0.167 
  7 1 0.88 6 1 1 0.86 0.50 0.9 0.143 
10 1 9 0.10 1 1 8 0.50 0.11 9.0 1.125 
  2 8 0.20 2 1 7 0.67 0.13 8.0 0.571 
  2 8 0.20 1 1 8 0.50 0.11 4.0 0.500 
  3 7 0.30 3 1 6 0.75 0.14 7.0 0.389 
  3 7 0.30 2 1 7 0.67 0.13 4.7 0.333 
  4 6 0.40 4 1 5 0.80 0.17 6.0 0.300 
  4 6 0.40 3 1 6 0.75 0.14 4.5 0.250 
  5 5 0.50 5 1 4 0.83 0.20 5.0 0.250 
  5 5 0.50 4 1 5 0.80 0.17 4.0 0.200 
  6 4 0.60 6 1 3 0.86 0.25 4.0 0.222 
  6 4 0.60 5 1 4 0.83 0.20 3.3 0.167 
  7 3 0.70 7 1 2 0.88 0.33 3.0 0.214 
  7 3 0.70 6 1 3 0.86 0.25 2.6 0.143 
  8 2 0.80 8 1 1 0.89 0.50 2.0 0.250 
  8 2 0.80 7 1 2 0.88 0.33 1.8 0.125 
  9 1 0.90 1 1 8 0.50 0.11 0.1 0.014 
11 1 10 0.09 1 1 9 0.50 0.10 10.0 1.111 
  2 9 0.18 2 1 8 0.67 0.11 9.0 0.563 
  2 9 0.18 1 1 9 0.50 0.10 4.5 0.500 
  3 8 0.27 3 1 7 0.75 0.13 8.0 0.381 
  3 8 0.27 2 1 8 0.67 0.11 5.3 0.333 
  4 7 0.36 4 1 6 0.80 0.14 7.0 0.292 
  4 7 0.36 3 1 7 0.75 0.13 5.3 0.250 
  5 6 0.45 5 1 5 0.83 0.17 6.0 0.240 
  5 6 0.45 4 1 6 0.80 0.14 4.8 0.200 
  6 5 0.55 6 1 4 0.86 0.20 5.0 0.208 
  6 5 0.55 5 1 5 0.83 0.17 4.2 0.167 
  7 4 0.64 7 1 3 0.88 0.25 4.0 0.190 
  7 4 0.64 6 1 4 0.86 0.20 3.4 0.143 
  8 3 0.73 8 1 2 0.89 0.33 3.0 0.188 
  8 3 0.73 7 1 3 0.88 0.25 2.6 0.125 
  9 2 0.82 9 1 1 0.90 0.50 2.0 0.222 
  9 2 0.82 8 1 2 0.89 0.33 1.8 0.111 
  10 1 0.91 9 1 1 0.90 0.50 0.9 0.100 
The “+1 proportions” column essentially "adds 1.0" to the numerator and denominator in order to do the OddsPath calculation. Odds of Pathogenicity and 
strength equivalents: <0.0029 (BS2_very strong^), <0.053 (BS3), <0.23 (BS3_moderate*), <0.48 (BS3_supporting), 0.48-2.1 (Indeterminate), >2.1 
(PS3_supporting), >4.3 (PS3_moderate), >18.7 (PS3), >350 (PS3_very strong). ^Very strong benign included only for modeling purposes as there are no 
very strong benign criteria in Richards et al.34 *BS3_moderate is equivalent to 2 instances of supporting-level benign evidence. 
Table 3.5 Odds of Pathogenicity (OddsPath) estimates for a perfect binary readout. 
Odds of Pathogenicity and evidence strength estimated by number and performance of 
known benign and known pathogenic variants tested, permitting one variant control (either 




CHAPTER 4: A VALIDATED FUNCTIONAL ANALYSIS OF PALB2 MISSENSE 
VARIANTS FOR USE IN CLINICAL VARIANT INTERPRETATION 
4.1 Introduction 
Detection of germline genetic variants has increased with the rise of clinical genetic 
testing.34,37,45 Yet, the rarity of many variants limits the evidence available to determine if a 
variant is pathogenic or benign, leading to many “variant of uncertain significance” (VUS) 
classifications. VUS cannot guide clinical decisions, complicating post-test patient 
counseling and management.50–52 Laboratory tests of a variant’s functional impact can 
potentially aid reclassification50,78, but require benchmarking against variants with definitive 
interpretations to have sufficient predictive power for clinical use.99 
Even among genes with clear links to disease and well-understood functions, VUS 
account for a large amount of total identified variation. For example, many of the genes 
implicated in hereditary breast cancer have known roles in homology-directed repair (HR) of 
DNA double-strand break (DSB) repair under normal conditions, but the clinical 
interpretation of missense variation in these genes remains a challenge. In one such gene, 
PALB2 (Partner and Localizer of BRCA2), ~50% of all clinically identified variants in the 
Clinical Variant database (ClinVar) are VUS and ~90% of VUS are missense variants.47 
 For high-fidelity repair of DSBs via HR, the coiled-coil (CC) regions in BRCA1 and 
PALB2 must first interact to stably localize PALB2 to the sites of DNA double-strand 
breaks.17,100 In turn, the PALB2 WD40 domain interacts with BRCA2 and RAD51 to form a 
complex directing the use of a homologous template strand to correctly repair 
DSBs.13,15,18,100 As such, PALB2 acts as the “molecular scaffold” in the BRCA1-PALB2-
BRCA2 complex.17 PALB2 homodimers can also form through self-interaction of the CC 
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domain, preventing heterodimerization with BRCA1 and potentially regulating HR 
efficiency.101,102 Defects in HR can lead to repair via alternative non-homologous end-joining 
(alt-NHEJ), an error-prone mechanism that leads to small inserts and deletions.14,19,20  
 Truncating (nonsense and frameshift) variants comprise the majority of pathogenic 
variation in PALB2 and demonstrate HR defects, relying instead on error-prone alt-NHEJ for 
DNA damage repair (DDR). As such, tumors with germline PALB2, BRCA1, and BRCA2 
defects demonstrate a pattern of genome-wide instability and a higher mutational 
burden.21,22 Recent reports show some missense PALB2 variants may also be pathogenic, 
but thus far functional studies have lacked sufficient benchmarking controls for validated use 
in clinical variant interpretation.28–31 Other hereditary cancer genes in the HR pathway have 
been sufficiently well-studied and have good benchmarking controls. For example, in 
BRCA2, missense variants have been characterized by their capacity for HR following 
induced DNA DSBs using a fluorescent reporter assay where green fluorescent protein 
(GFP) served as a marker for HR.32 Benign variants retain HR capacity and thus strongly 
express GFP, while pathogenic variants defective for HR do not. The established BRCA2 
benign and pathogenic variants used in developing this assay constitute a gold standard 
panel for functional assay validation.33 We evaluated whether this BRCA2 missense panel 
could benchmark a DDR assay for PALB2. 
4.2 Materials and methods 
Plasmids, cloning, and siRNA 
Human N-terminal, FLAG-tagged PALB2 was a gift from Daniel Durocher (pDEST-
FRT/T0-FLAG-PALB2, plasmid #71114, Addgene, Watertown, MA, USA)103. Human wild-
type (WT) BRCA2 was obtained from pcDNA3 236HSC WT (BRCA2), a gift from Mien-Chie 
Hung (#16246, Addgene)104. BRCA2 was then Gateway cloned into pDONR221 (kind gift of 
Jeff Sekelsky).  
attB sites were introduced by touchdown, gradient polymerase chain reaction (PCR), 
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using the following primers: 
B2_attbF ggggacaagtttgtacaaaaaagcaggctccaccatgcctattggatccaaa 
B2_attbR ggggaccactttgtacaagaaagctgggtattagatatattttttagt 
This was followed by stitching PCR and restriction digest/ligation using Acl-I and SphI-HF 
sites to generate a complete attB-PCR product. BP recombination reaction was performed 
according to manufacturer protocol (Thermo Fisher Scientific, Waltham, MA, USA). To 
standardize plasmid delivery across genes, pDONR221-BRCA2 was then subcloned into 
pDEST-FRT/T0-FLAG by LR reaction, according to manufacturer protocol (Thermo Fisher 
Scientific). Constructs were confirmed by Sanger sequencing (Genewiz, Morrisville, NC, 
USA) (see Table 4.2 in supplemental material for primer sequences). 
The BRCA2 and PALB2 constructs were made siRNA resistant by introducing three 
silent mutations with the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, Cedar 
Creek, TX, USA), according to the manufacturer’s protocol. For BRCA2, siRNA resistance 
was conferred with the following silent mutations: c.4773T>C, c.4779A>G, c.4785G>A. For 
PALB2, siRNA resistance was achieved with the following silent mutations: c.1635A>G, 
c.1641C>A, c.1647C>T. The sequences of the site-directed mutagenesis primers used to 
confer siRNA resistance are as follows: 
BRCA2 forward: gctgccccaaagtgcaaagagatgcaaaattctctcaataatg 
BRCA2 reverse: cattattgagagaattttgcatctctttgcactttggggcag 
PALB2 forward: ggtccaaggaagaggtcacatcacataaatatcagcacg 
PALB2 reverse: cgtgctgatatttatgtgatgtgacctcttccttggacc 
The siPALB2 target sequence was GAAGUCACCUCACACAAAU (D-012928-04, 
Dharmacon, Lafayette, CO, USA) and siBRCA2 target sequence was 
GUAAAGAAAUGCAGAAUUC (D-003462-02, Dharmacon).105 As a control in all knockdown 




AUGUAUUGGCCUGUAUUAG, AUGAACGUGAAUUGCUCAA (D-001206-13-05, 
Dharmacon). As a positive control, we used siRNA against the human ubiquitin B (UBB) 
gene, which results in cell death upon knockdown. The siUBB control pool targeted the 
following sequences: GCCGUACUCUUUCUGACUA, GUAUGCAGAUCUUCGUGAA, 
GACCAUCACUCUGGAGGUG, and CCCAGUGACACCAUCGAAA (M-013382-01-005, 
Dharmacon). 
All variants were generated in the siRNA-resistant constructs using the same site-
directed mutagenesis kit as above. All clones were confirmed by sequencing at Genewiz. 
Sequences of primers used for Sanger confirmation are provided as supplemental material 
(Table 4.2). For a list of all variants tested and corresponding mutagenesis primers, see 
Table 4.3 and Table 4.4 in the supplemental material.  
Cell culture and Traffic Light Reporter (TLR) cell line generation 
 HEK293T/17 cells were purchased from American Type Culture Collection (ATCC) 
(Old Town Manassas, VA, USA) and tested negative for mycoplasma. For TLR lentivirus 
production, we used Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) to transfect 
HEK293T/17 cells with the pCVL Traffic Light Reporter (TLR) construct, a gift from Andrew 
Scharenberg (#31482, Addgene)106, and lentiviral packaging plasmids pMD2.G and pCMV 
delta R8.2, gifts of Didier Trono (Addgene plasmids #12259 and 12263).107 HEK293T/17 
cells were transduced at a low multiplicity of infection (100 colony-forming units) with TLR 
lentivirus to generate a stable, polyclonal cell line with a high likelihood of single integration, 
as previously described.107 We will henceforth refer to these cells as 293T/TLR. 
293T/TLR cells were maintained in Dulbecco’s Modified Eagle’s Medium- High 
Glucose (DMEM-H) (Sigma-Aldrich, St. Louis, MO, USA) with 10% fetal bovine serum (FBS) 
(VWR, Radnor, PA, USA), 1% antibiotic-antimycotic (Gibco, Grand Island, NY, USA), 4mM 
L-Glutamine (Corning, Manassas, VA, USA), and 10 µg/mL puromycin (Corning). Cells were 
grown at 37°C, 5% CO2 in a humidified incubator. All siRNA and DNA transfections were 
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performed in antibiotic-free DMEM-H with 10% FBS and 4 mM L-Glutamine.  
Traffic Light Reporter Assay 
 We adapted the Traffic Light Reporter (TLR)106 system for the analysis of missense 
variant DDR outcomes. Upon the transient expression of I-SceI nuclease (pRRL sEF1a 
HA.NLS.Sce(opt).T2A.IFP, Addgene plasmid #31484)106 and a homologous donor template 
(pRRL SFFV d20GFP.T2A.mTagBFP Donor, Addgene plasmid #31485)106, cells that repair 
induced DNA DSBs by HR express GFP, while mCherry serves as a marker for alt-NHEJ 
(Figure 4.1). 
 
Figure 4.1: TLR assay diagram. TLR assay schematic, adapted from Certo et al.106, shows 
stably integrated TLR construct and possible repair outcomes after an I-SceI-induced DNA 
double-strand break in mutGFP. Position relative to reading frame is indicated in 
parentheses, where +1 leads to gene expression, while +3 is 2 base pairs (bp) out of 
reading frame. If the homology-directed repair (HR) pathway is intact, cells can use the 
truncGFP donor to restore GFP expression. Alternatively, cells can undergo mutagenic non-
homologous end-joining (NHEJ), which restores mCherry expression if it results in a 2-bp 
frameshift. T2A acts as a linker, keeping mCherry out of reading frame at baseline. 
 
Preliminary assay validation 
After the generation of our stable 293T/TLR cell line, we performed a preliminary test 
of the system, as previously described.106 On day one, we seeded 6 x 105 293T/TLR cells 
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or both using Lipofectamine 2000 (Invitrogen). Antibiotic-free media was replaced the next 
day. On day three, cells were transferred to a 6-well plate. On day four, 1 x 106 cells were 
analyzed by flow cytometry using an LSRFortessa (BD Biosciences, San Jose, CA, USA). 
DSB repair timing 
In order to determine the optimal timing for DNA transfection and flow cytometry 
analysis, 5.0 x 105 cells were reverse transfected in a 12-well plate with 0.5 µg of I-SceI-IFP 
and 0.5 µg of GFPdonor-BFP using Lipofectamine 2000 (Invitrogen) at 12, 24, 48, or 72 
hours before flow cytometry. Controls included untreated cells and cells transfected with 0.5 
µg of empty vector only. To track DNA transfection efficiency and timing of plasmid 
expression, IFP+/BFP+ cells were analyzed as a percentage of single, live cells. DSB repair 
timing was measured by the percent of cells that were GFP+ (%HR) or mCherry+ (%NHEJ). 
At least 100,000 single, live cells were analyzed in duplicate for each condition.  
Timing siRNA-mediated knockdown 
 In order to determine the timing of siRNA-mediated knockdown, 3.0 x 105 293T/TLR 
cells were reverse transfected with 75 nM of siRNA (either non-targeting control siRNA 
(siNT), siPALB2, or siUBB) per well of a 6-well plate using Lipofectamine RNAiMAX 
(Invitrogen) according to the manufacturer’s protocol. Cells were harvested by enzymatic 
release after 24, 48, 72, or 96 hours. Pellets were stored at -20°C until RNA or protein 
extraction was performed. mRNA expression was analyzed by RT-PCR for three 
independent experiments. For protein analysis, western blots were performed using 15 µg of 
whole-cell lysate per well, with siNT-treated cells serving as a control for each timepoint. 
Assessing transient re-expression of PALB2 variants 
 To evaluate transient PALB2 re-expression, 3.0 x 105 293T/TLR cells were treated 
with 75 nM siPALB2, followed by co-transfection 24-hours later with 1.25 µg of I-SceI, 1.25 
µg of GFPdonor, and 0.71 µg of the indicated pDEST-FRT/T0-FLAG-PALB2 construct. Cells 
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were harvested by enzymatic release 48 hours after the siRNA transfection and pellets were 
stored at -20°C until protein extraction. For protein analysis, western blots probing for FLAG-
tagged PALB2 were performed using 25 µg of whole-cell lysate per run. WT PALB2 served 
as a control on each blot. 
TLR analysis of BRCA2 and PALB2 variants 
For the analysis of DDR outcomes for BRCA2 or PALB2 variants, experiments were 
performed as follows (Figure 4.2). On day one, we reverse transfected approximately 3.0 x 
105 - 5.0 x 105 293T/TLR cells with 75 nM of siRNA per well of a 6-well plate using 
Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocol. Twenty-four 
hours later, medium was changed and Lipofectamine 2000 (Invitrogen) was used to forward 
transfect cells with 1.25 µg of the IFP-tagged I-SceI nuclease construct, 1.25 µg of 
pGFPdonor-BFP, and either 1.25 µg of empty vector, 1.25 µg of the indicated siRNA-
resistant pDEST-FLAG/BRCA2, or 0.71 µg of the indicated siRNA-resistant pDEST-
FLAG/PALB2 construct. 72 hours after DNA transfection, cells were harvested by enzymatic 
release, resuspended in cold 1% Bovine Serum Albumin (BSA) (Sigma-Aldrich) in 
Dulbecco’s Phosphate-Buffered Saline (D-PBS) (Gibco) to 1 x 106 cells/mL, and 1.0-3.0 x 
106 cells were filtered for analysis by flow cytometry. Remaining cells were pelleted and 
stored at -20°C for subsequent RNA analysis. 
Flow cytometry 
Flow cytometry analysis was performed using a LSRFortessa cell analyzer (BD 
Biosciences). Live cells were gated based on forward scatter area versus side scatter area. 
Single cells were then gated based on forward scatter area versus forward scatter height. 
GFP was excited by a 488-nm laser and detected by a 530/30 filter. mCherry was excited by 
a 561-nm laser and detected by a 610/20 filter. Infrared Protein (IFP) was excited by a 640-
nm laser and detected by a 710/50 filter. Blue Fluorescent Protein (BFP) was excited by a 
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405-nm laser and detected by a 450/50 filter. Data were analyzed using FACS Diva (BD 
Biosciences) and FCS Express 6 (De Novo Software, Pasadena, CA, USA) software.  
For TLR analysis of BRCA2 and PALB2 variants, at least 10,000 doubly transfected 
(IFP+/BFP+), single, live cells were analyzed per condition. From this population of cells, we 
obtained readouts of GFP+/mCherry+ ratio (HR/NHEJ) and the percent of cells that were 
GFP+ (an indicator of %HR). Each variant was tested in at least three independent 
experiments. Each 6-well plate included the following conditions as controls: non-targeting 
siRNA (siNT)-treated cells rescued with empty vector, siBRCA2- or siPALB2-treated cells 
rescued with empty vector, and siBRCA2- or siPALB2-treated cells rescued with siRNA-
resistant WT BRCA2 or PALB2. 
 
 
Figure 4.2: TLR assay timeline: Schematic of TLR assay timing shows siRNA is reverse 
transfected in 293T/TLR cells, transient rescue plasmid DNA in pDEST-FLAG is co-
transfected with I-SceI nuclease and truncGFP donor constructs 24 hours later, and flow 
cytometry is performed 72 hours after DNA transfection. 
 
Western blots 
For protein extraction, cell pellets were resuspended in Pierce RIPA buffer (Thermo 
Scientific, Rockford, IL, USA), containing 1mM Phenylmethylsulfonyl fluoride (PMSF) 
























Germany), 0.1% 2-Mercaptoethanol (Gibco), 0.1% Dithiothreitol (DTT) (Thermo Scientific), 
and 1 tablet of Pierce phosphatase inhibitor (Thermo Scientific) per 10 mL of buffer. 
Resuspended pellets were shaken for 10 minutes at 4°C and lysed by sonication in a 4°C 
water bath (Diagenode Biorupter, Denville, NJ, USA) for five minutes (30 seconds on/30 
seconds off). Lysate was then centrifuged for 10 minutes at 14,000 x g at 4°C and 
supernatant transferred to a new tube. Protein concentration was measured by reducing-
agent compatible microplate BCA Assay (Thermo Scientific) according to kit protocol. Plates 
were read using a GloMax Multi-Detection System (Promega, Madison, WI, USA).  
For western blotting, reduced whole cell lysates were electrophoresed on a NuPAGE 
7% Tris-Acetate pre-cast 1.0 mm gels (Invitrogen) for 50 minutes at 150 V and transferred to 
polyvinylidene difluoride (PVDF) membrane (Merck Millipore, Cork, Ireland) at 30 V for 1 
hour. Membranes were blocked in 5% BSA in Tris-buffered saline (TBS) (Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA) for 1 hour at room temperature. Primary antibodies 
used were a mouse monoclonal anti-FLAG antibody (1:1,000; #F1804, Sigma-Aldrich), a 
polyclonal rabbit antibody against an epitope between residues 200-250 of PALB2 (1:2,000; 
#A301-247A, Bethyl Laboratories, Montgomery, TX, USA), and a rabbit monoclonal 
antibody against GAPDH (1:2,500; #AB9485, Abcam, Cambridge, MA, USA). Primary 
antibody incubation was performed for 1 hour at room temperature, or overnight at 4°C. 
Secondary antibodies used were IRDye 800CW Goat anti-mouse or anti-rabbit IgG 
(1:20,000-1:25,000, #925-32210 and 925-32211, respectively) (LI-COR, Lincoln, NE, USA). 
Membranes were incubated with secondary antibodies for 1 hour at room temperature, 
protected from light. After primary and secondary antibody incubation, membranes were 
washed 3 times for 10 minutes at room temperature with 0.1% Tween 20 (Sigma-Aldrich) in 
1X TBS. Membranes were then rinsed with 1X TBS and blots were visualized using a LI-
COR Odyssey CLx Imager. 
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Real-Time PCR (RT-PCR) 
 RNA was isolated and purified from pelleted 293T/TLR cells using a RNeasy Plus 
Mini Kit (Qiagen, Hilden, Germany). 100 ng of RNA was used as template with a TaqMan 
RNA-to-CT 1-Step Kit (Applied Biosystems, Carlsbad, CA, USA) for gene expression 
analysis of PALB2 or BRCA2 relative to B2M in 25 mL triplicate reactions run on an Applied 
Biosystems StepOne Real-Time PCR System. TaqMan Gene Expression Assay IDs 
(Applied Biosystems) used were Hs00609073_m1 (BRCA2), Hs00954121_m1 (PALB2), 
and Hs00187842_m1 (B2M). 
In silico predictions 
For missense single nucleotide variants (SNVs) with available reference single 
nucleotide polymorphism (SNP) identification numbers (rs ID), prediction scores for Sorting 
Intolerant From Tolerant (SIFT), PolyPhen2, Combined Annotation Dependent Depletion 
(CADD), Rare Exome Variant Ensemble Learner (REVEL), and MetaLR were retrieved from 
Ensembl (release 98, accessed 12/24/2019).108 One missense SNV (PALB2 c.110G>C, 
p.(R37P)) did not have an available rs ID, but did have an assigned Clinical Genome 
Resource (ClinGen) Canonical Allele Identifier (CAID). This CAID was then used to access 
SIFT, PolyPhen2, REVEL, and MetaLR prediction scores via the ClinGen Variant Curation 
Interface (VCI) (demo version available at https://curation-test.clinicalgenome.org, accessed 
12/30/2019). A CADD score for PALB2 R37P was retrieved directly using model GRCh38-
v1.5 (https://cadd.gs.washington.edu/snv, accessed 1/4/2020).109 Mutation Assessor110 
(release 3) was accessed directly to generate predictions for all missense SNVs examined 
in this study (mutationassessor.org/r3, accessed 12/31/2019). 
Statistical Analysis 
Data normalization 
For BRCA2 and PALB2 TLR assays, data from each six-well plate is normalized 
according to the performance of the in-plate control (siNT + empty vector), which is included 
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in every run of the experiment. To do this, the readout (either %HR or HR/NHEJ ratio) for 
each experimental condition is divided by the readout for the in-plate control tested on the 
same plate.  
Thresholding 
 We used the normalized HR/NHEJ readout from the TLR for BRCA2 variant controls 
to set thresholds for interpreting PALB2 assay readouts as having a normal or abnormal 
functional impact. First, we grouped BRCA2 WT and benign variants as one group and 
empty vector and pathogenic variants together as another group and used GraphPad Prism 
v8.3.0 to test for normal distributions using the Anderson-Darling, D’Agostino & Pearson, 
Shapiro-Wilk, and Kolmogorov-Smirnov tests at an alpha of 0.05. Next, we determined 90, 
95, and 99% confidence intervals (CI) for the mean and median of these two groups.  
 On the PALB2 HR/NHEJ readout data, we plotted the lower boundary of the 90, 95, 
and 99% CI of the mean HR/NHEJ for BRCA2 WT/benign controls, as well as the upper 
boundary of the 90, 95, and 99% CI of the mean HR/NHEJ for BRCA2 pathogenic 
controls/empty vector. These preliminary thresholds performed similarly at each confidence 
interval, so we proceeded with the most stringent values (99%CI) as the minimum 
requirement for normal functional readout and the maximum allowed HR/NHEJ to be 
considered having an abnormal functional impact. 
Assigning evidence strength 
 Each of the evidence criteria outlined in the American College of Medical Genetics 
and Genomics (ACMG)/Association for Molecular Pathology (AMP) sequence variant 
interpretation guidelines has an assigned weight (supporting, moderate, strong, very strong) 
at which the evidence can be applied.34 These categorical strengths have also been 
modeled as Bayesian Odds of Pathogenicity (OddsPath).39 Together with the ClinGen 
Sequence Variant Interpretation Working Group (SVI), we recently described 
recommendations for using statistical analyses to determine the strength at which the 
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ACMG/AMP functional evidence criteria can be applied in variant curation in support of a 
pathogenic or benign classification (PS3 or BS3 codes, respectively).99 Adhering to this, we 
sought to derive the strength of evidence that could be applied at various thresholds for 
abnormal/normal/intermediate assay readout.  
 We considered the performance of our preliminary thresholds set by the BRCA2 99% 
CI of the means for the nine benign/likely benign (B/LB) and three pathogenic/likely 
pathogenic (P/LP) PALB2 variant controls. The proportion of P/LP controls out of the total 
number of variant controls tested served as the prior probability (P1). To calculate an 
OddsPath corresponding to the level of strength that can be applied to an abnormal readout, 
the posterior probability (P2) considers what proportion of P/LP variant controls had median 
HR/NHEJ below the threshold for abnormal function. To calculate an OddsPath 
corresponding to the level of strength that can be applied to a normal readout, the posterior 
probability (P2) considers what proportion of B/LB variant controls had median HR/NHEJ 
above the threshold for normal function. Any variant controls with median HR/NHEJ 
between the thresholds are considered to have an indeterminate readout. The OddsPath 
was estimated as:  
 OddsPath= [P2 x (1- P1)] / [(1- P2) x P1].99 
Finally, we converted the OddsPath to a categorical strength of evidence (very strong, 
strong, moderate, or supporting), as described in the Bayesian adaptation of the 
ACMG/AMP variant interpretation framework.39 
Regression analysis 
 Scatterplots and linear regression were generated to test the correlation between 
functional data and in silico predictors, using squared correlation coefficients (R2) to 
measure the strength of correlation (GraphPad Prism v8.3.0). Three studies of the functional 
impact of PALB2 missense variants were recently published.29–31 To test the correlation 
between the TLR’s HR/NHEJ readout and recently published HR functional data, we 
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repeated our regression analysis using published %HR efficiency values30 or homology-
directed repair (HDR) fold change29. We cannot directly compare HR/NHEJ to HR readout 
from the third study31, as raw HR data was not published. 
4.3 Results 
Preliminary validation of TLR 
Originally developed for optimization of genome editing protocols, the Traffic Light 
Reporter (TLR) uses GFP and mCherry expression to visualize the repair of induced DNA 
DSBs by HR and alt-NHEJ, respectively.106 Preliminary validation of this system is shown in 
Figure 4.3. Untreated 293T/TLR cells are non-fluorescent at baseline, as GFP gene 
expression is disrupted by an I-SceI nuclease target site, and mCherry expression is kept 
out of reading frame by a T2A linker (Figures 4.1 and 4.3A). The truncated GFPdonor 
(truncGFP) construct does not encode full-length GFP and its transfection can be monitored 
by BFP expression (Figure 4.3B). I-SceI nuclease transfection can be monitored by IFP 
expression. In the absence of a homologous donor copy of GFP, only breaks repaired by 
alt-NHEJ are detected, as indicated by mCherry expression (Figure 4.3C). mCherry gene 
expression is restored when alt-NHEJ leads to a two-base pair frameshift (about one-third of 
events)106. In the absence of I-SceI, cells are typically non-fluorescent (Figure 4.3A-B). Co-
transfection of both I-SceI and GFPdonor results in expression of both IFP and BFP, 
respectively, and DSBs can be repaired by both HR and alt-NHEJ, indicated by GFP and 





Figure 4.3: Preliminary TLR reporter validation. Flow cytometry plots showing mean 
fluorescence intensity of live, single cells expressing BFP versus IFP (top) and GFP versus 
mCherry (bottom). Untreated 293T/TLR cells (A), versus cells transfected with: GFPdonor 
(B), I-SceI (C), or both GFPdonor and I-SceI (D).  
 
Optimization of TLR assay timing and knockdown efficiency  
 Efficiency and timing of cDNA expression and DSB repair outcomes were monitored 
by flow cytometry and results are shown in Figure 4.4. Detectable expression of I-SceI 
nuclease and GFPdonor plasmids peaks between 24- and 72-hours post-transfection, and 
repair events can be detected after 48- to 72-hours. For subsequent experiments, we 
performed flow cytometry 72-hours after DNA transfection, as both plasmid cDNA and DSB 




Figure 4.4: Timing DSB repair by flow cytometry. 293T/TLR cells transfected with I-SceI-
IFP and truncGFP Donor-BFP at 12, 24, 48, or 72 hours before flow cytometry was 
performed. IFP+/BFP+ cells (doubly transfected with both nuclease and truncGFP), are 
shown as percent of single, live cells. mCherry and GFP expression serve as markers for 
alt-NHEJ and HR events, respectively. 
 
Monitoring knockdown efficiency 
 siRNA-mediated knockdown timing was monitored by RT-PCR, which found >70% 
knockdown of PALB2 was attained by 24-hours after siRNA transfection, and was sustained 
for 96-hours (Figure 4.5). The timing of PALB2 knockdown at the protein level was 
qualitatively assessed by western blot, which suggests PALB2 protein levels decrease by 48 
hours, relative to siNT-treated cells (supplemental Figure 4.12). Knockdown efficiency was 
also monitored by RT-PCR for all TLR flow cytometry assessments of BRCA2 or PALB2 
variants and results are shown in supplemental Figure 4.13. All experiments demonstrated 
>50% knockdown of the target gene relative to siNT-treated cells at the time of flow 
cytometry (96-hours post-siRNA transfection). The only exception was the sample from the 
PALB2 flow analysis performed on 3/8/2019, which appears to have had poor RNA integrity, 
as this RT-PCR result does not reflect the level of knockdown observed by flow cytometry 
(normalized HR/NHEJ of 0.625 for empty vector rescue). 
























Figure 4.5: Time course of siRNA-mediated knockdown of PALB2. Expression of 
PALB2 mRNA after siRNA-mediated knockdown relative to siNT treated cells. 293T/TLR 
cells were transfected with 75 nM siRNA and cells were pelleted after the indicated number 
of hours and frozen for later RNA extraction and analysis. RT-PCR was performed using 
primers for PALB2 and B2M. Results from 3 independent experiments shown as mean with 
standard deviation. 
 
BRCA2 validation of TLR assay 
BRCA2 missense variants have been previously characterized by their capacity for 
HR using the direct repeat-GFP (DR-GFP) reporter assay, where GFP serves as a marker 
for HR following an induced DNA DSB.59,111 Benign variants retain HR capacity and thus 
strongly express GFP, while pathogenic variants defective for HR do not. The established 
BRCA2 benign and pathogenic variants used in developing this assay constitute a gold 
standard panel for functional assay validation.33,59 We evaluated whether we could use 
these same BRCA2 gold standard missense variants to benchmark an assay of DDR for 
PALB2 missense variants.  



























Figure 4.6: TLR’s performance for BRCA2 gold standard variants. For each variant or 
control listed across the x-axis, HR/NHEJ ratio (normalized to in-plate siNT control) is plotted 
on the y-axis. Summary data for wild-type (WT) and empty vector are shown as boxes and 
whiskers (5-95 percentile, N=21). For missense variants, each point represents the one run 
of the experiment and a horizontal bar denotes the median value for at least three 
independent experiments. Following siBRCA2-mediated knockdown, WT BRCA2 restores 
HR/NHEJ, but the ratio decreases when rescued with empty vector alone. Benign variants 
performed similarly to WT BRCA2 and pathogenic variants performed similarly to empty 
vector.  
 
 We selected eight benign and eight pathogenic BRCA2 variants from this list of gold 
standards33 and tested their effect on DDR with the TLR assay. Following siRNA-mediated 
knockdown, cells were co-transfected with plasmids encoding the truncGFP donor, I-SceI 
nuclease, and either empty vector or siRNA-resistant FLAG-BRCA2 (encoding either WT, 










































































included siNT-treated cells rescued with empty vector, siBRCA2-treated cells rescued with 
empty vector, and siBRCA2-treated cells rescued with WT BRCA2. We measured the ratio 
of GFP+/mCherry+ cells (HR/NHEJ) for at least 10,000 doubly transfected (IFP+/BFP+) cells 
and the results of each experiment were divided by the HR/NHEJ ratio for siNT-treated cells 
rescued with empty vector. 
 
 
WT + B/LB EV + P/LP 
Number of values 48 50 
Mean 0.9212 0.5026 
Standard Deviation 0.1666 0.1062 
Standard Error of Mean 0.02405 0.01502 
Lower 90% CI of mean 0.8808 0.4774 
Upper 90% CI of mean 0.9615 0.5278 
Lower 95% CI of mean 0.8728 0.4724 
Upper 95% CI of mean 0.9695 0.5328 
Lower 99% CI of mean 0.8566 0.4624 
Upper 99% CI of mean 0.9857 0.5429 
Table 4.1: Confidence intervals of BRCA2 mean HR/NHEJ readout. The two groups for 
analysis were (1) WT and B/LB BRCA2 variants, and (2) empty vector (EV) and P/LP 
BRCA2 variants. CI = confidence interval. 
 
 We found that WT and benign/likely benign (B/LB) BRCA2 variants restore HR 
capacity as indicated by a higher HR/NHEJ ratio (medians range from 0.795-1.036) (Figure 
4.6). Empty vector and pathogenic/likely pathogenic (P/LP) BRCA2 variants demonstrate 
abnormal HR function, as indicated by a lower HR/NHEJ ratio (medians range from 0.381-
0.595). Median HR/NHEJ ratio appears to decrease continuously from the highest (H2074N) 
to the lowest (N3124I), though there is not a clear separation between benign and 
pathogenic variant control groups. The HR/NHEJ readouts for WT and B/LB BRCA2 variants 
are normally distributed, as are those for empty vector and P/LP BRCA2 variants. The 90, 
95, and 99% confidence interval (CI) of the mean HR/NHEJ for WT and B/LB BRCA2 
variants did not overlap with those of empty vector and P/LP controls (Table 4.1). These 
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results demonstrate that the TLR assay is able to distinguish between normal and abnormal 
DDR function, and thus we proceeded by testing missense variants in PALB2. 
 
Figure 4.7: Representative flow plots. Typical flow plots for one run of the TLR assay. 
Row 1 (left to right): Controls for siRNA/DNA transfection and batch effects. Row 2 (left to 
right): Transient rescue with PALB2 variants L35P (potentially pathogenic missense 
variant)28, N497Mfs*64 (known pathogenic), and A712V (known benign).  
 
TLR adaptation for PALB2 analysis 
As with BRCA2 experiments, following siRNA-mediated knockdown, cells were co-
transfected with plasmids encoding the truncGFP donor, I-SceI nuclease, and either empty 
vector or siRNA-resistant FLAG-PALB2 (encoding either WT, control variant, or VUS). Each 
experiment included siNT-treated cells rescued with empty vector, siPALB2-treated cells 
rescued with empty vector, and siPALB2-treated cells rescued with WT PALB2. We 
measured the ratio of GFP+/mCherry+ cells (HR/NHEJ) for at least 10,000 doubly 
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transfected (IFP+/BFP+) cells and the results of each experiment were divided by the 
HR/NHEJ ratio for siNT-treated cells rescued with empty vector. Typical flow plots for one 
run of the PALB2 adaptation of the TLR assay are represented in Figure 4.7. 
Previous studies in PALB2 have primarily been domain-specific.20,26,112 In order to 
validate an assay for PALB2 as a whole, we selected variants across the length of the 
protein (Figure 4.8B). As controls, nine benign/likely benign missense variants (N241D, 
I309V, Q559R, E672Q, I676T, A712V, P864S, V932M, and G998E) were selected from the 
Clinical Variant Database (ClinVar).47 As there are currently no definitive likely 
pathogenic/pathogenic missense variants in PALB2,47 we selected three frameshift/early 
truncating variants (C77Vfs*100, N497Mfs*64, L531Cfs*30) that could reach at least a likely 
pathogenic classification without functional evidence to serve as controls. It should be noted 
that expression of these truncating variants from cDNA may not reflect the true biological 
context (in which nonsense mediated decay would be expected to occur), however these 
cDNA constructs should still produce a non-functioning protein given that a large portion of 
the C-terminal end of the protein will be absent. We found that WT and benign PALB2 
variants restore HR, as indicated by a higher HR/NHEJ ratio (medians range from 1.108-
1.695) (Figure 4.8A). Empty vector and truncated PALB2 variants exhibit fewer HR events, 
with a lower HR/NHEJ ratio (medians range from 0.172-0.650) (Figure 4.8A). 
25 missense VUS were selected from ClinVar or the literature, or were synthetically 
designed (for ClinVar ID and classification, see supplemental Table 4.5). As available, we 
examined the evidence considered in a variant assertion and prioritized those that did not 
apply functional evidence criteria (K18R, L24S, K30N, R37S, N186I, E331Q, F404L, P490A, 
A712P, N821Y, L939W, A1025T, I1037T, L1070P, P1097R), as these VUS would stand the 
benefit the most from the addition of new functional data. Other VUS selected from ClinVar 
include PALB2 variants Y28C, L35P, R37H, and T1030I. Synthetic variants and those 




Figure 4.8: PALB2 data & variants tested. A: siPALB2 knockdown rescued with PALB2 
variant or control as listed across the x-axis. HR/NHEJ ratio (normalized to in-plate control) 
is plotted on the y-axis. Each point represents the one run of the experiment and a 
horizontal bar denotes the median value for at least three independent experiments. WT and 
empty vector data represented as boxes with whiskers (5-95 percentile, N=40). Thresholds 
for normal and abnormal functional impact are indicated by blue or gray dashed lines, 
respectively. B: Lollipop diagram115 of PALB2 protein variants tested. VUS are colored by 
functional impact. CC, ChAM, and WD40 protein domains are indicated by colored boxes. 
CC, coiled-coil; ChAM, chromatin association motif; HR, homologous recombination; NHEJ, 
non-homologous end-joining; P/LP, pathogenic/likely pathogenic; siPALB2, siRNA targeting 
PALB2 gene expression; WD1-7, seven blades of WD40 beta propeller; WT, wild-type.  
17 41 77 186 241 309 404 435 490 531 559 672 712 821 864 932 998 1025 1070 1097 1186
CC WD1 2 3 4 5 6 7ChAM
























































































































































 We used the TLR readouts from the BRCA2 variant controls to set thresholds for 
interpreting PALB2 assay readouts as having a normal or abnormal functional effect. We 
applied the lower boundary of the 99% CI of the mean HR/NHEJ for BRCA2 WT/benign 
controls (0.8566) as the minimum value required for normal functional readout. The median 
HR/NHEJ of the PALB2 WT and B/LB variant controls exceeded this value. Below a median 
HR/NHEJ readout of 0.5429 (the upper boundary of the 99% CI of the mean HR/NHEJ for 
BRCA2 pathogenic controls/empty vector), we considered a variant to have an abnormal 
functional effect. Two of truncating variants (N497Mfs*64 and L531Cfs*30) had median 
HR/NHEJ values below this threshold. Empty vector control and one truncating variant 
(C77Vfs*100) had median HR/NHEJ between these thresholds and were considered of 
intermediate or indeterminate functional impact.  
 To determine the approximate strength of this evidence for clinical variant 
interpretation, we estimated the odds of pathogenicity that could be derived for an abnormal 
or normal readout in this assay.99 At the thresholds set by BRCA2 controls, the TLR 
correctly classified all nine PALB2 B/LB controls and two out of three P/LP controls. This 
roughly corresponds to a moderate level of evidence in support of a pathogenic 
interpretation (PS3_moderate) for an abnormal functional readout and a supporting level of 
evidence in favor a benign interpretation (BS3_supporting) for a normal functional readout. 
With these thresholds, we can characterize VUS as having either normal or abnormal 
function based on their TLR readout. 
Functional assessment of PALB2 missense VUS 
PALB2 missense VUS appear to span the range of functional readout from normal to 
abnormal, with some of intermediate or indeterminate function. Interestingly, we found 
substantial effects on DDR for seven VUS with median HR/NHEJ ratios between 0.278-
0.503. Consistent with Foo and colleagues’ original report28, as well as subsequent 
investigations29–31, we found that L35P had a robust abnormal functional impact on 
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HR/NHEJ. Other variants displaying abnormal function include: L17P, L21P, L24P, L24S, 
A1025R, and P1097R. We also found five PALB2 missense variants with intermediate 
function (Y28C, Y28P, R37P, T1030I, and L1070P), with median HR/NHEJ ratios between 
0.573-0.834. The remaining 13 VUS tested performed above the threshold for normal 
function (median HR/NHEJ: 0.968 -1.610). These results indicate that the TLR assay is able 
to distinguish missense variants with normal and abnormal repair functions. Our results also 
suggest that some missense variation in the BRCA1 and BRCA2-interacting domains of 
PALB2 may have deleterious effects on DDR, as seen previously in truncating PALB2 
variants. 
Next, we performed follow-up evaluation of protein re-expression by western blotting 
for FLAG-tagged missense PALB2 variants, including six with abnormal and one with 
intermediate HR/NHEJ (Y28P), as well as empty vector and a benign variant control, 
N241D. Empty vector control does not express FLAG-tagged PALB2. These seven VUS 
had detectable expression, similar to N241D and WT PALB2 (Figure 4.9). For L17P, L21P, 
L24P, L24S, L35P, and P1097R, this suggests that their abnormal HR/NHEJ ratios are not 
due to reduced expression or protein stability. Consistent with our results, Boonen et al. 
recently demonstrated normal protein expression for L24S and L35P variants.30 They also 
found normal protein expression for K18R, Y28C, R37H, L531Cfs*30, Q559R, E672Q, 
P864S, L939W, G998E, and A1025R, but decreased expression/stability for T1030I, 




Figure 4.9: Monitoring PALB2 variant re-expression. Western blot analysis of whole-cell 
lysates from 293T/TLR cells transiently transfected with empty vector (empty v.) or pDEST-
FRT/T0-FLAG-PALB2 encoding wild-type (WT) or variant PALB2. Exogenous PALB2 
expression was probed with 1.0 µg/ml anti-FLAG antibody. GAPDH serves as a loading 
control. 
 
In silico predictions of PALB2 missense variants 
 In silico tools are frequently used as supporting evidence in clinical variant 
interpretation79 and have been used to prioritize potentially damaging candidate variants for 
functional assessment.29 To assess how well various in silico predictors performed relative 
to TLR assay readout, we generated scatterplots and performed simple linear regression for 
missense SNVs in our test set with available predictions from six different tools (SIFT, 
PolyPhen-2, CADD, REVEL, MetaLR, and MutationAssessor) (Figure 4.10). SIFT considers 
sequence homology and physiochemical differences between the native and substituted 
amino acid. PolyPhen-2 considers sequence homology, Pfam annotations, 3D structures, 
and other tools to estimate a probability of deleteriousness. CADD combines functional and 
conservation annotations for its prediction score. REVEL is a meta-predictor, integrating 
pathogenicity predictions from thirteen different tools, including SIFT, PolyPhen-2, 
MutationAssessor, and others. Similarly, MetaLR116 uses logistic logression to combine 
multiple function, conservation, and ensemble scores with population frequency data. 
MutationAssessor generates a functional impact score based on evolutionary conservation 
in protein homologs.110,117 
R-squared values from the regression analyses range from 0.2237 to 0.6263, 
indicating that these tools are overall poor predictors of actual DSB repair function. Of those 
examined here, meta-predictors MetaLR and REVEL had the highest degree of 
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concordance with our HR/NHEJ data (R2 of 0.6263 and 0.3991, respectively). Ensembl 
considered SIFT scores <0.05 to be “deleterious”; PolyPhen scores >0.908 were listed as 
“probably damaging”, ≤0.446 as “benign”, and all scores in between as “possibly damaging”. 
At these thresholds, SIFT and PolyPhen both misclassified two B/LB variants (G998E and 
V932M) as “deleterious”, indicating that these particular classifiers may have a greater 
propensity for false positives (for raw data, see Supplemental Table 4.5). Ensembl predicts 
that variants with CADD scores above 30 are the 0.1% most “deleterious” substitutions 
possible. No variant we examined exceeds a CADD score of 30, suggesting that this 
threshold is too stringent. Variants with abnormal HR/NHEJ had CADD scores in the mid-to-
upper 20’s, but two B/LB variants and several VUS with intermediate or normal HR/NHEJ 
scored in this range as well. According to Ensembl, it is predicted that ~75% of pathogenic 
variants and only ~11% of benign variants will have a REVEL score above 0.5. If REVEL 
scores above 0.5 are considered “likely disease causing”, no variants here meet this 
threshold. All B/LB variants had REVEL scores <0.13, with the exception of G998E at 0.251. 
There is no cutoff that would perfectly discriminate between variants of normal and 
abnormal function. MetaLR seems to perform the best, based on the R2 of the linear 
regression of MetaLR score and the HR/NHEJ ratio. However, all available MetaLR scores 
for the tested PALB2 missense variants were <0.5 and considered “tolerated”. This is likely 
an overly conservative threshold for calling the score “tolerated” versus “damaging”. Overall, 
this suggests that the thresholds for interpreting quantitative scores as qualitative categories 
require gene or disease-specific assessment and that predictive results should be 
interpreted with caution. 
TLR readout is concordant with other assays of HR in PALB2 
 Next, we asked how the readout of our TLR assay correlates with recently published 
functional assessments of HR in PALB2 missense variants. Boonen30, Wiltshire29, and 
colleagues both examined HR capacity using the DR-GFP fluorescent reporter system in a 
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Trp53KO/Palb2KO mouse embryonic stem (mES) cell line. For missense variants tested 
across these two assays and the TLR, we generated scatterplots and performed linear 
regressions. When plotted against TLR median HR/NHEJ, R-squared values from these 
regressions (0.76 and 0.71) suggest that our results are generally consistent with the 
published DR-GFP data (Figure 4.11, top row). We also considered that using the TLR 
readout of %HR might make a more direct comparison, and repeated the regressions with 
this data. Interestingly, the R2 value decreased slightly to 0.62 and 0.68 for the Boonen et al. 
and Wiltshire et al. datasets, respectively (Figure 4.11, bottom row). Overall, the positive 
correlation of TLR HR/NHEJ readout with other data in the literature increases our 





 Figure 4.10: Correlation of HR/NHEJ and in silico predictors. Scatterplots and linear 
regression were performed on normalized median HR/NHEJ versus six different in silico 
predictions. Each plot displays the best-fit line and measure of goodness-of-fit (R2). B/LB 
variants are shown in blue and VUS are colored magenta. N=29. For source data, see 
supplemental Table 4.5. 




























































































Figure 4.11: HR/NHEJ correlates with published HR functional data. Top row (left to 
right): Linear regression of normalized median HR/NHEJ versus %HR efficiency (Boonen et 
al.30, N=15), or HDR fold change (Wiltshire et al.29, N=16). Bottom row (left to right): Linear 
regression as above, but using normalized median %HR instead of HR/NHEJ ratio. 
Benign/likely benign variant controls are shown in blue, VUS in magenta, and truncating 
variants in black. For data used, see supplemental Table 4.6. 
 
4.4 Discussion 
 To assess the functional impact of missense variants in PALB2 for clinical variant 
interpretation, we developed and validated a fluorescent reporter assay of HR and alt-NHEJ 
DDR outcomes: the TLR. We first determined the TLR’s dynamic range using 16 BRCA2 
missense variants as benchmarks for normal/abnormal HR function. Our results for these 
controls were consistent with previous studies.59,118,119 
We then tested WT PALB2 and 37 variants, generating functional data for germline 
PALB2 variants at a moderate level of evidence for a pathogenic interpretation 
(PS3_moderate) or a supporting level of evidence in favor of a benign interpretation 
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(BS3_supporting). The rationale for using the thresholds set by BRCA2 missense variants to 
interpret the TLR readouts for PALB2 is that they provided a robust group of known benign 
and known pathogenic controls. A major caveat to this approach is that different levels of 
PALB2 knockdown and re-expression means that the dynamic range of assay readout may 
be different for each gene. However, when applying the BRCA2 thresholds to the PALB2 
data, they can still differentiate between benign and pathogenic variants at a level of 
PS3_moderate/ BS3_supporting. In the absence of a gold-standard set of BRCA2 variants, 
we could have set thresholds based on the dynamic range of the PALB2 assay alone, which 
would return a similar strength of evidence albeit a slightly different threshold. The exact 
thresholding would most likely affect the interpretation of the intermediate variants on the 
cusp of an abnormal or normal classification. Those set by BRCA2 are the most 
conservative, which appropriately prevents assigning too much weight to the functional 
evidence for VUS with intermediate effect. 
 PALB2 missense VUS seem to cluster by normal and abnormal functional impact, 
with some of intermediate or indeterminate function. Of the 25 PALB2 missense VUS 
examined, seven demonstrated abnormal function comparable to empty vector and 
truncating variants. These seven variants are all located in either the N-terminal coiled-coil 
(CC) domain or the C-terminal WD40 domain of PALB2, suggesting that these regions are 
critical for normal PALB2 DDR activity and may be hot spots for pathogenic missense 
variation. 
Coiled-coil domain and BRCA1 interaction 
 The CC domain (residues 9-44) is made up of a heptad of supercoiled alpha helices 
and is the site of PALB2 homodimerization, as well as heterodimerization with BRCA1.17,23 
Alpha helical structures are disrupted by proline substitutions.101 As such, it is unsurprising 
that most of the CC domain variants where the amino acid changed to a proline (L17P, 
L21P, L24P, L35P) had an abnormal readout. Variants Y28P and R37P were of 
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intermediate functional effect. Based on previous work, L17, L21, L24, Y28, T31 and L35 
are the key residues of the PALB2-PALB2 interface.101 The exact role of PALB2 
homodimerization in regulating HR is still unclear, as L17, L21, L24, Y28, and L35 also 
make up the hydrophobic interface with BRCA1. Recently, two other groups found L24S to 
have abnormal HR function, in addition to decreased RAD51 foci, some increased sensitivity 
to poly(ADP-ribose) polymerase inhibitors (PARPi), and impaired interaction/complexing 
with BRCA1.29,30 They also found L24S to have normal protein expression, consistent with 
our findings (Figure 4.9), normal nuclear localization, and even increased protein stability in 
one report.29,30 This suggests that defects in DNA damage repair are likely mediated by 
impaired BRCA1 interaction, rather than issues of protein expression, stability, or 
localization.  
 PALB2 variants Y28C and Y28P fell in the range of intermediate functional impact 
(median HR/NHEJ of 0.664 and 0.573, respectively) in the TLR assay. Data in the literature 
for Y28C have not reached consensus on its functional impact. Wiltshire et al. considered it 
to have normal HR activity (fold change of 4.8) in a mES cell DR-GFP assay29, but Boonen 
et al. considered Y28C to have intermediate function (32.92% HR efficiency) in the same 
assay30. Rodrigue and colleagues showed between 25-40% residual HR activity by the 
CRISPR-LMNA assay31, while Foo et al. found a 65% reduction in HR activity (35% of 
normal) and decreased PALB2-BRCA1 co-immunoprecipitation (co-IP), but normal 
recruitment to BRCA1 foci.28 Y28P was on the cusp of the abnormal threshold in our assay, 
and it may reach an abnormal classification with a slightly higher threshold, though with 
lower strength of evidence. 
 PALB2 residues K18, K30, and R37 are also part of the coiled-coil protein-interacting 
domain, but are not points of direct contact.28 This may help explain why certain CC domain 
residues we tested may be more sensitive to alterations than others. K18R is listed as 
having conflicting interpretations in ClinVar (Accession: VCV000126758.3), with a 
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combination of likely benign, benign, and VUS classifications reported from different clinical 
laboratories47. In addition to its normal HR function demonstrated here and elsewhere29–31, 
its MAF is too high to be considered pathogenic for hereditary breast cancer, at 0.01813 in 
Africans (428/23610 alleles, 3 homozygotes) in gnomAD v2.1.1 (non-cancer) 
(gnomad.broadinstitute.org, accessed 1/5/2020)91. While K30N has been reported in 1/747 
Australasian females with multiple-case breast cancer families120, we and others found it to 
have normal HR function28,29. 
 Variants R37H and R37S exhibited normal function by the thresholds we applied. 
Available functional literature for R37H is generally consistent with our interpretation28–30, 
though one group reported ~40% of normal HR, congruent with a mild increase in olaparib 
sensitivity31. Internally, R37S was observed in exomes of two research participants 
evaluated for non-cancer-related indications, including cardiomyopathy, dysmorphology, and 
neurodevelopmental disorders. In the literature, R37S has been observed in a patient with 
breast cancer and it was noted that it may have an effect on gene splicing121, though 
according to one report in ClinVar, “multiple internal splicing models do not predict an effect 
on splicing” (Accession: SCV000565339.3)47. For variants where we have demonstrated a 
supporting level of evidence for normal DDR activity, it is important to note that we have not 
assessed all functions of PALB2 that may lead to disease pathogenesis, such as splicing, 
and thus caution is still merited in applying benign functional criteria for clinical variant 
interpretation. 
 R37P (median HR/NHEJ of 0.850) just barely missed the cutoff for a functionally 
normal interpretation. Given what is known about the impact of prolines in the CC domain, it 
is not surprising that R37P appeared to perform at a slightly lower level than other amino 
acid substitutions at the same residue.  
Interestingly, pathogenic frameshift variant C77Vfs*100 appeared to have a higher 
median HR/NHEJ ratio (0.650) than empty vector alone (0.585) and both fell in the 
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intermediate range when the BRCA2-determined thresholds were applied. Tischkowitz and 
colleagues first described this frameshift variant in a family of Scottish ancestry with strong 
history of breast cancer—7 breast cancers in 3 female mutation carriers. They found 
c.229delT (p.C77Vfs*100) had decreased HR activity and increased sensitivity to mitomycin 
C (MMC), a DNA cross-linking agent.25 This alteration is predicted to result in loss of normal 
protein function through either protein truncation or nonsense mediated decay, as the 
frameshift leads to the creation of a premature stop codon at position 100 in the new reading 
frame. The truncated protein includes the complete CC domain of PALB2, which would 
permit interaction with BRCA1 and PALB2-PALB2 binding. While this is also true of the 
other frameshift variants examined, it is possible that our artificial expression system led to 
overexpression (since we transfected the same total µg of plasmid cDNA for all PALB2 
variants) and enough of the C-terminal function was retained to affect the relative HR/NHEJ. 
Alternatively, our result may reflect the true range of HR/NHEJ activity for pathogenic 
variants.  
WD40 domain and BRCA2 interaction 
Two variants in the PALB2 C-terminal WD40 domain, a ring-like beta-propeller 
structure common in protein-protein interactions112,114, demonstrated robust effects on 
HR/NHEJ in the TLR assay: A1025R and P1097R. These variants are located in the 4th and 
5th blades of the WD40 domain, which interact with BRCA2. PALB2 residues V1019, M1022, 
A1025, I1037, L1046, K1047, L1070, P1097, and K1098 line a hydrophobic pocket that 
binds BRCA2.114 Interestingly, the C-terminal variants with the greatest impact on HR/NHEJ 
affected one of these residues specifically, suggesting that the observed abnormalities in 
HR activity may be related to impaired BRCA2 interaction. 
First, we found that P1097R demonstrated abnormal HR/NHEJ activity, but did not 
affect PALB2 protein expression by western blot (Figure 4.9). Truncation of PALB2 after 
P1097 abrogates BRCA2 binding112, further supporting that this is a key residue for BRCA2 
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interactions and HR activity. Prediction algorithms for the impact on splicing suggest that 
P1097R may activate an exonic cryptic donor site.122 Though beyond the scope of this 
study, to better understand the mechanism of P1097R’s abnormal HR function, future work 
could test for any splicing abnormalities, as this cannot be adequately assessed in the cDNA 
constructs used here. Additionally, defects in PALB2’s ability to complex with BRCA2 could 
be further explored. 
The other PALB2 variant in the WD40 domain with abnormal HR/NHEJ was A1025R, 
consistent with previous reports.30,123 It has also been shown that A1025R abrogates the 
PALB2-BRCA2 interaction26,29,31,114,123,124, increases sensitivity to olaparib and cisplatin29,30, 
and affects progression through the G2/M checkpoint30,125. However, A1025R does not 
seem to impact PALB2 protein stability30,114. Of note, a change to threonine at the same 
A1025 residue had normal readout in our assay and in the DR-GFP assay in mES cells29. 
Threonine is a relatively conservative physiochemical change and multiple mammalian 
species have threonine at this position (ClinVar Accession: SCV000290863.4)47, suggesting 
it does not substantially alter protein function. Interestingly, the only two PALB2 variants in 
the WD40 domain with clear abnormal functional consequences (A1025R and P1097R) 
were alterations predicted to substitute an arginine for the native residue. Future studies to 
elucidate which amino acid substitutions are tolerated in this region would be pertinent.  
Like A1025T, I1037T also affects a residues located in the hydrophobic pocket of 
PALB2 that binds BRCA2114, but did not have a marked effect on HR/NHEJ in the TLR 
assay. I1037T had an intermediate functional impact on HR (38.86% efficiency) by DR-GFP 
in Trp53KO, Palb2KO mES cells.30 In the same study, I1037T showed decreased protein 
expression, but normal mRNA expression and normal PARPi sensitivity.30 The incongruency 
between the TLR and DR-GFP assays may reflect differences in thresholding that could be 
resolved by benchmarking assay readout with variant controls.  
 L1070P is also located in the hydrophobic pocket, but was just above the threshold 
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for abnormal functional impact with a median HR/NHEJ of 0.635. Other studies considered 
L1070P to have defects in HR, with 23.09% HR efficiency in one study and an HDR fold 
change of 1.7 (equivalent to less than 34% of normal) in another.29,30 Recent work has 
further shown L1070P to impact protein expression/stability, potentially increase sensitivity 
to olaparib and cisplatin, partially disrupt the BRCA2 interaction, decrease PALB2 
recruitment to DSBs, and increase cytoplasmic retention.29,30 As these findings conflict with 
our overall interpretation, it is possible that our threshold is too stringent, or theirs too 
permissive. 
Another PALB2 variant in the WD40 region, T1030I, also demonstrated an 
intermediate functional impact on HR/NHEJ (0.834) in the TLR assay. Wiltshire’s DR-GFP 
assay (fold change of 3.0) agreed with this intermediate classification, though Rodrigue’s 
CRISPR-LMNA assay and Boonen et al.’s DR-GFP assay considered it to have abnormal 
function (23.6% and 14.68% of normal HR, respectively). T1030I has demonstrated modest 
impacts on RAD51 and RAD51C interactions31,112 and PARPi sensitivity30,31. and no defect in 
BRCA2 complex formation.31 T1030 is not one of the key residues in the hydrophobic pocket 
that interacts with BRCA2, and others have found no defect in BRCA2 complex formation. 
There are reports that T1030I has decreased protein stability30,112 and one group found 
increased localization to the cytoplasm31, which could help explain some decreased HR 
function, depending on how much T1030I is active in the nucleus. The overall functional 
impact of T1030I remains unclear.  
It is possible that T1030I, L1070P, and other variants of intermediate function are 
hypomorphic, which could be interpreted as having a modestly increased risk of cancer, or 
an increased risk of a less severe cancer phenotype. There is some precedent for 
hypomorphic variants in BRCA2126 conferring modest increases in cancer risk. There are 
also hypomorphic PALB2 variants that have been associated with a less severe Fanconi 
Anemia phenotype.127 Family studies and correlation with clinical phenotype could help 
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resolve these questions moving forward. 
A final PALB2 VUS in the WD40 domain, L939W, revealed normal HR/NHEJ 
function in the TLR assay. L939W is listed as having conflicting interpretations in ClinVar, 
with a combination of likely benign, benign, and VUS classifications reported from different 
clinical laboratories. There are previous reports that L939W displays a modest decrease in 
BRCA2 and RAD51 binding, and affects HR capacity112, but others have been unable to 
reproduce this HR finding29,30,128. Given that the original studies of abnormal activity were 
conducted without validation controls, these results do not qualify as strong PS3 evidence 
and should be ignored in light of substantial refuting evidence. Located in the second blade 
of the WD40, L939 is not in direct interaction with BRCA2. Internally, L939W was observed 
in four exomes analyzed for non-cancer-related indications, including cardiomyopathy, 
neuromuscular disorders, dysmorphology, and neurodevelopmental disorders. Furthermore, 
the reported MAF is too high to be considered pathogenic for hereditary breast cancer.129 
Rigorous assay thresholding for result concordance 
While the majority of our results are consistent with published studies (Figure 4.11), 
most discrepant interpretations involve variants that are of intermediate function. The overall 
interpretation depends on each assay’s thresholds for calling the readout “abnormal”, 
“normal”, or “intermediate”. Comparing results is further complicated if some assays use a 
binary classifier, eliminating an “intermediate function” category. We also note that while 
many assays use WT as a control to normalize the functional readout, this approach masks 
the true variation in WT readout and creates potential challenges when drawing thresholds 
for normal versus abnormal function. In collaboration with the ClinGen Sequence Variant 
Interpretation Working Group, we developed guidance for validating functional assays and 
setting strength thresholds for evidence application99. The discrepancies in the interpretation 
of DDR assay readout highlight the importance of rigorous assay design to enable 
reproducible statistical thresholding.  
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Many in silico tools consider amino acid characteristics and evolutionary 
conservation data to predict the effect of missense variants on protein structure/function. 
These kinds of results are frequently applied as supporting evidence in the context of clinical 
variant interpretation.50 Predictions are often inconsistent between tools, and are especially 
unreliable for missense variants.130,131 Gene and disease expertise are necessary to select 
and threshold appropriate in silico tools for clinical application.130 Our results further 
underscore that in silico tools are poor predictors of missense SNV function in PALB2, as 
inferred from linear regression R-squared values (≤ 0.63). We also found that it is important 
to consider thresholding qualitative interpretations, such as “damaging” or “tolerated”, using 
gene-specific information rather than using generic cutoffs. This was most striking for 
MetaLR, which had the greatest correlation with HR/NHEJ readout, but a rather limited 
dynamic range of scores for the PALB2 variants examined here. Correlating additional B/LB 
variant functional performance with these in silico scores may improve the ability to discern 
a threshold for improved in silico criteria application. It is important to note that no frameshift 
P/LP variants are assessed by these in silico predictors, which only provide scores for 
missense SNVs. As such, without good benchmarks of pathogenicity or abnormal functional 
impact, it is difficult to set thresholds that would permit meaningful interpretation of these 
predictive scores.  
Conclusions 
 The work presented here represents the first validated functional assay for PALB2 
with statistically determined thresholds of evidence strength for application of PS3/BS3 
criteria in clinical variant interpretation. Our novel approach to validation using 16 known 
benign and pathogenic variants in BRCA2 demonstrates that pathway-based approaches for 
assay development are promising when benchmarking controls are limited. We also used 
nine B/LB PALB2 missense controls, along with WT PALB2 and 3 truncating P/LP variants 
to further benchmark the TLR assay. While results for variants with normal readout can be 
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applied immediately at a supporting level of evidence in favor of a benign classification 
(BS3_supporting) and abnormal readouts as moderate evidence supporting a pathogenicity 
(PS3_moderate), testing additional variants of known significance (as they become 
available) would further increase the strength of evidence that can be applied. We found that 
L35P is not the only PALB2 missense variant with abnormal HR function—others in the 
BRCA1- and BRCA2- interacting domains have now demonstrated abnormal functional 
impact on DDR outcomes. As such, further exploration of missense variation in these 
domains is merited. Adapting the TLR assay for multiplexed assessment of PALB2 VUS 
would permit evaluation of every possible missense variant before it is even seen in a 
patient, preempting delays in conclusive variant interpretation while functional evidence is 
generated. Overall, the new functional data presented here will contribute the additional 
evidence required to help reclassify these VUS within the ACMG/AMP variant interpretation 




4.5 Supplemental material 
 
Figure 4.12: Timing of PALB2 protein knockdown after siRNA transfection. Western 
blot analysis of whole-cell lysates from 293T/TLR cells 48-, 72-, or 96-hours (h) after 
transfection with non-targeting control siRNA (siNT) or siRNA against PALB2 (siPALB2). 15 
µg of whole-cell lysate was loaded per lane and endogenous PALB2 expression was probed 
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Figure 4.13: Monitoring siRNA knockdown in flow cytometry experiments. Results of 
RT-PCR performed in triplicate on 293T/TLR cells treated with either siNT, siBRCA2, or 
siPALB2 and rescued with empty vector and pelleted at the time of flow cytometry, 96 hours 




Gene Primer name Sequence 
Corresponding 
nucleotides (CCDS) 
BRCA2 BRCA2_1F atgcctattggatccaaag 1-19 
BRCA2 BRCA2_1342R gtggcaaagaattctctg 1342-1325 
BRCA2 BRCA2_1207F ctaaatggagcccagatg 1207-1224 
BRCA2 BRCA2_2541R tcttgaaggtgatgctac 2541-2524 
BRCA2 BRCA2_2406F ttatgaatctgatgttga 2406-2423 
BRCA2 BRCA2_3748R cctcactaatattctcaa 3748-3731 
BRCA2 BRCA2_3610F gcttctggttatttaaca 3610-3627 
BRCA2 BRCA2_5059R gtaatgaagtctgactcacag 5059-5039 
BRCA2 BRCA2_4831F gtgccacctaagctctta 4831-4848 
BRCA2 BRCA2_6193R gctttccacttgctgtac 6193-6176 
BRCA2 BRCA2_6058F gaacattcagaccagctc 6058-6075 
BRCA2 BRCA2_7400R gctactgcttgattggag 7400-7383 
BRCA2 BRCA2_7251F cagagttgaacagtgtgt 7251-7268 
BRCA2 BRCA2_8580R cttttgttgggcctccac 8580-8563 
BRCA2 BRCA2_8434F ggaggaaatgttggttgt 8434-8451 
BRCA2 BRCA2_9769R tctcccctttacaagact 9769-9752 
BRCA2 BRCA2_9634F ggaaacaagcttctgatg 9634-9651 
BRCA2 BRCA2_10257R ttagatatattttttagttg 10257-10238 
PALB2 P2_1F atggacgagcctcccggg 0-18 
PALB2 P2_1305R gacatccaaatgactctg 1305-1288 
PALB2 P2_1147F ctggaagcaacctctcct 1147-1164 
PALB2 P2_2505R ggaatgtttatgcagctc 2505-2488 
PALB2 P2_2370F agtgtcaggcaggcaagg 2370-2387 
PALB2 P2_3561R ttatgaatagtggtatac 3561-3544 
Table 4.2: Sanger sequencing primers. Sanger sequencing primers used to confirm 
BRCA2 and PALB2 construct and variant sequences. Primer name ends with “F” for 
“forward” or “R” for “reverse” primer direction. Reference sequences used were: 









change Forward Mutagenesis Primer Reverse Mutagenesis Primer 
c.3055C>G p.(L1019V) cagcttcaaataaggaaatcaaggtctctgaacataacattaagaag cttcttaatgttatgttcagagaccttgatttccttatttgaagctg 
c.4570T>G p.(F1524V) aacctactctgttgggtgttcatacagctagcggg cccgctagctgtatgaacacccaacagagtaggtt 
c.6220C>A p.(H2074N) agcaagtttccattttagaaagttccttaaacaaagttaagggagtg cactcccttaactttgtttaaggaactttctaaaatggaaacttgct 
c.7415A>C p.(K2472T) tcaagcagcagctgtaactttcacaacgtgtgaagaagaac gttcttcttcacacgttgtgaaagttacagctgctgcttga 
c.7544C>T p.(T2515I) ggcagtctgtatcttgcaaaaatatccactctgcc ggcagagtggatatttttgcaagatacagactgcc 
c.7879A>T p.(I2627F) ggtttataatcactatagatggttcatatggaaactggcagctat atagctgccagtttccatatgaaccatctatagtgattataaacc 
c.7940T>C p.(L2647P) atttgctaatagatgcccaagcccagaaagggtgc gcaccctttctgggcttgggcatctattagcaaat 
c.7958T>C p.(L2653P) ctaagcccagaaagggtgcctcttcaactaaaatacagat atctgtattttagttgaagaggcaccctttctgggcttag 
c.8063T>C p.(L2688P) cagctgcaaaaacacttgttccctgtgtttctgacataatttc gaaattatgtcagaaacacagggaacaagtgtttttgcagctg 
c.8165C>G p.(T2722R) cccaaaaagtggccattattgaacttagagatgggtggtatg cataccacccatctctaagttcaataatggccactttttggg 
c.8167G>C p.(D2723H ) agtggccattattgaacttacacatgggtggtatgctg cagcataccacccatgtgtaagttcaataatggccact 
c.8187G>T p.(K2729N) agatgggtggtatgctgttaatgcccagttagatc gatctaactgggcattaacagcataccacccatct 
c.8243G>A p.(G2748D) gaatggcagactgacagttgatcagaagattattcttcatg catgaagaataatcttctgatcaactgtcagtctgccattc 
c.8525G>A p.(R2842H) atcatctggattatacatatttcacaatgaaagagaggaagaaaagg ccttttcttcctctctttcattgtgaaatatgtataatccagatgat 
c.8567A>C p.(E2856A) agcagcaaaatatgtggcggcccaacaaaagagac gtctcttttgttgggccgccacatattttgctgct 
c.9371A>T p.(N3124I) catatgttaattgctgcaagcatcctccagtggcg cgccactggaggatgcttgcagcaattaacatatg 
Table 4.3: BRCA2 site-directed mutagenesis primers. Complete list of all BRCA2 mutagenesis primers used in this study. Human 





Nucleotide change Amino acid change Forward Mutagenesis Primer Reverse Mutagenesis Primer 
c.49_50delinsCC p.(L17P) cagctgtgaggagaaggaaaagccaaaggagaaattagcattcttg Caagaatgctaatttctcctttggcttttccttctcctcacagctg 
c.53A>G p.(K18R) agctgtgaggagaaggaaaagttaagggagaaattagcattc Gaatgctaatttctcccttaacttttccttctcctcacagct 
c.61_62delinsCC p.(L21P) gctgtgaggagaaggaaaagttaaaggagaaaccagcattcttgaaaaggg cccttttcaagaatgctggtttctcctttaacttttccttctcctcacagc 
c.70_71delinsCC p.(L24P ) aaagttaaaggagaaattagcattcccgaaaagggaatacagcaagacacta tagtgtcttgctgtattcccttttcgggaatgctaatttctcctttaacttt 
c.71T>C p.(L24S) gttaaaggagaaattagcattctcgaaaagggaatacagcaagacac gtgtcttgctgtattcccttttcgagaatgctaatttctcctttaac 
c.83A>G p.(Y28C) agcattcttgaaaagggaatgcagcaagacactagccc gggctagtgtcttgctgcattcccttttcaagaatgct 
c.82_83delinsAC p.(Y28P) ggagaaattagcattcttgaaaagggaaaccagcaagacactagc gctagtgtcttgctggtttcccttttcaagaatgctaatttctcc 
c.90G>T p.(K30N) cttgaaaagggaatacagcaatacactagcccgcct aggcgggctagtgtattgctgtattcccttttcaag 
c.104T>C p.(L35P) cactagcccgccctcagcgtgccca tgggcacgctgagggcgggctagtg 
c.110G>A p.(R37H) gcccgccttcagcatgcccaaagagct agctctttgggcatgctgaaggcgggc 
c.110G>C p.(R37P) cccgccttcagcctgcccaaagagc gctctttgggcaggctgaaggcggg 
c.109C>A p.(R37S) agcccgccttcagagtgcccaaagagc gctctttgggcactctgaaggcgggct 
c.229delT p.(C77Vfs*100) gctaaaacactcagaacctaaaaataaaatagtgtttatgacaagttacacat atgtgtaacttgtcataaacactattttatttttaggttctgagtgttttagc 
c.557A>T p.(N186I) aggaacaggaagaaatcagtagcaaaattcctgctagatcac gtgatctagcaggaattttgctactgatttcttcctgttcct 
c.721A>G p.(N241D) cattcctaagaagacctgatttcaccagggcgact agtcgccctggtgaaatcaggtcttcttaggaatg 
c.925A>G p.(I309V) aacctccttgtaaataaagctgtaagtaaaagtggccaactgc gcagttggccacttttacttacagctttatttacaaggaggtt 
c.991G>C p.(E331Q) ttagaggcaaatatttcatgttctctaaatcaactcacctacaataac gttattgtaggtgagttgatttagagaacatgaaatatttgcctctaa 
c.1212T>A p.(F404L) gcctgaaggccttctgttacctgcagaatattatg cataatattctgcaggtaacagaaggccttcaggc 
c.1468C>G p.(P490A) tcattaactaaagtcagctctgccgctgggccc gggcccagcggcagagctgactttagttaatga 
c.1490delA p.(N497Mfs*64) gctgggcccactgaagatatgacttgtctagga tcctagacaagtcatatcttcagtgggcccagc 
c.1592delT p.(L531Cfs*30 ) gcatcagatcattgtgaaccactttgccaacttctagc gctagaagttggcaaagtggttcacaatgatctgatgc 
c.1676A>G p.(Q559R) atatcagcacgaaaaattatttattcgagtgaaagggaagaaaagtcg cgacttttcttccctttcactcgaataaataatttttcgtgctgatat 
c.2014G>C p.(E672Q) gatacagaaatggaggacttacaagaggaccttattgttcta tagaacaataaggtcctcttgtaagtcctccatttctgtatc 
c.2027T>C p.(I676T) aggacttagaagaggaccttactgttctaccaggaaaatc gattttcctggtagaacagtaaggtcctcttctaagtcct 
c.2134G>C p.(A712P) gtcattatcatcaggcggaaccgtatttaaaggagtataaagta tactttatactcctttaaatacggttccgcctgatgataatgac 
c.2135C>T p.(A712V) actcctttaaatacggttgtgcctgatgataatgacagg cctgtcattatcatcaggcacaaccgtatttaaaggagt 
c.2461A>T p.(N821Y) ccacccattgagtcattcacttttaaagaatatcagctctgtagaaa tttctacagagctgatattctttaaaagtgaatgactcaatgggtgg 
c.2590C>T p.(P864S) acctacaattggtttcagagttaaagaattcttcaggttcctgttc gaacaggaacctgaagaattctttaactctgaaaccaattgtaggt 
c.2794G>A p.(V932M) gcctgatgtgtataatctcatgtgtgtagctttgggaaa tttcccaaagctacacacatgagattatacacatcaggc 
c.2816T>G p.(L939W) ctcgtgtgtgtagctttgggaaattgggaaatcagagag ctctctgatttcccaatttcccaaagctacacacacgag 
c.2993G>A p.(G998E) gacgtttgcagaagatgaaggaggcaaagaaaacc ggttttctttgcctccttcatcttctgcaaacgtc 
c.3073_3074delinsCG p.(A1025R) aggtccaagggatgcaagaacgtctgcttggtactac gtagtaccaagcagacgttcttgcatcccttggacct 
c.3073G>A p.(A1025T) gaggtccaagggatgcaagaaactctgcttggta taccaagcagagtttcttgcatcccttggacctc 
c.3089C>T p.(T1030I) gcaagaagctctgcttggtactattattatgaacaacattgttattt aaataacaatgttgttcataataatagtaccaagcagagcttcttgc 
c.3110T>C p.(I1037T) gctgaggtccaagggacgcaagaagctctg cagagcttcttgcgtcccttggacctcagc 
c.3209T>C p.(L1070P) ctattctgaaatggggcttccctttattgtcctgagtcatc gatgactcaggacaataaagggaagccccatttcagaatag 
c.3290C>G p.(P1097R) gctcattgtgattaaccgtaagacgactctcagcg cgctgagagtcgtcttacggttaatcacaatgagc 
Table 4.4: PALB2 site-directed mutagenesis primers. Complete list of all PALB2 mutagenesis primers used in this study. Human 
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A1025T rs746872839 217917 VUS D 0.04 benign 0.34 23 0.127 0.092 low 1.24 
A712P rs765942523 186485 VUS T 0.14 benign 0.01 5 0.023 0.028 low 0.975 
A712V rs141458731 126637 B/LB T 0.25 benign 0 0 0.041 0.017 neutral 0.28 
E331Q rs878855126 241574 VUS D 0.02 possibly damaging 0.66 18 0.066 0.066 low 1.7 
E672Q rs45532440 126630 B/LB T 0.08 benign 0.05 8 0.029 0.013 low 1.7 
F404L rs1064793221 418394 VUS D 0 probably damaging 1 26 0.348 0.218 medium 2.215 
G998E rs45551636 126699 B/LB D 0.05 probably damaging 1 23 0.251 0.177 medium 2.57 
I1037T rs1555459356 484219 VUS D 0 probably damaging 1 26 0.408 0.208 medium 1.955 
I309V rs3809683 126780 B/LB T 1 benign 0 0 0.031 0.002 neutral -0.83 
I676T rs200875161 142310 B/LB T 0.2 benign 0.01 6 0.003 0.02 low 0.805 
K18R rs138789658 126758 VUS T 0.07 probably damaging 1 24 0.181 0.073 medium 2.79 
K30N rs515726130 126779 VUS D 0 probably damaging 0.97 25 0.088 0.137 medium 2.735 
L1070P rs863224785 216752 VUS D 0 probably damaging 1 25 0.466 0.207 medium 2.005 
L24S rs876658653 230588 VUS D 0 probably damaging 1 25 0.167 0.249 medium 2.79 
L35P rs141047069 657328 VUS D 0 probably damaging 1 26 0.35 0.25 medium 2.79 
L939W rs45478192 126683 VUS D 0 probably damaging 1 26 0.359 0.196 medium 2.57 
N186I rs587782164 141993 VUS D 0 possibly damaging 0.8 18 0.112 0.09 medium 2.665 
N241D rs113217267 126765 B/LB T 0.29 benign 0 1 0.013 0.011 neutral -0.14 
N821Y rs958566673 480228 VUS D 0 possibly damaging 0.89 21 0.031 0.079 medium 2.255 
P1097R rs587781308 140834 VUS D 0 probably damaging 1 25 0.442 0.458 medium 2.045 
P490A rs878855101 241531 VUS T 0.27 benign 0.43 9 0.05 0.04 medium 2.135 
P864S rs45568339 126669 B/LB T 0.16 benign 0.34 16 0.062 0.041 medium 1.98 
Q559R rs152451 126613 B/LB T 0.13 benign 0.01 8 0.015 0.024 neutral -0.41 
R37H rs202194596 126590 VUS D^ 0 probably damaging 0.98 23.8 0.218 0.144 medium 2.725 
R37P CA395139484   N/A D 0 probably damaging 0.99 24.3 0.203 0.1461 medium 2.725 
R37S rs200048921 185108 VUS D^ 0 probably damaging 1 28 0.28 0.165 medium 2.725 
T1030I rs876660109 232977 VUS D^ 0 probably damaging 1 26 0.434 0.202 medium 2.085 
V932M rs45624036 126682 B/LB D 0 probably damaging 0.99 23 0.127 0.098 medium 2.515 
Y28C rs515726129 126774 VUS D 0 probably damaging 0.99 26 0.224 0.231 medium 2.79 
Table 4.5: Predicted effect of PALB2 single nucleotide missense variants. For the variants shown here, all CADD and REVEL 
predictions were considered "likely benign" and all MetaLR classifications were "tolerated". Key: ^ indicates low confidence; B, 
benign; CAID, canonical allele identifier; D, deleterious; dbSNP, Single Nucleotide Polymorphism Database; LB, likely benign; LP, 





















HR (% of WT) 
VUS A1025R 0.499 0.303 17.62     
VUS A1025T 1.089 0.899   3.9   
VUS A712P 1.533 1.281       
B/LB A712V 1.464 1.344       
P/LP C77Vfs*100 0.710 0.448       
VUS E331Q 1.621 1.457       
B/LB E672Q 1.056 1.001 79.52     
Control Empty vector 0.568 0.515     4.38 
VUS F404L 1.252 1.334       
B/LB G998E 1.369 1.045 95.16   >75 
VUS I1037T 1.207 1.470 38.86     
B/LB I309V 1.576 1.150   5.8    
B/LB I676T 1.186 1.083       
VUS K18R 1.199 0.961 100.19   >75 
VUS K30N 1.252 1.126   4.6   
VUS L1070P 0.612 0.413 23.09 1.7   
VUS L17P 0.342 0.284       
VUS L21P 0.299 0.517       
VUS L24P 0.382 0.494       
VUS L24S 0.493 0.444 20.67 1.7   
VUS L35P 0.379 0.434 10.40 0.8 5  
P/LP L531Cfs*30 0.179 0.212 7.75     
VUS L939W 1.077 1.065 60.28 4.8   
VUS N186I 1.238 1.251       
B/LB N241D 1.444 1.330       
P/LP N497Mfs*64 0.427 0.297       
VUS N821Y 1.086 1.123       
VUS P1097R 0.281 0.361       
VUS P490A 1.320 1.261       
B/LB P864S 1.050 1.115 85.80   >75 
B/LB Q559R 1.272 1.076 95.02     
VUS R37H 1.003 0.729 44.90 4.1 25-40 
VUS R37P 0.844 0.618       
VUS R37S 1.123 0.941   4.5   
VUS T1030I 0.845 0.637 14.68 3 23.6 
B/LB V932M 1.165 1.274     >75 
Control Wild-type 1.284 1.233     100 
VUS Y28C 0.733 0.690 32.92 4.8 25-40 
VUS Y28P 0.591 0.667       
Table 4.6: TLR performance compared to recent publications. Raw data used for 
scatterplots and linear regression as seen in Figure 4.11. Color shading indicates assay 
readout category: abnormal (gray), intermediate (pink), or normal (blue). Key: B/LB, 
benign/likely benign; HR, homologous recombination; NHEJ, non-homologous end-joining; 




CHAPTER 5: SUMMARY AND DISCUSSION 
 
 Variants of uncertain significance (VUS) are numerous and their ambiguity presents 
challenges to both patients and providers, as they cannot be used to guide risk 
management or clinical decision-making. Missense variants make up the majority of VUS. 
The rarity of individual missense variants limits the availability of clinical data needed to 
reach a definitive interpretation. For this reason, strong functional data has been touted as a 
solution to the evidence gap, as clinical information is not required to be able to test the 
effect of a variant on gene/protein function in the laboratory. However, functional assays are 
costly and time-consuming to develop, and questions about what constitutes a “well-
validated” assay have limited their application in a consistent manner. The studies 
presented in this dissertation investigate the role of functional assays in clinical variant 
interpretation and address issues in their development and application. Our findings lay the 
groundwork for variant and assay prioritization, define the characteristics of a well-
established functional assay, standardize procedures for PS3/BS3 evidence application, and 
present a practical application of assay design and validation for missense variants in the 
hereditary breast cancer gene PALB2. 
 In chapter 2, we demonstrated the theoretical potential of functional assays to 
reclassify VUS and examined their use by VCEPs to identify gaps in the application of 
PS3/BS3 evidence codes. We found that 97% of VUS evidence combinations in the 
categorical ACMG/AMP framework could be reclassified if strong, functional evidence were 
available. We also found that VUS interpretations resulting from conflicting evidence can be 
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potentially resolved in a Bayesian, quantitative framework. Our analysis was limited to 
published variant curations that cited the evidence used in the interpretation. This highlights 
the importance of openly sharing data and curations through databases such as ClinVar. In 
the future, we aim to mine a larger dataset for similar analyses, which might reveal gene-
specific characteristics relevant to functional assay utility. Even so, this study supports 
previous assertions that functional evidence can resolve VUS classifications for variants 
previously limited by available data. Overall, this work represents the first steps towards a 
prioritization method for the development of functional assays for many genes, as well as for 
which variants to examine in established assays, so as to have the greatest impact on VUS 
reclassification. 
 One limitation of the 2015 ACMG/AMP guidelines is that they do not provide a 
detailed procedure for how to evaluate “well-established” functional assays demonstrating a 
variant has an abnormal or normal gene/protein function.34 Differences in the application of 
these codes represent a major source of discordant interpretations between clinical 
laboratories.57 After publishing our work presented in chapter 2, several other VCEPs 
established gene/disease-specific refinements to the interpretation guidelines. We used 
these published curations to expand our understanding of how expert groups approved 
assays for use in clinical variant interpretation, and these findings were published in 
Genome Medicine.71 I led an effort by the ClinGen consortium to address salient disparities 
amongst expert specifications, as detailed in chapter 3, developing recommendations for 
applying PS3/BS3 criteria and establishing a preliminary framework for evaluating functional 
evidence  
 One of the inconsistencies we identified from our analysis of expert variant 
curations71 was the strength at which PS3/BS3 was used, ranging from supporting to strong 
evidence. The 2015 ACMG/AMP guidelines provide a mechanism for the adjustment of 
evidence strength, for example the PM3 code, which can be upgraded in strength with 
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additional case data.34 Since then, adjustments to the strength of evidence at which a code 
can be applied has been recommended for several other criteria (e.g. PVS1)73. To 
harmonize strength determination for PS3/BS3, in chapter 3, I describe a decision tree that 
facilitates the evaluation of assay validation parameters such as controls, replicates, and 
statistical analysis. If rigorous statistical calculations permit the odds of pathogenicity to be 
determined, this can be directly correlated with a categorical strength of evidence 
(supporting, moderate, strong, very strong). In the absence of these statistical analyses, an 
estimated 11 total control (known pathogenic and benign) variants would be required to 
reach a moderate level of evidence. These represent specific, easy-to-follow steps that 
variant curators and experimentalists can use to determine the level of validation and 
therefore appropriate evidence strength for a given assay. Ultimately, improved 
standardization of functional assay validation and utilization can potentially reduce 
conflicting variant interpretations.  
 Of note, the baseline decrease in functional evidence strength suggested by these 
recommendations may temporarily affect the classification of some variants. For example, if 
data from historical assays performed without the appropriate controls were used as strong 
evidence, a decrease in evidence strength to moderate or supporting could result in a 
downgrade in classification. The development of these guidelines was an iterative process 
and feedback from their implementation will elucidate any such issues and guide future 
revisions. Additionally, the next version of the ACMG/AMP guidelines are under 
development, and it is likely that the strength of many other evidence types will be rescaled. 
As such, the preliminary framework in chapter 3 will need to be evaluated in this new 
context. 
 To ensure the most accurate variant interpretation, it is key that each piece of 
evidence considered be independent and not “double counted”. During working group 
discussions and feedback from the ClinGen community, the issue of “stacking” evidence 
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emerged as a point of contention. One position was that multiple functional assays of low-to-
moderate weight should be able to be combined for a stronger weight if the results are 
consistent, as this increases confidence in the readout. The working group considered 
providing separate guidance based on whether the assays tested the same gene/protein 
function, but it became clear how challenging it is to discern whether functions are 
independent or overlapping. The group did not come to a consensus on this subject, and 
pilot testing of the recommendations will need to explore this matter further. 
 Finally, in chapter 4, I demonstrate the development and validation of a functional 
assay for the assessment of PALB2 missense VUS. In the process, I addressed many of the 
considerations for evaluating functional assays for use in clinical variant interpretations that 
are presented in chapter 3. I present a fluorescent reporter assay in the HEK293T/17 human 
cell line, which was selected for its ease of transfectability, relatively normal genetic context, 
and potential scalability. The Traffic Light Reporter was selected because it captured two 
mechanisms of DNA damage repair that are directly related to disease pathogenesis for the 
genes of interest. To be able to analyze variants in multiple genes (BRCA2 and PALB2) in 
the same assay set-up and cell line, and because PALB2 knockout is embryonic lethal132,133, 
I performed siRNA-mediated transient knockdown of endogenous gene expression. This 
work represents the first assay of PALB2 missense variants to use a substantial number of 
benign and pathogenic variant controls to set thresholds for the discrimination of normal and 
abnormal functional readout. Analyses are underway that will permit a Bayesian 
determination of the odds of pathogenicity and corresponding evidence strength that can be 
applied to assay readout.  
 As a result of our validation study, we now have the opportunity to address questions 
regarding the functional impact of missense variation in PALB2 throughout the length of the 
protein, in different functional domains. Of the 25 PALB2 missense VUS tested here, we 
found 7 with abnormal function (median HR/NHEJ below 0.52), 13 with normal function 
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(median HR/NHEJ above 0.85), and 4 with intermediate function. Variants with clearly 
abnormal function were located in the N-terminal coiled-coil domain, where PALB2 interacts 
with BRCA1, or in the C-terminal WD40 domain, where PALB2 interacts with BRCA2. This 
adds to the growing understanding of key functional domains and the role of missense 
variation in PALB2.  
 Typical post-hoc, gene-specific assays cannot test variants as fast as they are 
identified in patients.50 An assay capturing a clinically relevant, informative metric, such as 
DNA double-strand break repair, that is common to multiple genes probes variant function 
more efficiently than traditional gene-specific assays. However, this approach is still 
relatively low-throughput. Recently, a novel approach to this issue has emerged in the form 
of multiplexed assays of variant effects (MAVEs), which test thousands of sequence variants 
simultaneously for their functional impact.50,134,135 Harnessing advances in next-generation 
sequencing and DNA synthesis, some MAVEs have been able to prospectively screen every 
possible single-amino acid substitution across the whole protein77, or for critical protein 
domains96,136, enabling functional data to be available for clinical variant interpretation before 
a variant is ever found in patient. Part of MAVE validation requires performance to be cross-
evaluated in a traditional, low-throughput version of the assay.135 As such, the development 
of traditional assays that generate a functional readout for individual variants remains an 
important first step. 
 Taking the first step towards reducing the VUS burden in PALB2, chapter 4 presents 
a validated pathway-based functional assay for PALB2 missense variation. Since PALB2 
has few missense variants with definitive benign and pathogenic interpretations to serve as 
benchmarking controls, we used well-studied BRCA2 missense variants to perform 
preliminary validation. Now that we know that HR/NHEJ can distinguish between PALB2 




 In the future, a synthetic library of every possible PALB2 missense variant can be 
introduced into 293T/TLR cells and the assay performed on all variants at once. A similar 
method has been employed to functionally assess every possible missense variant in 
PPARG.77 In this way, fluorescence-activated cell sorting (FACS) can be used to separate 
populations of cells expressing mCherry (a marker for NHEJ) or GFP (a marker for HR), 
which can then be followed by sequencing to determine which variants are in each 
population and at what frequency. In this experiment, we would expect variants with normal 
function (thus providing evidence for a benign interpretation) to be enriched in the GFP 
expressing cells, and variants with abnormal function to be enriched in the mCherry 
expressing cells (While we have shown that specific variants in the coiled-coil domain and 
BRCA2-interacting region of the WD40 domain display abnormal HR/NHEJ, the role of 
PALB2 missense variants in cancer risk is still debated. Comprehensive assessment of the 
functional consequences of all PALB2 missense variants would permit the methodical 
determination of mutational hotspots and improve understanding of the underlying disease 
biology. As more MAVEs are established, we will be better positioned to reduce the VUS 
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